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Investigating the roles of p63 & p73 isoforms to therapeutically treat
p53-altered cancers
Avinashnarayan Venkatanarayan, M.S.
Supervisory Professor: Elsa R. Flores, Ph.D.
The TP53 tumor suppressor is mutated in approximately 50% of human
cancers rendering cancer therapies ineffective. p53 reactivation suppresses tumor
formation in mice. However, this strategy has proven difficult to implement
therapeutically. An alternate approach to overcome p53 loss is to manipulate the
p53-family members, p63 and p73, which interact and share structural similarities to
p53. p63 and p73, unlike p53 are less frequently mutated and have two major
isoforms with distinct functions which makes them unique targets for therapeutic
intervention. The full-length acidic transactivation (TA) isoforms of p63 and p73
function similar to p53. While the deltaN (ΔN) isoforms of p63 and p73, which lack
the acidic transactivation domain, are overexpressed in cancers and function in a
dominant negative manner against p53, TAp63 and TAp73. As result of the
opposing isoform-specific function, the roles of p63 and p73 in tumorigenesis
requires further characterization. In an attempt to identify novel therapeutic
approaches to treat p53-altered cancers by utilizing the p53-family members, I aim
to delineate the roles of ΔN isoforms of p63 and p73 in tumorigenesis.
I have demonstrated that deletion of ΔNp63 or ΔNp73 in p53-deficient tumors
mediates tumor regression through the upregulation of tumor suppressive isoforms,
TAp63 and TAp73. Upon loss of ΔNp63 or ΔNp73, TAp63 and TAp73 activate IAPP
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a metabolic regulator, which induces metabolic reprogramming resulting in tumor
regression in p53-deficient mice. I have shown that IAPP, which encodes amylin, a
37-amino acid peptide functions as a tumor suppressor in p53-deficient cancers.
IAPP functions through the calcitonin and RAMP3 receptors to limit glucose uptake
and reduce glycolysis in the cancer cells resulting in ROS accumulation and
apoptosis. Additionally, I have also shown that use of Pramlintide, a synthetic analog
of IAPP, mediates tumor regression in p53-deficient mice and apoptosis in multiple
p53-mutant human cancer cell lines.
Further, to therapeutically treat p53-deficient cancers in vivo, liposomal
nanoparticle siRNA’s targeting ΔNp63 and ΔNp73 were administered into p53deficient mouse thymic lymphomas, which resulted in tumor regression. Taken
together, my work has defined the isoform specific functions of p63 and p73 in
tumorigenesis. Importantly, I have also demonstrated the use of pramlintide, a
diabetic drug to treat p53-altered cancers. Thus, by understanding the interplay
among the p53-family members, novel therapeutic methods could be designed to
treat p53-altered human cancers.
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Chapter 1: Introduction
1.1. p53 as a tumor suppressor
The TP53 gene encodes for p53, which is located on the chromosome locus
17p13.1(1, 2). The TP53 gene is regarded as the “Guardian of the genome” due to
its tumor suppressive functions, however TP53 is highly mutated in multiple
cancers(3, 4). More than 50% of human cancers, harbor a complete inactivation of
p53 function or gain of function of p53 due to mutations(5). This effect is well
documented in Li-Fraumeni syndrome individuals who harbor p53 loss and are
highly susceptible to tumor formation(6) and also the ability of the mouse models to
develop spontaneous tumors upon loss of p53(7, 8).
The p53 protein upon initial discovery as a complex with the SV40 T-antigen
was hypothesized to function as a proto-oncogene(1). This notion was later proved
to be incorrect as the initial experiments were performed using a mutated version of
the TP53 gene. Later, wild-type p53 loss of function was observed in a subset of
colon carcinomas suggesting that p53 could have tumor suppressive functions(1). In
many cancers, loss of one copy of TP53 initiates the tumorigenesis process, which
is immediately followed by the loss of heterozygosity further accelerating the tumor
formation. However, in some cancers, TP53 loss could be the end result of a much
more malignant tumor phenotype that could eventually lead to differentiation of the
tumor cells further increasing their invasive and metastatic potential. Thus far,
current research has been trying to determine the underlying mechanisms by which
TP53 executes its tumor suppressive function.
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Thirty years from its initial discovery, TP53 is also referred to as the “Master
regulator of the genome” for its well-documented cellular functions. TP53 is a
transcriptional factor that is involved in a multiple cellular functions and helps
maintains cellular homeostasis. At physiological levels, the protein levels of p53 are
low and under the regulation of E3 ubiquitin ligase called MDM2 and MDM4(9, 10),
which bind to the amino terminus of p53. Upon different types of cellular stressors
like DNA damage, hypoxia and oncogene activation, p53 levels increase in the cells
imparting its protective genomic function. p53 forms a homotetramer and functions
as a tumor suppressor by inducing cell death by activating PUMA(2, 11, 12),
Noxa(2) and BAX(13, 14) or induces transient cell cycle arrest(15, 16) by activating
p21(17, 18), p16(15, 19, 20) and PML. p53 can also induce cellular senescence, a
more permanent form of cell cycle arrest. The normal function of p53 is to activate
DNA damage repair pathway upon genomic instability. Apart from these classical
functions of p53, more recently p53 has been demonstrated to play important roles
in autophagy, cellular metabolism and stem cell maintenance.
Our understanding of the function and roles of p53 in human cancers, were
well-recapitulated using mouse models in which p53 is functionally inactivated(21).
Trp53-null mice primarily develop thymic lymphomas at 90% incidence while the
Trp53-heterzygous mice develop osteosarcomas and thymic lymphomas(22).
However, in most cancers, TP53 is highly mutated that results in p53 gain of function
further promoting aggressive tumor formation. The mutation related functions of p53,
have generated a whole new area of research in characterizing the mutation related
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Figure 1: p53-mutational frequency in human cancers. Spider plot representing
the mutation frequency in TP53 across a panel of human cancers. Sequencing data
from the Cancer Genome Atlas (TCGA) deposited from multiple human sequencing
studies provide an overall mutational frequency for TP53 in multiple cancer types.
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properties of mutant p53 in human cancers using mouse models specific to the
common p53-mutations that have been identified(7, 8).
1.2. p53 mutations in human cancer
TP53 gene is highly mutated in multiple human cancers. Recent sequencing
efforts from the cancer genome atlas (TCGA) have identified a huge array of
cancers in which TP53 is mutated (Figure 1). Somatic mutations generally occur in
multiple genes in human cancer. In the case of TP53, due to its vital tumor
suppressive functions it seems to be a commonly mutated target. Unlike most genes
which have frame-shift or non-sense mutations, p53 in general has missense
mutations that is characterized by single amino acid substitutions(23). These point
mutant versions of p53 are stable and serve as dominant negative regulators of wildtype p53. Typically, when mutant p53 expression is higher it affects the tetramer
formation of wild-type p53 altering its function. Importantly, in tumors, when one
copy of p53 is mutated it is followed immediately by the loss of heterozygosity (LOH)
of the wild-type p53. This has led to the classification that p53-mutations result in
“gain of function” activities accelerating tumor formation(7, 8). Although in some
instances mutant p53 can mediate gain of function activities independent of wildtype p53. Further, from the sequencing efforts on human cancers, p53 mutations are
mostly restricted to the DNA binding domain and some of these frequent mutations
in p53 are referred as “hotspot” mutations. To the test the effect of these mutations
in tumorigenesis, similar to the Trp53-null mice that demonstrated the tumor
suppressive function of p53, two knock-in mouse models that harbor hotspot
mutations at R175 and R270 were generated(7, 8). These mice had diverse tumor
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spectrum with increased metastasis highlighting the aggressiveness of p53-mutation
driven tumors in these mice.
Mutant p53, unlike wild-type p53 does not directly bind to DNA to promote its
proto-oncogenic functions. However, mutant p53 can interact with targets like NF-Y,
Ets1, Pin1, MRE11, PML to promote oncogenic transformation(24, 25) or repress
the activity of the other family members p63 and p73 that function as tumor
suppressors(26, 27). Because of these widespread effects of mutant p53 function or
p53 inactivation in human cancers current therapeutic approaches are targeted
towards either reactivating wild-type p53 or to degrade mutant p53. Although,
preliminary data in mouse models demonstrating active tumor suppression upon
p53-reactivation has shown great promise, thus far therapeutically it is not been
feasible. Also, drug inhibitor based approach to degrade mutant p53 is still under
developmental stages which necessitates the need to find and develop alternate
approaches to treat these human cancers(28-30).
1.3. Therapeutic Strategies to activate the p53-pathway
p53 upon cellular stress, functions to induce cell cycle arrest or cell death in
the “radiosensitive” tissues(15). This is one mechanism by which p53-potects the
genome from different types of cellular stressors and DNA damage. In the context of
the tumor, one mechanism by which chemotherapy functions is to induce damage
which elicit a p53 response activating a downstream cellular cascade targeting the
tumors cells. However, as previously discussed p53 is completely inactivated with a
“loss of function” phenotype or mutated resulting in “gain of function” effects. This
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necessitates the need to restore the function of the p53-pathway. Interestingly, in
vitro restoration of p53 function induced cancer cell death and cell cycle arrest in
human cancer cells(31). This was further validated in vivo using a conditional p53 in
vivo mouse model of lymphomagenesis and osteosarcoma(32, 33). Interestingly,
when p53 expression was restored the thymic lymphoma cells underwent cell death
while

the

osteosarcoma

cells

underwent

cell

cycle

arrest

and

cellular

senescence(16, 32). This suggests that p53 executes its tumor suppressive function
in a tissue dependent manner. Although these experiments provide a proof of
principle mechanism to activate the p53-pathway, thus far restoring p53-function
therapeutically as been challenging.
1.3.1. Activating wild-type p53 function in human cancers
At physiological conditions, p53 is under the regulation of its E3 ubiquitin
ligase MDM2(9, 34). Research work has demonstrated that in multiple human
cancers, MDM2 and its counterpart, MDM4 are significantly overexpressed thereby
repressing wild-type p53 function. Hence, one approach that is under development
is to abrogate the p53-MDM2 interaction, which will restore wild-type p53 activity(3537). Multiple small molecule inhibitors(38) are under clinical development, but Nutlin3a has made significant progress in restoring wild-type p53 activity(39-41). Also, loss
of p53 function in some tumors arises due to the mis-folding of the p53 protein.
Currently, reconstituting levels of Zinc (Zn) in these cells have corrected the p53
protein conformation in wild-type p53 thereby restoring its function(42). However,
this approach cannot be used in mutant p53, as the residues that correspond to the
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Zinc are mutated. Hence, alternate approaches need to be adopted to
therapeutically treat p53-mutated cancers.
1.3.2. Degrading mutant p53 function in human cancers
Mutant p53 exhibits a “gain of function” effect promoting tumor formation.
Hence, current therapeutic strategies are targeted towards abolishing the activity of
mutant p53 either directly or indirectly. Mutant p53 stabilization is achieved through
its interaction with Hsp70 and Hsp90 through HDAC6(43, 44). Therapeutic use of
HDAC inhibitors like SAHA have shown increased efficacy in degrading the mutant
p53 in cancer cells, however, use of HDAC inhibitors has been demonstrated to
degrade wild-type p53 restricting its use towards cancer treatment. Additional
methods to downregulate the mutant p53 function is by targeting the effector
pathways like the MAPK or PI-3K pathway that are activated by mutant p53 function.
Thus far restoration of the p53-pathway still remains a challenge due the intricate
complexities and this necessitates the need to identify and characterize alternate
mechanisms to treat these p53-deficient human cancers.
1.4. Utilizing the p53 family members p63 and p73 towards cancer treatment
The p53 superfamily comprises of TP63 and TP73 along with TP53. For the
last 30 years, the role of TP53 in tumor suppression has been well documented.
Inactivation of TP53 in human tumors has defined the role of TP53 as a bonafide
tumor suppressor. However, the functional roles of the family members TP63 and
TP73 in tumorigenesis have been shadowed. TP63 and TP73 are located in the
3q28 and 1p36 chromosome(45). Although TP63 and TP73 are evolutionarily older
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to TP53, they are still considered as “younger siblings” of the TP53 gene. Although,
p63 and p73 were initially identified as developmental regulators, the roles of these
genes in tumorigenesis were indispensible as mice that harbor loss of p63 and p73
were predisposed to tumor formation suggesting the role of these genes in tumor
suppression(46).
1.4.1. Structural homology among the p53 family members
The p53 family members, p63 and p73 share significant structural homology
with p53 particularly in the DNA binding domain(45). As a result, several functions
among the family members tend to overlap with each other. However, there is less
similarity between p53 versus p63 and p73 in the oligomerization domain and the
transactivation domain (TAD). This might be one of the reasons that p63 and p73
does not form tetramers with p53 while activating other downstream targets.
Interestingly, p63 and p73 are unique and encode multiple isoforms at both the Nterminus and C-terminus (Figure 2). In general, TP63 and TP73 are broadly
classified into two categories, the isoforms that encode an acidic transactivation
domain (TA) which produce either TAp63 or TAp73 and the isoforms that lack the
acidic domain called ΔN isoforms, which produce either ΔNp63 or ΔNp73 (Figure
2)(45). The function of each of these isoforms is complex and tissue dependent. The
full-length TAp63 and TAp73 isoforms in general are thought to function very similar
to p53, while the shorter ΔN isoforms of p63 and p73, exhibit dominant negative
effects against p53, TAp63 and TAp73(47-49). Similar, to the N-terminal isoforms,
more than seven different kinds of C-terminal splice variants have been identified.
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Figure 2: Sequence and structural homology of p53, p63 and p73. p63 and p73
share significant structural homology with p53 particularly in the DNA binding
domain. Both, p63 and p73, have unique N-terminal isoforms, the full-length acidic
transactivation isoform, TAp63 or TAp73 and the shorter isoform that lacks the
transactivation domain called ΔNp63 or ΔNp73 is transactivated from the 3’ cryptic
promoter. Also, p63 and p73 encompass multiple C-terminal isoforms which requires
further characterization.

(Figure is taken with permission from Su, X., Chakravarti, D. and Flores, E.R. p63
steps into the limelight: crucial roles in the suppression of tumorigenesis and
metastasis. Nat. Rev Cancer. 2013; 13(2):136-43.) Licence Number: 351121299603.
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The function of these C-terminal isoforms is under investigation and requires more
characterization.
1.4.2. Mutational status of p63 and p73 in human cancers
More than 50% of human cancers harbor p53 mutations that makes it difficult
to target the p53-pathway. These mutations may be a result of the tumor
suppressive function exhibited by p53. However, compared to p53, the other family
members, p63 and p73 are less frequently mutated (Figure 2). Recent, sequencing
data from multiple human cancers has demonstrated that mutation rates in p63 and
p73 are less frequent compared to any of the other tumor suppressor genes
including p53 (Figure 3). This makes both p63 and p73 novel targets for therapeutic
intervention. Importantly, due to the structural similarlity, the functions of the family
members could be used to target the p53-pathway. One speculation as to why p63
and p73 are not mutated may be due to the important development roles played by
the genes.
1.5. Developmental roles of p63 and p73
p63 and p73 knockout mouse models targeting the DNA binding domains had
severe developmental abnormalities suggesting the roles of these genes as
developmental regulators. p63 knockout mice had a deformed epidermal skin layer
with improperly formed limbs and facial structures(50, 51). Most of these mice were
embryonic lethal and died due to desiccation and water loss. The phenotype of the
p63 knockout mice closely resembled the cleft lip and palate syndrome in humans
referred to as the ectrodactyly ectodermal dysplasia (EEC). Upon further
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characterization of the developmental roles of the N terminal isoforms using
conditional in vivo mouse models, it was evident that splice variants have distinct
functions. The TAp63 isoforms are required to maintain the skin stem cells in
quiescence(50) while the loss of ΔNp63 isoforms prevents skin cell differentiation
and targets the cells to be more pluripotent(52, 53). On the contrary, the p73 has
been demonstrated to play critical roles in immune response and neural
development. p73 knockout mice are embryonically viable but are characterized by a
runted phenotype and shortly die a few weeks after birth(54, 55). Upon
characterization of the specific roles played by the TAp73 and ΔNp73 isoforms, it
has become evident that loss of these isoforms results in defective closure of the
neural tube and growth of the sub-ventricular zone (SVZ) required for normal brain
development(56-58). This highlights the important developmental functions of p63
and p73.
1.6. Tumor suppressive functions of p63 and p73
The roles of p63 and p73 in the development of skin and the neural
development were well documented. However, the functional roles of these genes in
other cellular processes were less studied. Given the structural similarity to p53, it
was hypothesized that p63 and p73 could have similar function as they function as
transcriptional factors as well. However, expression analysis from the human cancer
tissues particularly from the colon, intestine and prostate demonstrated increased
expression of p63 and p73(59-62). These findings suggested that both p63 and p73
could have oncogenic properties. To further add to the complexity, mouse models
targeting p63 and p73 had an accelerated tumorigenesis(46). The tumor spectrum of

	
  

12	
  

Figure 3: Graph representing the mutational status across p53-family
members in human cancers. Unlike TP53, which is highly mutated, TCGA
sequencing analysis has revealed that TP63 and TP73 are less frequently mutated.
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the p63 and p73 deficient mice had significant carcinomas and was completely
divergent from the p53-deficient mice that generally develop lymphomas and
sarcomas. This data highlights the indispensable role of p63 and p73 in tumor
suppression(46). However, the reason for the increased expression of p63 and p73
in the human tumor samples were not clear.
More recent experiments highlighted the independent roles of the N-terminal
isoforms of p63 and p73. The antibodies used for detecting p63 and p73 did not
differentiate the individual isoforms but rather p63 and p73 totally. It was
demonstrated that TAp63 and TAp73, the full-length isoforms of p63 and p73 had
functions similar to p53. In vitro experiments that express TAp63-gamma and
TAp73-alpha in the human cancer cells induced cell death and cell cycle arrest
independent of p53 function(63). Interestingly, in response to genotoxic stress,
TAp63 and TAp73 were stabilized and had an increased effect in directing the
cancer cells to undergo cell death. Further, to support the tumor suppressive notion
of TAp63 and TAp73, mouse models targeting TAp63 and TAp73 were generated.
Total loss of TAp63 in these mice had accelerated tumor spectrum with increased
incidence of adenocarcinomas and metastasis(64, 65). It was also demonstrated
that TAp63 functions to inhibit metastasis through Dicer regulated mechanism(66).
Further, the roles of TAp63 in metabolism(67), stem cells(68) and polarity are
currently being characterized. Similarly, the TAp73 knockout mice develop lung
adenocarcinomas at a higher incidence, which correlates with a previous finding that
p73-deficient mice have a 60% lung adenocarcinoma incidence(46). These findings
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clearly demonstrate the key roles played by the TA isoforms of p63 and p73 in
tumorigenesis and that they function as bonafide tumor suppressors.
1.7. Roles of ΔN isoforms of p63 and p73 in tumorigenesis
In vitro cell culture and in vivo experiments have delineated the functions of
the different isoforms of p63 and p73 in tumorigenesis and development(63, 69).
Particularly, the roles of the TAp63 and TAp73 as tumor suppressors are well
documented. However, the roles of the ΔN isoforms of p63 and p73 are less studied
and controversial. Studies from human cancer tissues detected p63 and p73
expression utilizing antibodies that do not differentiate the isoforms. Later, semiquantitative analysis demonstrated that these tumor samples had increased
expression of ΔNp63 and ΔNp73 suggesting the oncogenic roles of these isoforms
in tumorigenesis(49, 70). Further, in vitro experiments expressing ΔNp63 and ΔNp73
inhibited apoptosis and cell cycle arrest in human cancer cells upon genotoxic
stress(63, 71, 72). This may be due to the dominant negative effect of ΔN isoforms
of p63 and p73 against p53, TAp63 and TAp73. Interestingly, in some instances,
both ΔNp63 and ΔNp73 seem to respond upon DNA damage by activating genes
involved in DNA repair like BRCA2, Rad51 and MRE11(69). This suggests that
ΔNp63 and ΔNp73 do have protective genomic physiological functions as well. Thus
in vitro experimental evidence has clearly demonstrated the complexity within the
roles of ΔN isoforms of p63 and p73 in tumorigenesis. This necessitates the
generation of conditional knockout mice that are required to decipher the role of
these isoforms in tumorigenesis.
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Previous total knockout mouse models for ΔNp63 and ΔNp73 have
highlighted the roles of these genes in development. The ΔNp63 knockout mouse
has defects in epithelial skin development and differentiation(53) while the ΔNp73
knockout mice have defects in neural tube growth and closure(73). However, these
models did not depict the roles of these genes in tumorigenesis. Hence, to test the
role of these genes, our lab generated conditional knockout mouse models to
determine whether ΔNp63(52, 74) and ΔNp73(74) function as oncogenes and tumor
suppressors. The ΔNp63 mice were generated with a loss of one allele as ΔNp63
homozygous deficient mice are embryonic lethal. Surprisingly, the ΔNp63 and
ΔNp73 deficient mice did not develop any tumors. Hence, to further accelerate
tumorigenesis and also determine the role of these isoforms in the context of p53loss, cohorts of mice harboring loss of ΔNp63 with p53 (ΔNp63+/-;p53-/-) and ΔNp73
with p53 (ΔNp73-/-;p53-/-) were generated.
1.8. Cancer cells and deregulated metabolism
Tumor cell metabolism has emerged as on the most important hallmarks of
cancer in the recent years. There has been a tremendous impetus in understanding
how a tumor evolves metabolically and adapts to the changes in the nutrients(75).
Multiple research groups and studies have tried to delineate the complexities
involved in the metabolic regulation. However, a complete characterization of these
metabolic circuits is still being a challenge as tumor cells constantly evolve switching
to multiple modes of nutrient sensing for survival. Research work is currently
focused in understanding how to limit the nutrient consumption of these cancer cells
or to deplete the nutrients to starve the cells, which could eventually reduce their
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Figure 4: Warburg’s hypothesis on tumor cell metabolism. Normal differentiated
tissues or cells, utilize glucose as an energy source through the glycolysis pathway
and enter into Kreb’s cycle to produce more energy through oxidative
phosphorylation. On the contrary, cancer cells, consume increased amounts of
glucose and switch to produce lactate without entering oxidative phosphorylation.
Cancer cells are dependent on this switch to aerobic glycolysis for proliferation.

(Figure is taken with permission from Vander Heiden, M.G., Cantley, L.C. and
Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 2009; 324(5930):1029-1033.)
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proliferation rates and reduce tumor growth and spread. However, this approach as
been challenging as the cancer cells do not depend on only one nutrient but
constantly switch to other nutrients for their survival and importantly the complexity
of the metabolic machinery makes it challenging to target a single pathway.
However, a clear understanding of these pathways makes it a viable option to
therapeutically target the cancer cells.
1.8.1. Warburg Hypothesis on tumor cell metabolism
In the early 1950, a german scientist Otto von Warburg, postulated that
cancer cells proliferate at much higher rates with increased consumption of
glucose(76). This results in an increased activity of the glycolysis pathway with the
cancer cells secreting an acidic product lactate instead of targeting the cells into
mitochondrial respiration. Based on this hypothesis, it was evident that cancer cells
have increased glucose consumption and lactate secretion (Figure 4)(75). The acidic
lactate medium provided a better environment for the cancer cells to proliferate.
Although the amount of ATP from the glycolytic pathway is less in comparison to the
Kreb’s cycle, the increased rate of proliferation in these cancer cells compensated
for ATP loss with increased glucose consumption. Hence, to therapeutically target
the glycolytic pathway to inhibit the cancer cells from proliferation and lactate
production became a viable option. Current research work as also identified the key
players that function as regulators of glucose uptake and those that could inhibit
glycolytic pathway. Interestingly many of these regulators are activated by multiple
transcription factors including p53(77).
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However, based on Warburg’s hypothesis, it was believed that cancer cells
do not depend on mitochondrial respiration(78). However, more recently, some
studies have shown that mutations in the mitochondria could have adverse effects in
the nutrient sensing functions of the cancer cells. Importantly, cancer cells attain the
ability to switch to nutrients like glutamine to continue proliferation. This sudden
influx in glutamine consumption accelerates the mitochondrial respiration further
promoting tumor cell proliferatio(75). Some of the current research focus is also now
targeted towards inhibiting the oxidative phosphorylation pathway in cancers.
1.9. p53 and cancer cell metabolism
p53 functions as a transcriptional factor activating several downstream targets
regulating classical cellular function like apoptosis, cell cycle arrest and cellular
senescence. More recently, the roles of p53 in new cellular functions like stem cell
maintenance, aging and metabolism have been explored. p53 has been
demonstrated to regulate and activate genes involved in glycolysis and
metabolism(77, 79). Primarily, p53 regulates GLUT2 and TIGAR (TP53-inducible
glycolysis and apoptosis regulator)(79, 80). GLUT2 function to uptake glucose into
the cell and p53 inhibits the activity of GLUT2. On the contrary, TIGAR, which is
activated upon DNA damage by p53, encodes a bis-phosphatase enzyme that
degrades fructose 2,6-bisphosphate and degrades glucose primarily inhibiting the
glycolytic pathway(81). However, in some tissues like the intestine, TIGAR has been
demonstrated to promote regeneration of the intestinal stem cells. As a result,
expression of TIGAR in an intestinal tumor model promotes tumor formation(80).
Another known regulator of p53 in metabolism is a gene involved in the
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mitochondrial respiration referred to GLS2. GLS2 functions to release cytochrome C
and regulate intracellular ROS in the cells. Upregulation of GLS2 releases
cytochrome C resulting in induction of the apoptosis pathway(82). More recently, a
p53 acetylation mutant mouse model demonstrated that p53 inhibits tumorigenesis
by activating the metabolic regulators GLS2, TIGAR and GLUT2(81). This further
suggests that utilizing these metabolic regulators could function as a novel approach
to target the deregulated metabolism of these cancer cells.
2.10. Islet amyloid polypeptide (IAPP)
IAPP is a transcriptional factor that encodes for amylin(83). Amylin is a 37amino acid polypeptide that is cosecreted along with insulin from the beta cells of the
pancreas. However, expression of IAPP has been detected in other tissues, which
include cornea, thymus and the ovary. At physiological levels, IAPP functions to
reduce insulin mediated glucose uptake, implicating its role in maintaining glucose
homeostasis(84). IAPP has also been demonstrated to induce apoptosis in some
cellular contexts(85). Some studies suggest that IAPP mediates apoptosis through
activation of p21 independent of p53 function(86), while some studies relate to
metabolic stress induced toxicity by IAPP upon glucose clearance in the liver(87).
IAPP since is a secreted protein has been shown to function through the activity of
the calcitonin and RAMP3 receptors(88). Additionally, a synthetic analog of IAPP
called pramlintide involved in glucose regulation is used commercially to treat type I
and type II diabetic patients(89).
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2.11. Reactive Oxygen Species (ROS)
ROS is a common by-product that is produced from different metabolic
processes in the cell. Although, ROS, a class of free radicals primarily originates
from

the

mitochondria,

recent

evidence

suggests

that

intracellular

ROS

accumulation occurs upon metabolic stress and inhibition of cellular nutrients like
glucose or glutamine or inhibition of the phosphate pentose pathway(78). At
physiological state, the levels of ROS in the cells are under tight regulation. Low
levels of ROS as in the case of cancer cells, generally promote tumor cell
proliferation by activating oncogenes and inducing stress. However, in instances
when cells accumulate increased amounts of ROS due to metabolic stress, it results
in apoptosis or cellular senescence(90, 91). Recent evidence suggests that targeting
a class of phosphatidyl kinases in p53-deficient tumors results in ROS-induced
cellular senescence in breast tumors. This highlights the role of ROS as tumor
suppressor(91). However, in some cancers, ROS accumulation activates oncogenes
like HIF-1alpha driving tumorigenesis representing its oncogenic functions(92).
Hence one approach to target cancer cells is to increase ROS levels, which will
result in apoptosis or senescence in the tumor cells. Interestingly, the effect of ROS
can be controlled or reversed using antioxidants. Antioxidants like hydrogen
peroxide and N-acetly cysteine could function to reverse the effect of intra-cellular
ROS suppressing the oncogenic functions of ROS(80, 93).
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2.12. Therapeutically targeting p53-deficient and mutant cancers
Therapeutically reactivating wild-type 53 or degrading mutant p53 in human
cancers has been challenging. But the role of this p53-pathway in activating
downstream cellular cascade to induce apoptosis or cell cycle arrest is
indispensable. By utilizing the p53-family members, p63 and p73, a new paradigm
approach can be taken to reactivate the downstream components of the p53pathway. Importantly, by delineating the interplay among the family members a more
clear strategy could be adopted to utilize p63 and p73 therapeutically(94).
TAp63 and TAp73 are bonafide tumor suppressors. However, because of the
dominant negative effect of ΔN isoforms against p53, TAp63 and TAp73, the
expression levels of the TA isoforms of p63 and p73 remain significantly low(49, 60).
Ideally, by targeting ΔNp63 and ΔNp73, if the repressive effect is reduced, TAp63
and TAp73 can compensate for p53 loss of function by activating downstream
targets involved in multiple cellular processes. Hence, approaches to target ΔNp63
and ΔNp73 in human cancers could be explored as an option to treat p53-deficient
cancers. One approach to target ΔN isoforms of p63 and p73 could be the
identification and use of small molecule inhibitors that could be used selectively to
downregulate ΔNp63 and ΔNp73. Second approach, could be to identify microRNA’s
(miRNA’s) that specifically bind to ΔNp63 or ΔNp73 and repress its function.
miRNA’s are approximately 22-35nt oligomers that function to repress gene
transcription. By activating these miRNA’s specific to ΔNp63/ΔNp73 or by
introducing them exogenously we can target ΔNp63 and ΔNp73 to treat these
tumors. Additionally, small interfering RNA’s (siRNA’s) could be used to target
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ΔNp63 and ΔNp73 in human cancers. Previously, the use of siRNA’s to
downregulate gene expression has been well demonstrated in human cancer cells.
Recent studies have highlighted the use of in vivo delivery methods to deliver these
siRNA’s. Some methods use cholesterol or other polymer based substances to coat
the siRNA oligomers. But with these methods the issue was poor resorption into the
tissues and also degradation by the phagosomes. One approach to deliver siRNA’s
into the tissues that has a high penetrance is to coat the siRNA oligomers with nanoliposomes. Nano-liposomes are neutral particles that do not carry any charge. These
particles could be delivered directly into the region of the tumor or by systemic
methods and are not phagocytosed. These options could be explored further to
target ΔNp63 and ΔNp73 in human cancers.
Alternatively, TAp63 and TAp73, very similar to p53 respond to genotoxic
stress and DNA damage. Hence, to illicit a TAp63 and TAp73 response, both ΔN
isoforms of p63 and p73 could be targeted along with treating the cells with a DNA
damaging agent like cisplatin or doxorubicin. However, in the case of human
cancers that harbor mutations in p53, this possibility would not feasible as mutant
p53 forms hetero-tetramers with TAp63 or TAp73 and inhibits its transcriptional
activity. Hence, to overcome the effects of mutant p53, we could simply target
pathways that are independent of the p53 pathway.
2.13. Long non-coding RNAs: Disease and Development
Long non-coding RNAs (lncRNAs) are a class of RNA molecules that are
>200 nt in length and do not code for proteins(95). These lncRNAs function very
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similar to mRNAs and are involved in multiple cellular process and functions.
lncRNAs comprise of the 80% of the non-coding part of the genome along with the
other know miRNAs, pseudoRNAs, piwi and piRNAs(96, 97). lncRNAs were
discovered in eighties but its functions were less characterized. However, unlike
miRNAs or mRNAs, lncRNA are not evolutionary conserved. But with the advent of
the sequencing efforts, the gene regulation and functions of the lncRNA in disease
and development is being delineated. lncRNAs are classified into multiple types
based on the position in the context of mRNA genes. The most common type of
lncRNA is called long intergenic non-coding (linc) RNA whose function does not
overlap with the neighboring genes(96). lncRNAs have been demonstrated to play
diverse roles in gene regulation. They perform these functions by acting as
scaffolding

proteins,

decoys,

cofactors

and

guides(97).

However,

current

understanding of these lncRNAs is limited to in vitro experiments and additional in
vivo models should be developed to completely characterize its function. The
functional characterization of these lncRNAs is gaining importance because of its
implication in diseases like cancers. HOTAIR is one such lncRNA that is significantly
overexpressed in prostate cancer(98). By determining the expression pattern of
these lncRNAs they can serve as biomarkers for disease prognosis. Additionally,
lncRNA can function as regulators or effectors of gene function. These roles of
lncRNAs determine whether they function as tumor suppressors or oncogenes.
2.14. lncRNAs and p53 regulation
p53 functions in multiple ways to regulate genomic functions. p53 apart from
its classical roles in apoptosis and cell cycle arrest also functions to mediate its
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effectors functions by activating lncRNAs. The lncRNAs regulated by p53 are often
grouped as “effectors”. This class of lncRNAs, which include linc-p21, PANDA and
H19

play

significant

roles

in

preventing,

cell

proliferation

and

prevent

tumorigenesis(99-102). Conversely, several lncRNAs function to regulate p53
function which include MALAT1, MEG3 and ROR. Thus, it is evident that regulation
of lncRNAs plays a significant role in regulating gene function. By understanding the
function of these lncRNAs in regulating mRNA expression we can delineate novel
pathways that could help design new therapies or serve as predictors of disease
outcome.
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2. Chapter 2. Materials & Methods
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Chapter 2. Materials & Methods
Contents of this chapter is based on Venkatanarayan, A., Raulji, P., Norton, W.,
Chakravarti, D., Coarfa, C., Su, Xiaohua., Sandur, S.K., Ramirez, M.S., Lee,
Jaehyuk., Kingsley, C.V., Sananikone, E.F., Rajapakshe, K., Naff, K., ParkerThornburg, J., Bankson, J.A., Tsai, K.Y., Gunaratne, P.H. and Flores, E.R. IAPP
driven metabolic reprogramming induces regression of p53-deficient tumors in vivo.
Nature. 2015; 517(7536),626-630. doi:10.1038/nature13910.

Copyright permission not required since Nature journal policy states “Author retains
the copyright to the published materials”
2.1. Generation of ΔNp73 Conditional Knockout Mice
The cre-loxP strategy was used to generate the ΔNp73 conditional knockout allele
(ΔNp73fl). Genomic p73 DNA from intron 3 to intron 3’ was amplified from BAC
clone DNA (BAC RP23-186N8, Children's Hospital Oakland Research Institute).
LoxP sites flanking exon 3’ of p73 and neomycin (neo) gene flanked by frt sites
inserted in intron 3’ were cloned into pL253(103). Mouse embryonic stem cells (G4)
electroporated with the targeting vector were analyzed by Southern blot analysis for
proper targeting of the ΔNp73 allele. Resulting chimeras were mated with C57BL/6
albino females and genotyped as described below. Mice with germ line transmission
of the targeted allele (conditional, flox neo allele, fn) were crossed to the FLPeR
mice to delete the neo cassette. Resulting progeny were intercrossed with Zp3-Cre
(C57BL/6) transgenic mice(104). ΔNp73fl/+; Zp3-Cre females were mated with
C57BL/6 males to generate ΔNp73+/- mice. The ΔNp73+/- mice were intercrossed
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to generate ΔNp73-/- mice. Compound mutant mice were generated by intercrossing
the ΔNp63+/- and ΔNp63fl/fl(52) and the ΔNp73-/- and ΔNp73fl/fl mice with the p53/- mice(22). All procedures were approved by the IACUC at U.T. M.D. Anderson
Cancer Center.
2.2. Genotyping
Genomic DNA from tail biopsies was genotyped by Southern blot analysis by
digesting genomic DNA with AflII and HindIII or by PCR using the following primers
and annealing temperatures: 1) for wild-type: wt-F, 5'- ACAGTCCTCTGCTTTCAGC3' and wt-R (fl-R), 5'- CACACAGCA CTGGCCTTGC -3’, annealing temp: 58°C, 2)
for ∆Np73flox: fl-F, 5' – CATAGCCATGGGCTCTCCT - 3' and fl-R (wt-R), 5'–
TGTCCTGCTGCTGGTTGTAT- 3', annealing temp: 63°C, 3) ΔNp73floxneo: flneo-F,
5’-GGGAGGATTGGGAAGACAAT-3’

and

flneo-R,

5’-

TGTCCTGCTGCTGGTTGTAT-3’ annealing temp:600C and 4) for ∆Np73KO: ko-F,
5’- CCTAGCCCAAGCATACTGGT-3’ and wt-R, 5’-TGTCCTGCTGCTGGTTGTAT-3’
annealing temp: 58°C. Primers used to genotype for the Cre gene are as follows:
Cre-F,

5'–TGGGCGGCATGGTGCAAGTT-3'

and

Cre-R,

5'–

CGGTGCTAACCAGCGTTTTC-3', annealing temp: 60° C. The primers for
ΔNp63WT, ΔNp63KO, ΔNp63flox and p53 were previously described(52, 105).
2.3. Cell Lines
Mouse embryonic fibroblasts (MEFs) for the indicated genotypes were generated as
described previously(63). Human lung adenocarcinoma cells (H1299), colorectal
adenocarcinoma cells (SW-480) and breast adenocarcinoma cells (MDA-MB-468)
were purchased from ATCC and cutaneous SCC cell lines (SRB12, COLO16) were
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a gift from Dr. K. Y. Tsai. The MEF’s, SW-480 and MDA-MB-468 cells were cultured
in DMEM (Cellgro) and H1299 cell lines were cultured in RPMI 1640 (Cellgro). The
SRB12 and COLO16(106) cell lines were grown in DMEM/Ham’s F12 50/50
(Cellgro). All cell lines used in the study tested negative for mycoplasma.
2.4. Immunhistochemistry
Mice thymic lymphomas or thymii were dissected, fixed in 10% formalin, and
embedded in paraffin.

Sections were dewaxed in xylene and re-hydrated using

decreasing concentrations of ethanol. Antigens were unmasked in citrate buffer
unmasking solution (Vector Laboratory) followed by incubation with blocking
solution, and 18 hour incubation at 40C with the following antibodies: cleaved
caspase 3 (1:200)(Cell Signaling), PCNA (1:500)(Cell Signaling), malondialdehyde
(1:50)(Abcam). Visualization was performed using the ImmPact DAB peroxidase
substrate kit (SK4105, Vector Laboratories) and counter-stained with Hematoxylin
(H-3401, Vector Laboratories). The slides were mounted using VectaMount (H-5000,
Vector Laboratories). Images were acquired using a Zeiss Axio microscope and
analyzed with ProgRes Capture Pro 4.5 software.
2.5. SA-β-gal staining
SA-β-gal staining on mouse thymic lymphoma was performed as described
previously(19).
2.6. Quantitative real time PCR
Total RNA was prepared from MEFs or mouse tissues using TRIzol reagent
(Invitrogen)(50, 65, 107). cDNA was synthesized from 5mg of total RNA using the
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SuperScript®

III

First-Strand

Synthesis

Kit

(Invitrogen)

according

to

the

manufacturer’s protocol followed by qRT PCR using the SYBR Fast qPCR master
mix (Kapa Biosystems). qRT-PCR was performed using a ABI 7500 Fast Real-time
PCR machine. Primers for mouse TAp63, ΔNp63, PUMA, Noxa, bax, PML, p16 and
p21(50, 65) and human TAp63, ΔNp63 and GAPDH were used as described
previously (66, 68). Human primers for PUMA, Noxa, bax, PML, p16, p21 were used
as described previously(19) and GLS2 and TIGAR as described previously. Mouse
primers for TAp73 are FOR:5’- GCACCTACTTTGACCTCCCC-3’, REV: 5’GCACTGCTGAGCAAATTGAAC-3’,

ΔNp73

are

FOR:

5’-

ATGCTTTACGTCGGTGACCC-3’, REV: 5’-GCACTGCTGAGCAAATTGGAAC-3’,
IAPP

are

FOR:

5’-

CTCCAAACTGCCATCTGAGGG-3’,

CGTTTGTCCATCTGAGGGTT-3’.

REV:

5’-

Human primers used for TAp73 are FOR: 5’-

CAGACAGCACCTACTTCGACCTT-3’, REV: 5’-CCGCCCACCACCTCATTA-3’ and
for

ΔNp73

are

FOR:

5’-

TTCAGCCAGTTGACAGAACTAAG-3’,

REV:

5’-

GGCCGTTTGTTGGCATTT-3’.
2.7. Western blot analysis
Fifty micrograms of protein were electrophoresed on a 10% or 15% SDS PAGE and
transferred to PVDF membrane as described previously(50, 65, 107). Blots were
probed with anti-p63 (1:500) (4A4, Santa Cruz), anti-TAp63 (1:1000) (BioLegend),
anti-TAp73 (1:500)(IMG-246, Imgenex), anti-p73 (Mouse) (1:250)(IMG-259A,
Imgenex),

anti-p73

(1:1000)

(human)

(EP436Y,

Abcam),

anti-p53

(WT)

(1:1000)(CM5, Vector Labs), anti-IAPP (1:1000)(ab103580, Abcam), anti-His
(1:1000)(G18, Santa Cruz), anti-Hexokinase II (1:10000)(C64G5, Cell Signaling),
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anti-calcitonin receptor (1:1000)(ab11042, Abcam), RAMP3(1:1000)(H125, Santa
Cruz), and cleaved caspase 3 (1:1000)(Asp 175, Cell Signaling), at 4oC for 18 hours
followed by incubation for one hour at room temperature with the appropriate
secondary antibodies conjugated to horseradish peroxidase (1:5000)(Jackson Lab).
b-actin (Sigma 1:5000) was used as a loading control. Detection was performed
using the ECL Plus Kit (Amersham) following the manufacturer’s protocol and x-ray
autoradiography.
2.8. Characterization of thymus using flow cytometry
Thymii from 4 week old mice and thymic lymphomas from 10 week old mice were
collected 48 hours after adenovirus infection. Single cells were obtained by
homogenizing the thymii through a 0.75 mM filter. Cells were stained with CD3-PE
(145-2C11), CD4-PerCP-Cy5.5 (RM4-5), CD8-APC (53-6.7), CD45-FITC (30F11)(BDPharmingen), AnnexinV-Pacific Blue (A35122, Life Technologies), and 7AAD (V35124, Invitrogen) and sorted using a BD Aria Cell Sorter or analyzed using
the LSR Fortessa Cell Analyzer and FlowJo software.
2.9. Chromatin Immunoprecipitation (ChIP)
MEFs were grown to near confluence at passage 2 on DMEM media with 10%
serum as previously described(63). Thymocytes from 6-week-old mice were
collected 48 hours after adenovirus infection. Cellular proteins were cross-linked to
DNA using 1% formaldehyde and chromatin was prepared as described
previously(50, 65, 107). TAp63 and ∆Np63 ChIP analysis was performed using a
pan-p63 antibody (4A4, Santa Cruz) as described previously and the TAp73 ChIP
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was performed using a TAp73 antibody (ab14430, Abcam) and ∆Np73 ChIP was
performed using a p73 antibody (IMG 259A, Imgenex). Putative TAp63 and TAp73
binding sites were scanned 3000bp upstream of the 5’UTR and in intron 1 of the
IAPP gene (NCBI Reference Sequence: NC_000072.5). qRT–PCR was performed
by using primers specific for the indicated regions of the IAPP promoter: Site 1 (406) -forward 5’-GTACATGAGGCTTGCTAAAGGC-3’ and (-329) -reverse 5’AGACCACAGAAAGCTCCCTC-3’,
5’GCACAGAGTTGTTGCT-3’

Site
and

2

(+842)

(+761)-forward
–

reverse

5’-

CACACATGCAATGACAAACATTCT-3’, and non-specific site (+74911)- forward 5’GGTGGCTCCTGTAGTATGTCT-3’

and

ACATCTCTAACAGCAAGAGACTCC-3’.

(+75011)

-

reverse

5’-

Similarly, putative ΔNp63 and ΔNp73

binding sites were scanned 10000 bp upstream of the 5’UTR and in intron 1 of
TAp63 and TAp73. qRT-PCR was performed by using the primers specific for the
indicated

regions

on

the

TAp63

promoter:

CAGGAGCTCTCAAATCAAGTCAGA-3’

Site

and

1

(-41)

(+37)

–forward

–reverse

5’5’-

ATCACAGAAGCCAGGACTTGTCAC-3’ , and non-specific site (-3030) - forward 5’GCTATAAATGTTTCCATGTGATGGATTGC-3’

and

(-2973)

-

reverse

5’-

TGCAGACTTAGCTATGGTCTCTTG-3’. Similarly, qRT-PCR was performed using
the primers specific for the indicated regions on the TAp73 promoter: Site 1 (-1103)
–forward 5’- CTAGCACACCAATCCAAGGAAAGA and (-1059) –reverse 5’GCCTGCAGTCCGGGTTT-3’

and

non-specific

5’ACTAGACCTCTGTACTTGTGAACATACATTT-3’
GCACTCTCAFFATCCTGTAACAAAA-3’.
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site
and

(-2488)

(-2382)

–forward

–reverse

5’-

2.10. Dual luciferase reporter assay
Luciferase assays were performed using p53-/-;p63-/- and p53-/-;p73-/- MEFs
as described previously(69). To generate the luciferase reporter gene (pGL3-IAPP),
the DNA fragment containing the TAp63/TAp73-binding site identified by ChIP was
amplified from C57BL/6 genomic DNA by PCR with the following primers containing
5’

XhoI

and

3’

HindIII

cloning

restriction

enzyme

sites:

ATACTCGAGGCACATCTAAGTTCATGAAGTGG-3’(forward)

IAPP

and

5’5’-

ATAAAGCTTAGTTAACTCCTCAGTGGCCTTG-3’ (reverse). Similarly, a mutant
version of the luciferase reporter gene (pGL3-IAPPMut) was generated using
QuikChange
instructions.

Lightning

(Agilent
The

Technologies)

following

following

the

manufacturer’s

primers

5’

CATGAAGTGGGCAATTATAAAAGTACATCAGGGTTGCTAAAGGCTTTT3’(forward)

and

5’-

AAAAGCCTTTAGCAACCCTGATGTACTTTTATAATTGCCCACTTCATG3’(reverse) were used to generate the mutant version.
2.11. Reverse Transfection
Cells were transfected with 50 nM siΔNp63 (SASI_Hs02 00328367)(Mission
siRNA, Sigma), siΔNp73 (SASI_Hs02_00326884)(Mission siRNA, Sigma), siTAp63
(SASI_Hs01_00246771) (Mission siRNA, Sigma), siTAp73 (SASI_Hs02_00339573)
(Mission siRNA, Sigma), siRAMP3 (SASI_Hs01_00199036)(Mission siRNA, Sigma),
siCalcitonin receptor (SASI_Hs01_00077738)(Mission siRNA, Sigma), siIAPP
(SASI_Hs01_00183962) (Mission siRNA, Sigma) or siNT(SIC_001)(Mission siRNA,
Sigma) using Lipofectamine RNAiMAX (Invitrogen). The mixture of siRNA and
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Lipofectamine were combined together and added to the well followed by the
addition of 200,000 cells/well in a 6-well dish.
2.12. Transfections - Generation of IAPP and Hexokinase II expressing cells
3x105cells were plated in 10cm dishes. MEFs and human cancer cells were
transfected with 8 mg Myc-DDK-IAPP (RC215074)(Origene) or 3.3mg HKII (Plasmid
#25529)(Addgene) using X-tremeGENE HP (Roche) and incubated for 48-60hrs.
Cells were selected with G418, MEFs (350mg/ml) and human cancer cells
(500mg/ml) for a period of 9 days.
2.13. Secreted IAPP Protein concentration
Twelve hours after knockdown of ΔNp63/ΔNp73 in human cancer cells, fresh
serum free media was added to the cells. Following a sixty-hour incubation, the
media was collected and concentrated using Amicon Ultra-15 Centrifugal Filter Units
(UFC901008, EMD Millipore).
2.14. RNA Sequencing and Analysis
Five µg of polyA+ RNA were used to construct RNA-Seq libraries using the
standard Illumina protocol. Mouse mRNA sequencing yielded 30-40 million read
pairs for each sample. The mouse mRNA-Seq reads were mapped using
TopHat(108) onto the mouse genome and build UCSC mm9 (NCBI 37) and the
RefSeq mouse genes. Gene expression and gene expression differences were
computed using Cufflinks(108). For each species, a combined profile of all samples
was computed; mRNA abundance was mean-centered and Z-score transformed for
each mRNA individually. Principal component analysis was executed using the
implementation within the R statistical analysis system. Hierarchical clustering of
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samples was executed by first computing the symmetrical sample distance matrix
using the Pearson correlation between mRNA profiles as a metric, supervised
sample analysis was performed using the t-test statistics, and heatmaps were
generated using the heatmap.2 package in R. For gene signatures and pathway
analysis gene list from the RNA-Seq comparing ΔNfl/fl;p53-/- versus ΔNp63Δ/Δ;p53/- and ΔNp73Δ/Δ;p53-/- were obtained at a p-value <0.01. The genes upregulated in
the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- and down regulated in the ΔNfl/fl;p53-/were selected. The relative fold change of the genes were calculated and sorted
from highest to lowest. Genes with a greater than 1.5 fold-increase were selected
and run through the Ingenuity Pathway Analysis (IPA) (Ingenuity Systems) to screen
for pathways and processes. Genes from the selected pathways were crossreferenced with the Gene Set Enrichment (GSEA)(Broad Institute) data analysis,
DAVID Bioinformatics Resource 6.7 and GSEA implementation at the Molecular
Signature Database (MSigD)(109).
2.15. Magnetic Resonance Imaging
MRI imaging was performed at 10 weeks of age when the tumours were
established and the volumes range from 2.3 mm3 to 5 mm3. To reduce the variation
between different groups of mice, a cohort of n=5 with similar tumour volumes was
established and tumors regression was monitored by MRI. All mice were scanned
once a week for a period of 35 weeks on a 7-Tesla, 30-cm bore BioSpec MRI
system (Bruker Biospin Corp., Billerica, MA) .
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2.16. Hyperpolarized Magnetic Resonance Spectroscopy
Dynamic MR spectroscopy (MRS) of hyperpolarized (HP) [1-13C] pyruvate
was performed in vivo in tumour bearing mice. To achieve polarization, a 26-mg
sample of pyruvic acid (Sigma-Aldrich, St. Louis, MO) with 15 mM of OX063 radical
(GE Healthcare, Waukesha, WI) and 1.5-mM Prohance (Bracco Diagnostics Inc.,
Monroe Township, NJ) was polarized in a HyperSense DNP system (Oxford
Instruments, Abington, Oxfordshire, UK) as previously described(110, 111). The
frozen sample was dissolved in a 4-mL buffer containing 40-mM TRIS, 80-mM
NaOH, and 50-mM NaCl, resulting in a final isotonic and neutral solution containing
80-mM [1-13C] pyruvate. A dual-tuned 1H/13C linear RF volume coil with 72mm ID
was used in conjunction with imaging gradients with 12cm ID.

For anatomic

imaging, the 1H channel was used in transmit/receive mode. In addition to localizing
scans, flow-weighted oblique gradient echo images (TE = 1.4ms; TR = 55ms; 90°
excitation; 3cm x 3cm FOV encoded over a 64 x 64 image matrix) were acquired to
confirm that the slice prescription for 13C measurements would not be obfuscated
by signals originating from within the heart. For carbon spectroscopy, the RF volume
coil was used in transmit-only mode in conjunction with a custom-built 15-mm ID

13

C

surface coil for signal reception. After dissolution, 200 µL of the HP [1-13C] pyruvate
solution was administered to the animals via tail-vein catheter. A slice-selective
pulse-acquire sequence (TR = 1,500 ms; 15° flip angle; 5 KHz spectral bandwidth;
2048 spectral points; 8-mm oblique slab; 120 repetitions) was used for dynamic
spectroscopy beginning approximately 15s prior to injection. Data were processed
to generate spectral time-courses of the HP-pyruvate and its lactate product.
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Spectra were phase adjusted and the area under the spectral peaks associated with
[1-13C] pyruvate and [1-13C] lactate were integrated over time to reflect the overall
signal observed from each metabolite over the course of the measurement. Total
lactate signal, which could only arise from interaction of HP pyruvate with relevant
metabolic enzymes, was normalized to the total signal from pyruvate.
2.17. Glycolysis Stress Assay
Extra-cellular acidification rate (ECAR) was measured using the extracellular
flux analyzer (SeaHorse Bioscience XF96) following the manufacturer’s instructions.
Forty-eight hours after transfection, the cells were plated at a density of 1.5x104 cells
per well in the XF 96-well cell culture plates. Twenty-four hours after seeding, the
culture medium was replaced with 180 ml of running medium and incubated for 1
hour at 370C in a non-CO2 incubator. Before calibration, 20 ml of 50 mM glucose, 11
mM oligomycin and 650 mM 2-DG were aliquoted into each port in the sensor
cartridge. ECAR was measured after the addition of glucose and oligomycin and
before the addition of 2-DG. Extra-cellular acidification rate was normalized to
mpH/min.
2.18. Glucose Uptake Measurement
Glucose uptake was calculated as a measure of glucose dependent proton
secretion from the maximum and basal glucose consumption after addition of 20 ml
of 50 mM glucose and measured using the extracellular flux analyzer (SeaHorse
Biosciences XF96).
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2.19. Glucose-6-phosphate Assay
Glucose-6-phosphate was measured using the Glucose-6-phosphate assay
kit (ab83426, Abcam) following the manufacturer’s instructions. Forty-eight hours
after transfection, 2x106 cells were collected, homogenized and passed through a 10
kD spin-column filter. The eluate was collected and glucose-6-phosphate enzyme
and substrate reaction was performed for 30 min and absorbance was measured at
450nm.
2.20. Proliferation Assay
The transfected human cancer cells were plated at a density of 5x103 cells in
6 replicates in a 96-well dish. Twelve hours later, the cells were labeled with 10 mM
EdU (5’-ethynyl-2’-deoxyuridine) for a period of 8 hours. The assay was performed
using the Click-iT EdU microplate assay (Invitrogen). Images were obtained using a
Zeiss Axio fluorescent microscope and analyzed using the AxioVision Image 4.5
software.
2.21. Apoptosis Assay
Cells were plated at a density of 1x104 cells in 6 replicates in a 96-well dish.
Twelve hours later, the cells were washed with 1X Annexin binding buffer and a
cocktail of 5ml Annexin V-Alexa Fluor 488 for 100mg/ml propidium iodide (PI) and
2mg/ml Hoechst 33342 (Invitrogen) was added. Images were captured using the
Zeiss fluorescent microscope and Axiovision Image 4.5 software. Quantification of
the percent apoptosis was obtained using a high-throughput immunofluorescence
plate reader (Celigo).
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2.22. ROS Assay
Cells were plated at a density of 1x104 cells in 6 replicates in 96-well dish.
Twelve hours later, the cells were incubated with a cocktail of 5 mM concentration of
CellROX Deep Red Reagent (C10422, Invitrogen) and 2 mg/ml Hoechst
33342(Invitrogen) for 45 minutes at 37oC. Images were captured using a Zeiss
fluorescent microscope and Axiovision Image 4.5 software. Quantification of the
percent ROS was obtained using a high-throughput immunofluorescence plate
reader (Celigo)(112).
2.23. In vitro Adeno-Cre Infection
ΔNp63fl/fl;p53-/- and ΔNp73fl/flp53-/- MEFs were plated at a density of
2.5x105 cells in 10 cm dishes before infection. Twelve hours later, MEFs were
infected with Adeno-CMV-mCherry or Adeno-CMV-Cre-mCherry (Gene Transfer
Vector Core Facility, University of Iowa). The cells were infected at an MOI of 6000
particles/cell. The efficiency of infection was quantified by assessing mCherry
positive cells.
2.24. In vivo Adeno-virus Infection and IVIS Lumina Imaging
All mice were anesthetized using isoflurane and 2% oxygen and placed on a
custom bed. An incision was performed to expose the sternum. Using a 28.5G U100
Insulin syringe, Adeno-mCherry/Adeno-Cre-mCherry (Gene Transfer Vector Core
Facility, University of Iowa), Adeno-IAPP-mCherry(Vector Labs) or Adeno-shIAPPU6-mCherry (TRCN0000416196, Mission shRNA)(Vector Labs) was surgically
administered by intra-thymic injection (5x1012 viral particles/gram of body weight)
through the 2nd and 3rd sternum. The incision was sealed using wound clips and
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mice were allowed to recover.

To determine the efficiency of the in vivo viral

delivery to the thymic lymphoma, IVIS Lumina Imaging (Perkin Elmer) was
performed 48 hours later. Images were captured using a Mid-600 series bandwidth
filter and analyzed using the Living Image® data analysis software.
2.25. shRNA Knockdown
shRNA plasmids for TAp63 (Clone ID: V3LMM_508694) and TAp73 (Clone
ID: V3LMM_438557) were obtained from the MD Anderson shRNA core facility
(Open Biosystems). 293T cells were plated at a density of 2.5 x 105 cells in 10 cm
dishes. Three micrograms of shRNA and packaging vectors were transfected as
described previously. Cells were selected using puromycin (3 mg/ml) for 7 days.
2.26. In vitro and in vivo administration of 2-Deoxy-D-glucose
1x104 cells were plated in 6 replicate wells in a 96-well dish. Twelve hours
later, the human cancer cells were treated with 50 mM final concentration of 2Deoxy-D-glucose (2-DG) (D8375-5G, Sigma) for 1 hour. Similarly, 2-DG (500 mg/kg
of tumour weight)(D8375-5G-Sigma) was administered directly into the lymphoma of
mice as described earlier(110).
2.27. N-acetyl-L-cysteine treatment
1x104 cells were plated in 6 replicate wells in a 96-well dish. Twelve hours
later, cells were treated with N-acetyl-L-cysteine (NAC) (2 mM)(A8199, Sigma) final
concentration for a period of 1 hour.
2.28. Amylin and caspase inhibitor treatment
2x105 cells were plated in triplicate in a 6-well dish. Twelve hours later, cells
were treated with Amylin peptide (5mM) (A5972, Sigma) or with a Caspase 1
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inhibitor (20mM)(Z-YVAD-FMK-218746, Calbiochem) for a period of 48 hours.
2.29. In vitro and in vivo administration of Pramlintide Acetate
2x105 cells were plated in duplicate in a 6-well dish. Twelve hours later, cells
were treated with 10 mg/ml Pramlintide acetate (AMYLIN Pharmaceuticals) or
placebo for a period of 48 hours. Pramlintide acetate (AMYLIN Pharmaceuticals) or
placebo (sodium acetate/acetic acid) was surgically administered through noninvasive intra-thymic injection using a multiple dose protocol of Pramlintide acetate
(30 mg/gram of tumour weight).

One injection per week for three weeks was

administered directly into the thymic lymphoma of the animal. Another cohort of mice
was treated bi-weekly for 3 weeks by intra-venous (I.V.) tail-vein injection of
Pramlintide acetate (45 mg/kg body weight) or placebo. The investigator was blinded
to the treatment administered to each mouse. Tumour volumes were monitored
weekly by MRI.

Health and blood glucose levels of the treated animals were

monitored weekly.
2.30. In vitro and In vivo administration of Calcitonin receptor antagonist
2x105 cells were plated in duplicate in a 6-well dish. Twelve hours later, cells
were treated with Calcitonin receptor antagonist (1 nM)(AC187, Tocris Bioscience)
for a period of 48 hours with or without simultaneous Pramlintide treatment.
Similarly, a chronic dose of Calcitonin receptor antagonist (1 nM/gram of tumour
weight) was administered through non-invasive intra-thymic injections with one
injection every week for a period of three weeks with or without simultaneous
Pramlintide treatment. Tumour volume was monitored and measured weekly by
MRI.
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2.31. Survival Analysis
Survival analysis was conducted for the IAPP, RAMP3 and CalCR gene in the
following datasets: the Memorial Sloan Kettering Cancer Center and the TCGA
Cancer cohort. We considered four major cancer types with high p53 mutation rates,
which include lung squamous cell carcinoma(113), head & neck squamous cell
cancer(114), basal breast cancer(115), and colon cancer(116). The co-expression of
the three genes was analyzed in cases only with p53-mutation. In all cases, we
considered gene expression changes above or below 2 standard deviations with
respect to the normal controls. The log-rank test and Cox P test was used to assess
significance between the samples with or without expression changes of the IAPP,
RAMP3 and CalCR gene using the cBioPortal for cancer genomics(117).
2.32. Statistics
Sample size for mouse cohorts in each experiment was chosen based on the
penetrance of the thymic lymphoma phenotype of the p53-/- mouse model (80%).
Twenty to thirty mice were used for survival analyses. Data were analysed using a
one-way ANOVA test or a Student’s t-test (two-sided) was used for comparison
between two groups of data. A p-value of 0.05 was considered significant. Data are
represented as mean ± s.e.m.
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3. Chapter 3: ΔNp63 and ΔNp73 function as oncogenes in a p53-deficient
model of thymic lymphoma
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Chapter 3. ΔNp63 and ΔNp73 function as oncogenes in a p53-deficient model
of thymic lymphoma
Contents of this chapter is based on Venkatanarayan, A., Raulji, P., Norton, W.,
Chakravarti, D., Coarfa, C., Su, Xiaohua., Sandur, S.K., Ramirez, M.S., Lee,
Jaehyuk., Kingsley, C.V., Sananikone, E.F., Rajapakshe, K., Naff, K., ParkerThornburg, J., Bankson, J.A., Tsai, K.Y., Gunaratne, P.H. and Flores, E.R. IAPP
driven metabolic reprogramming induces regression of p53-deficient tumors in vivo.
Nature. 2015; 517(7536),626-630. doi:10.1038/nature13910.

Copyright permission not required since Nature journal policy states “Author retains
the copyright to the published materials”
3.1. Introduction & Rationale
Most human cancers harbor inactivating or gain of function mutations in the
p53 tumor suppressor gene(118).

In order to develop a better therapeutic

alternative to treat these human cancers with p53 mutation, we explored the role of
the p53-family members p63 and p73(119). However, the function of p63 and p73 is
complex due to the presence of multiple splicing isoforms, namely the TA and ΔN
isoforms(45). Previous research work has demonstrated that both TAp63 and TAp73
function as bonafide tumor suppressors(65, 120). However, the role of the ΔN
isoforms has been controversial due to its dominant negative functions(60). Both
ΔNp63 and ΔNp73 function as dominant negative inhibitors of p53, TAp63 and
TAp73. In vitro experiments suggest that ΔNp63 and ΔNp73 could function both as
tumor suppressors and oncogenes(72, 121). Hence, to determine the role of the ΔN
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isoforms of p63 and p73 in tumorigenesis, we generated conditional knockout
mouse models for ΔNp63 (ΔNp63fl/fl)(74) and ΔNp73 (ΔNp73fl/fl)(74). These mice
were further crossed to a Zp3 transgenic mouse to generate a ΔNp63+/-(52) and a
ΔNp73-/- (74)compound mouse.
To further accelerate tumorigenesis and also understand the role of ΔNp63
and ΔNp73 in the context of p53 deficiency, I crossed the ΔNp63+/- mice to the p53null mice and generated a ΔNp63+/-;p53-/- mice cohort and similarly, the ΔNp73-/mice were crossed to the p53-null mice to generate a ΔNp73-/-;p53-/- mice. In this
chapter, I further characterize the tumor spectrum obtained from these double
mutant compound mice. I also investigate the response of these double mutant
compound mice in response to genotoxic stress. Finally, I perform an acute deletion
of the ΔN isoforms in the p53-deficient thymic lymphomas in vivo to determine the
mechanistic function of the ΔN isoforms of p63 and p73 and also the interplay
among the p63 and p73 isoforms in cancer.

3.2. Results
3.2.1. ΔNp63 and p53 or ΔNp73 and p53 double deficient compound mice have
reduced thymic lymphomagenesis
A cohort of ΔNp63+/-;p53-/- (n=30) and ΔNp73-/-;p53-/- (n=30) mice were
generated along with a cohort of p53-/- mice (n=30). I observed that the mice double
deficient for ΔNp63 and p53 or ΔNp73 and p53 had a significant reduction in the
thymic lymphomagenesis compared to the p53-/- mice (Figure 5a). The ΔNp63+/	
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Figure 5: Decreased thymic lymphomagenesis and increased survival in mice
double deficient for ∆Np63 and p53 or ∆Np73 and p53. Quantification of thymic
lymphoma incidence (n=30 mice) (a). Table showing thymic lymphoma volumes.
The difference in tumour volumes between p53-/- and ∆Np63+/-;p53-/- and p53-/and ∆Np73-/-;p53-/- was statistically significant with p values of <0.03 and <0.002
respectively (b). Kaplan Meier survival in mice (c). Boxed numbers indicate median
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survival. Western blot analysis of thymic lymphomas of the indicated genotypes.
Arrows indicate specific isoforms. Asterisks indicate non-specific bands (d & e).
Q-RT PCR for PUMA (f), Noxa (g), and bax (h) in thymic lymphomas of the
indicated genotypes, n=4, p<0.005.

Immunohistochemistry (IHC) for cleaved

caspase 3 in thymic lymphomas (i). Quantification of apoptosis as assessed by
cleaved caspase 3 staining (j), n=20 fields of 3 biological replicates, p<0.005. Q-RT
PCR for PML (k), p16 (l), and p21 (m) in indicated thymic lymphomas, n=4, p<0.005.
IHC for PCNA in indicated thymic lymphomas (n). Quantification of the percentage
of proliferation as assessed by PCNA staining (o), n=20 fields of 3 biological
replicates, p<0.005. Statistical significance indicated by black asterisks.
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;p53-/- mice had a tumor incidence of 29.7% and the ΔNp73-/-;p53-/- mice had a
tumor incidence of 63.3% compared to the p53-/- mice which develop thymic
lymphomas at a 90% incidence rate. Importantly, I also observed significant
differences in the tumor volumes between the double deficient compound mice
compared to the p53-null mice (Figure 5b). The thymic lymphomas from the
ΔNp63+/-;p53-/- mice measured 2.8mm3 and the ΔNp73-/-;p53-/- mice measured
1.3mm3 in volume compared to the p53-/- mice that measured 3.4mm3 in volume.
Interestingly, I also observed that the double deficient compound mice (ΔNp63+/;p53-/- and ΔNp73-/-;p53-/-) mice had increased survival compared to the p53-null
mice which normally die by 4 months of age (Figure 5c). Thus, the in vivo analysis
from the double deficient mouse cohorts suggests that ΔNp63 and ΔNp73 could
have oncogenic roles in p53-deficent thymic lymphomas.
To further characterize the phenotype of reduced thymic lymphoma incidence
and decreased tumor volume in the double deficient compound mice, thymic
lymphoma tissues from the double deficient compound mice (ΔNp63+/-;p53-/- and
ΔNp73-/-;p53-/-) and p53-null mice were collected to perform western blot analysis,
quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC). Western
blot analysis (Figure 5d-e) of the thymic lymphoma tissues from the ΔNp63+/-;p53-/and ΔNp73-/-;p53-/- mice had increased expression of full-length isoforms of p63
and p73, namely TAp63 and TAp73 compared to the p53-/- thymic lymphoma
samples. This suggests that loss of ΔN isoforms of p63 and p73, results in the
activation or upregulation of TAp63 and TAp73 in the thymic lymphoma tissues.
Since, TAp63 and TAp73 are tumor suppressors(65, 120), I hypothesized that
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TAp63 and TAp73 could function to mediate the reduced thymic lymphomagenesis
in these double deficient mice. Indeed, qRT-PCR analysis of the double deficient
thymic lymphoma tissues revealed a significant upregulation of the genes involved in
apoptosis like PUMA, Noxa and BAX (Figure 5f-h). This correlated with an increase
in apoptosis in the double deficient lymphomas compared to the p53-null lymphomas
as demonstrated by immunohistochemistry (Figure 5i-j). Also, cell-cycle arrest
targets, namely, p16, p21 and PML were also upregulated in the double deficient
thymic lymphomas compared to the p53-null lymphoma tissues (Figure 5k-m). This
correlated with reduced proliferation in the double deficient lymphomas compared to
the p53-null lymphoma tissues (Figure 5n-o). This suggests that upon loss of ΔNp63
and ΔNp73 in p53-deficient lymphomas, TA isoforms of p63 and p73 are
upregulated and compensate for p53-loss of function by activating downstream
apoptosis and cell cycle targets mediating tumor regression.
3.2.2. Increased apoptosis and cell-cycle arrest in the ΔNp63+/-;p53-/- and
ΔNp73-/-;p53-/- thymocytes after genotoxic stress
TAp63 and TAp73 are tumor suppressors that are usually activated in
response to genotoxic stress and DNA damage(63). Hence, to determine whether
TAp63 and TAp73 induce apoptosis and cell cycle arrest in the double deficient
thymus tissues, 4 week-old mice were treated with 10Gy gamma radiation, a dose
that was previously demonstrated to induce a p53-dependent response. The double
deficient thymocytes had an increased expression of TAp63 and TAp73 after DNA
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Figure 6: Increased apoptosis and cell cycle arrest in ∆Np63+/-;p53-/∆Np73-/-;p53-/- thymocytes after genotoxic stress.

and

Western blot analysis in

thymocytes derived from mice 6 hours after treatment with 0 Gy or 10Gy gamma
irradiation (a). Q-RT PCR for TAp63 (b), TAp73 (c), PUMA (d), Noxa (e), and bax
(f) from samples shown in (a), n=4, p<0.005. Q-RT-PCR normalized to samples
treated with 0 Gy. Immunohistochemistry (IHC) for cleaved caspase 3 in samples
from (a) (g). Quantification of the percentage of apoptosis as assessed by cleaved
caspase 3 staining (h), n=20 fields of 3 biological replicates, p<0.005. Q-RT PCR
for PML (i), p16 (j), and p21 (k) using total RNA from samples shown in (a), n=4,
p<0.005.
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Quantification of the

percentage of proliferation as assessed by PCNA staining (m), n=20 fields of 3
biological replicates, p<0.005. Statistical significance is indicated by black asterisks.
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damage compared to the p53-null thymocytes (Figure 6a-c). This correlated with the
increased relative expression of the apoptosis targets PUMA, Noxa and BAX (Figure
d-f) and increased cell death as denoted by the IHC (Figure g-h) in the double
deficient thymic lymphoma tissues compared to the p53-deficient lymphomas. Also,
increased relative expression of the cell cycle targets namely p16, p21 and PML
(Figure i-k) and reduced expression for cell proliferation (Figure l-m) was observed in
the double deficient thymic lymphoma tissues compared to the p53-null samples.
These data suggest that TAp63 and TAp73 are upregulated upon genotoxic stress
and can compensate for p53 function by activating apoptosis and cell cycle targets.
3.3.3. In vivo deletion of ΔNp63 or ΔNp73 in p53-deficient mice suppresses
thymic lymphomagenesis
Initial analysis utilizing the ΔNp63+/-;p53-/- and ΔNp73-/-;p53-/- have clearly
demonstrated that loss of ΔNp63 and ΔNp73 results in reduced thymic
lymphomagenesis in the p53-deficeint mice(74). Additionally, TAp63 and TAp73 are
upregulated in the double mutant thymic lymphoma and also upon genotoxic stress
in the double deficient mouse thymocytes. Hence to further test whether TAp63 and
TAp73 can compensate for p53-loss in suppressing lymphomagenesis, a cohort of
ΔNp63fl/fl;p53-/- and ΔNp73fl/fl;p53-/- mice were generated. These mice were aged
up to 10 weeks and the presence of the thymic lymphoma was determined using a
magnetic resonance imaging (MRI). Mice that have a tumor volume ranging from
2.5mm3 to 5.8mm3 were selected for further analysis. A cohort of ΔNp63fl/fl;p53-/-
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Figure 7: Acute deletion of ΔNp63 or ΔNp73 in p53-deficient thymic
lymphomas mediates tumor regression. IVIS Lumina imaging of thymic
lymphomas of mice of the indicated genotypes infected with Adenovirus (Ad)mCherry (a) or Ad-Cre-mCherry (b & c) at 10 weeks of age and 48 hours after
adenoviral delivery. Red fluorescence indicates viral delivery to the thymus shown
by the yellow dashed ovals.

Red fluorescence near the mouth is due to auto-

fluorescence of calcium and mineral deposits in the teeth. Magnetic Resonance
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Imaging (MRI) of thymic lymphomas of indicated mice (d-i). Tumour volume (mm3)
within each panel. UN-D = undetectable. Tumours indicated by the dashed yellow
line. Quantification of the indicated thymic lymphomas (j-l), n=9 mice. Kaplan Meier
curve (m), n=9, p<0.005. Boxed numbers represent median survival.
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and ΔNp73fl/fl;p53-/- mice were administered either adenovirus CRE (Ad-CRE) or
adenovirus-mCherry (Ad-mCherry) by intratumoral delivery. The intratumoral
adenovirus delivery localization only to the region of the lymphoma was validated by
IVIS lumina imaging (Figure 7a). The adenovirus CRE specifically deletes ΔNp63 or
ΔNp73 in the p53-deficient thymic lymphomas, generating a ΔNp63Δ/Δ;p53-/- or a
ΔNp73Δ/Δ;p53-/-

cohort.

Interestingly,

upon

administering

Ad-CRE

to

the

ΔNp63fl/fl;p53-/- and ΔNp73fl/fl;p53-/- thymic lymphomas, the mice had a significant
reduction in the thymic lymphomas as accessed by the MR images compared to the
ΔNfl/f;p53-/- mice administered with Ad-mCherry (Figure 7d-l). By 18 weeks, the
thymic lymphoma in the ΔNp63Δ/Δ;p53-/- (Figure 7e, h & k) and ΔNp73Δ/Δ;p53-/(Figure 7f, I & l) mice were undetectable while the ΔNfl/fl;p53-/- (Figure 7d, g & j)
while mice administered with Ad-mCherry had a significant tumor burden.
Importantly, the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- mice had significant survival
compared to the ΔNfl/fl;p53-/- mice which died by 18 weeks of age (Figure 7m).
In order to further characterize, the reduction in the thymic lymphoma upon
deletion of ΔNp63 or ΔNp73 in the p53-deficent mice, thymic lymphoma tissues from
the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- mice were collected 48 hours after
administering Ad-CRE. Since, most of the biological functions like apoptosis or cellcycle arrest occur transiently, I was interested in understanding the molecular
responses that could be activated after deleting ΔNp63 or ΔNp73 in the p53deficient thymic lymphomas. Interestingly, the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53/- thymic lymphoma tissues had increased expression of TAp63 and TAp73 after
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Figure 8: Loss of ΔNp63 or ΔNp73 in p53-deficient thymic lymphomas results
in upregulation of TAp63 and TAp73 with induction of apoptosis and cell cycle
arrest. Quantitative real time (qRT-PCR)

(a-d). n=4, p<0.005 and western blot

analysis using lysates from indicated thymic lymphomas 48 hours after infection with
Adenovirus (Ad)-mCherry or Ad-Cre-mCherry (e). Quantitative real time (qRT-PCR)
of thymic lymphomas 48 hours after infection with Ad-mCherry (∆Nfl/fl;p53-/-) or AdCre-mCherry

(∆Np63∆/∆;p53-/-

or

∆Np73∆/∆;p53-/-)

(f-g).

n=4,

p<0.005.	
  	
  

Immunohistochemistry (IHC) for cleaved caspase 3 in thymic lymphomas 48 hours
after infection with Ad-mCherry (∆Nfl/fl;p53-/-) or Ad-Cre-mCherry (∆Np63∆/∆;p53-/or ∆Np73∆/∆;p53-/-) (h). Quantification of apoptosis as assessed by cleaved
caspase 3 staining of the indicated thymic lymphomas (i), n=20 fields of 3 biological
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replicates, p<0.005. Q-RT-PCR of thymic lymphomas 48 hours after treatment with
Ad-mCherry (∆Nfl/fl;p53-/-) or Ad-Cre-mCherry (∆Np63∆/∆;p53-/- or ∆Np73∆/∆;p53-/), n=4, p<0.005 (j-k). Senescence associated beta galactosidase (SA-β-gal) staining
(blue) of thymic lymphomas 48 hours after treatment with Ad-mCherry (∆Nfl/fl;p53-/-)
or Ad-Cre-mCherry (∆Np63∆/∆;p53-/- or ∆Np73∆/∆;p53-/-) (l)
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deleting ΔNp63 and ΔNp73 compared to the ΔNfl/fl;p53-/- lymphoma tissues
administered with Ad-mCherry (Figure 8a-e). This suggests that TAp63 and TAp73
are activated upon loss of ΔNp63 and ΔNp73 in the p53-deficient thymic
lymphomas. Interestingly, the increased expression of TAp63 and TAp73 in the
ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- thymic lymphomas correlated with the
increased expression of the apoptosis targets PUMA, Noxa and BAX (Figure 8f-g)
and an increase in apoptosis (Figure 8h-i) compared to the ΔNfl/fl;p53-/- thymic
lymphomas. Similarly, increased expression of cell cycle targets p16, p21 and PML
(Figure 8j-k) and cellular senescence (Figure l) was observed in the ΔNp63Δ/Δ;p53/- and ΔNp73Δ/Δ;p53-/- thymic lymphomas. This data suggests that TAp63 and
TAp73 can compensate for p53-loss of function by activating apoptosis and cellcycle arrest targets mediating tumor shrinkage.
3.3.4. Loss of ΔNp63 and ΔNp73 in p53-deficient thymic lymphomas
accelerates tumor regression
Ablation of ΔNp63 or ΔNp73 in p53-deficient thymic lymphomas mediates
tumor regression(74). Importantly, the ΔNp63/ΔNp73 deleted p53-deficient mice
have increased survival compared to the p53-deficient mice. Hence, to test whether
deleting both ΔNp63 and ΔNp73 in the p53-deficient thymic lymphomas accelerates
the tumor regression a cohort of ΔNp63fl/fl;ΔNp73fl/fl;p53-/- mice was generated. At
10 weeks, MR imaging was performed to confirm the presence of a thymic
lymphoma. ΔNp63 and ΔNp73 was acutely deleted using adeno-CRE in the p53deficient thymic lymphomas. Loss of ΔNp63 and ΔNp73 in the p53-deficient thymic
lymphomas resulted in rapid reduction in the tumor volume (Figure 9a-t) and
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Figure 9:

Ablation of ΔNp63 and ΔNp73 in p53-deficient mice accelerates

tumor regression. Magnetic Resonance Imaging (MRI) of mice of the indicated
genotypes. (a-p) (n=4). Mice were administered with either Adeno-mCherry (a-d) or
Adeno-CRE-mCherry (e-p). Tumour volume (mm3) within each panel. UN-D =
undetectable.

Tumours indicated by the dashed yellow line.

Tumor volume

quantification of thymic lymphomas (q-t), n=4 mice. Kaplan Meier curve (n), n=4,
p<0.005. Boxed numbers represent median survival.
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Figure 10: Ablation of ΔNp63 and ΔNp73 in p53-deficient thymic lymphomas
results in accumulation of ROS, apoptosis and cell-cycle arrest. IHC panels of
the indicated genotypes representing staining for ROS, apoptosis and proliferation.
Brown nuclei represent positive cells
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Figure 11: Loss of ΔNp63/ΔNp73 in p53-deficient thymic lymphomas affects
the CD4-CD8 double positive cells. Flow cytometry plots of the indicated
thymocytes at 4-week of age (a-d). Bar graph showing quantification of CD4, CD8,
and CD4/CD8 double positive (DP) cells. n=3 mice per genotype, p<0.005 (e). Flow
Cytometry plots of thymic lymphoma cells 48 hours after adenovirus-mCherry or
adenovirus-CRE treatment for the indicated genotypes (f-h). Bar graph showing
quantification of CD4, CD8, and CD4/CD8 double positive (DP) cells in the indicated
genotypes. n=3 mice per genotype, p<0.005 (i). Cartoon representation of isolation
of CD45-postive thymic lymphoma cells from 10 week old mice of indicated
genotypes (j). Western blot analysis of CD45-postive thymic lymphoma cells after
treatment with Ad-mCherry (ΔNfl/fl;p53-/-) or Ad-CRE-mCherry (ΔNp63Δ/Δ/;p53-/and ΔNp73Δ/Δ;p53-/-) (k). Statistical significance is indicated by black asterisks.
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increased survival (Figure 9n). The tumor regression phenotype also correlated with
the increase in ROS, cell death and reduction in cell proliferation (Figure 10). This
suggests that targeting ΔN isoforms of p63 and p73 could be used as a viable option
to treat p53-deficient cancers.
3.3.5. Loss of ΔNp63 or ΔNp73 in p53-deficient thymic lymphomas affects the
CD4-CD8 double positive cells
The p53-deficient mice develop thymic lymphoma, which are of T-cell
origin(22). In order to test whether depletion of either ΔN isoforms of p63 and p73
affects the T cells development, a cohort of mice at 4 weeks was established. FACS
analysis with the mouse thymocytes was performed using CD3, CD4 and CD8
markers, which label the T-cell receptor complex, T-helper cells and T-lymphocytes
respectively. The ΔNp63+/-;p53-/- and ΔNp73-/-;p53-/- mouse thymocytes had
decreased number of CD4-CD8 double positive cells compared to the p53-deficient
and the wild-type mouse thymocytes (Figure 11a-e). This suggests that reduction in
the number of CD4-CD8 double positive cells correlates with the reduced tumor
volume and incidence in the double mutant compound mice. Hence, to test whether
this is the case, ΔNp63 and ΔNp73 were acutely deleted in the thymic lymphomas of
ΔNp63fl/fl;p53-/- and ΔNp73fl/fl;p53-/- mice. Upon analyzing the p53-deficient thymic
lymphoma cells, 48 hours after deletion of ΔNp63 or ΔNp73, I observed a significant
reduction in the CD4-CD8 positive cells compared to the ΔNfl/fl;p53-/- thymic
lymphoma cells (Figure 11f-i). This suggests that loss of ΔNp63 and ΔNp73 in the
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Figure 12: ΔNp63 and ΔNp73 transcriptionally repress TAp63 and TAp73.
Western blot analysis in ΔNp63fl/fl;p53-/- MEFs before (∆Np63fl/fl;p53-/-) and after
(∆Np63∆/∆;p53-/-) Ad-cre administration (a). Q-RT-PCR for ΔNp63 (b) and TAp63
(c)

in indicated MEFs. Western blot analysis in ΔNp73fl/fl;p53-/-

and

∆Np73∆/∆;p53-/- MEFs (d). Q-RT-PCR for ΔNp73 (e) and TAp73 (f) in indicated
MEFs. n=4, p<0.005. Q-RT-PCR of chromatin Immunoprecipitation using indicated
MEFs and an antibody for p63 (g) or p73 (h) n=3, p<0.005.
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Table 1: Table showing ΔNp63 and ΔNp73 binding sites on the TAp63 and
TAp73 promoter regions
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p53-deficient thymic lymphomas affects T-cell development, thereby preventing Tcell lymphoma formation.
Addtionally, to determine whether the stromal cells contribute to apoptosis in
the p53-deficient thymic lymphoma cells after depletion ΔNp63 and ΔNp73,
ΔNfl/fl;p53-/-, ΔNp63fl/fl;p53-/- and ΔNp73fl/f;p53-/- thymic lymphoma cells were
FACS sorted for CD45 marker to select for T-lymphocytes. T-Lymphocytes from the
indicated genotypes were infected with either Ad-CRE or Ad-mCherry (Figure 11j).
Upon, deleting either ΔNp63 or ΔNp73 in the p53-/- T-lymphocytes, I observed
increased expression of Caspase 3 compared to the ΔNfl/fl;p53-/- T-lymphocytes
(Figure 11k). This suggests that upon loss of ΔN isoforms of p63 and p73, TAp63
and TAp73 induce downstream apoptosis in the T-lymphocytes independently of the
stromal cell populations in the thymic lymphomas of the p53-deficient mice.
3.3.6. ΔN isoforms of p63 and p73 function as transcriptional repressors of
TAp63 and TAp73
ΔN isoforms function dominant negatively against p53, TAp63 and
TAp73(45). Also, ΔNp63 and ΔNp73 function as transcriptional factors activating or
repressing certain targets(69). Loss of ΔNp63 and ΔNp73 in the p53-deficient thymic
lymphomas resulted in the upregulation of tumor suppressive isoforms, namely
TAp63 and TAp73. Hence, to test whether this is the case, ΔNp63fl/fl;p53-/- and
ΔNp73fl/fl;p53-/- mouse embryonic fibroblasts (MEFs) were generated. The MEFs
were infected with adeno-CRE or Adeno-mCherry. Upon deleting ΔNp63 or
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Figure 13: TAp63 and TAp73 are required for activation of apoptosis and cell
cycle targets in p53-deficient cells. Western blot analysis in ∆Np63-/-;p53-/- (a) or
∆Np73-/-;p53-/- (b) MEFs treated with the indicated shRNAs; (shNT) indicates a
non-targeting scramble shRNA.	
  Q-RT PCR for PUMA (c), Noxa (d), bax (e), PML (f),
p21 (g), and p16 (h) in the indicated MEFs expressing the indicated shRNAs, n=5,
p<0.005. Statistical significance indicated by black asterisks.
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ΔNp73 in the p53-deficient MEFs, I observed that TAp63 and TAp73 were
significantly upregulated (Figure 12a-f). This suggests that ΔN isoforms could
repress transcription of the tumor suppressive isoforms, TAp63 and TAp73. To test
whether this is the case, chromatin immunoprecipitation

(ChIP) for ΔNp63 and

ΔNp73 was performed on the promoter region of TAp63 and TAp73 (Table 1). I
observed that ΔNp63 and ΔNp73 bind to the promoter region of TAp63 (Figure 12g)
and TAp73 (Figure 12h), thereby transcriptionally repressing the activity of TA
isoforms of p63 and p73. Thus targeting the ΔN isoforms in p53-deficient cells
restores the transcriptional function of TAp63 and TAp73. TAp63 and TAp73 in-turn
compensate for p53-loss by activating downstream apoptosis and cell cycle targets.
3.3.7. TAp63 and TAp73 are required apoptosis and cell cycle arrest in p53deficient cells
Loss of ΔN isoforms of p63 and p73 results in upregulation of TAp63 and
TAp73 in the p53-deficient cells and thymic lymphomas. TAp63 and TAp73
upregulation correlates with the increased expression of downstream apoptosis and
cell cycle arrest targets. This suggests that TAp63 and TAp73 compensate for p53loss. Hence, to test whether this is the case, TAp63 (Figure 13a) and TAp73 (Figure
13b) were knocked down in the ΔNp63-/-;p53-/- and ΔNp73-/-;p53-/- MEFs. Upon
down-regulation of TAp63 and TAp73, I observed a reduced expression of apoptosis
targets (Figure c-e), PUMA, Noxa and BAX and the cell cycle arrest targets (Figure
f-h), p21, p16 and PML. This suggests that apoptosis and cell cycle arrest targets
are dependent on TAp63 and TAp73 function in the p53-deficient cells and thymic
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lymphomas. This further highlights the tumor suppressive role of the TA isoforms of
p63 and p73 in treating cancers.
Discussion
TP53 gene is highly mutated in human cancers and therapeutic intervention
to reactivate or target the p53-pathway is pivotal due to its tumor suppressive
functions(5, 122). Here, we utilized the p53-family members, p63 and p73 as an
alternative strategy to treat p53-deficient cancers. p63 and p73 are structurally
similar to p53 and are less frequently mutated which makes them unique targets for
therapeutic intervention(45). Interestingly, p63 and p73 have multiple splice variants,
broadly classified as TA (trans-activating) isoforms and ΔN (dominant negative)
isoforms of p63 and p73. I have demonstrated that deleting ΔNp63 or ΔNp73 in p53
deficient thymic lymphomas results in rapid tumor regression and increased survival.
The loss of ΔN isoforms in these p53-deficient tumor samples correlates with
increased expression of TAp63 and TAp73 and downstream apoptosis and cell cycle
arrest pathways. This suggests that ΔNp63 and ΔNp73 function dominant negatively
against TAp63 and TAp73. Indeed, ΔNp63 and ΔNp73 binds to the promoters of the
TAp63 and TAp73 preventing their transcriptional function. Upon loss of ΔN isoforms
of p63 and p73, TAp63 and TAp73 are activated further inducing downstream
apoptosis and cell cycle targets. Interestingly, I was also able to demonstrate that
the induction of apoptosis and cell cycle arrest in the p53-deficient cells and thymic
lymphomas

were

dependent

on

TAp63

and

TAp73.

This

highlights

the

compensatory tumor suppressive role of TAp63 and TAp73 in targeting p53-deficient
cancers. Importantly, I have demonstrated that ΔNp63 and ΔNp73 function as
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oncogenes in the p53-deficient thymic lymphomas and therapeutic targeting of these
oncogenic isoforms serves as a novel approach to treat p53-deficient cancers.
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4. Chapter 4: IAPP driven metabolic reprogramming induces regression of
p53-deficient tumors in vivo through the calcitonin and RAMP3 receptors
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Chapter 4: IAPP driven metabolic reprogramming induces regression of p53deficient tumors in vivo through the calcitonin and RAMP3 receptors
Contents of this chapter is based on Venkatanarayan, A., Raulji, P., Norton, W.,
Chakravarti, D., Coarfa, C., Su, Xiaohua., Sandur, S.K., Ramirez, M.S., Lee,
Jaehyuk., Kingsley, C.V., Sananikone, E.F., Rajapakshe, K., Naff, K., ParkerThornburg, J., Bankson, J.A., Tsai, K.Y., Gunaratne, P.H. and Flores, E.R. IAPP
driven metabolic reprogramming induces regression of p53-deficient tumors in vivo.
Nature. 2015; 517(7536),626-630. doi:10.1038/nature13910.

Copyright permission not required since Nature journal policy states “Author retains
the copyright to the published materials”
4.1. Introduction and Rationale
ΔNp63 and ΔNp73 function dominant negatively against p53, TAp63 and
TAp73(47, 60). I have demonstrated that targeting the ΔN isoforms of p63 and p73
in p53-deficient tumors mediates tumor regression in a TAp63 and TAp73
dependent manner(74). This suggests that TAp63 and TAp73 function as bonafide
tumor suppressors activating apoptotic and cell cycle targets to mediate tumor
suppression. Thus TAp63 and TAp73 compensate for p53-loss of function in p53deficient tumors. This makes p63 and p73 as important targets for therapeutic
intervention to treat p53-deficient cancers. Hence it is necessary to understand and
delineate the global mechanisms by which TAp63 and TAp73 mediate its tumor
suppressive functions apart from activating apoptosis and cell cycle arrest pathway.
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More recently, p53 has been demonstrated to mediate its tumor suppressive
functions by activating certain metabolic and immune regulators, suppressing
pluripotent factors and also impacting lipid biosynthesis. Given that tumor cells
consume increased amounts of glucose and switch to a more aerobic form of
respiration, regulation of the glycolytic pathway serves as an important pathway to
be targeted. The p53 tumor suppressor activates two well-known metabolic
regulators GLS2, TIGAR to suppress tumorigenesis. Given the similarity to p53, I
was interested in understanding global transcriptional profile or targets activated by
TAp63 and TAp73 independent of p53 in suppressing tumorigenesis.

4.2. Results
4.2.1. Loss of ΔNp63 and ΔNp73 establishes a novel metabolic gene signature
in p53-deficient thymic lymphomas
Loss of ΔNp63 and ΔNp73 in p53-deficient thymic lymphomas mediates
tumor regression by induction of apoptosis and cell cycle arrest in a TAp63 and
TAp73 dependent manner. To test whether TAp63 and TAp73 could activate other
upstream regulators or pathways to mediate tumor suppression, we performed RNAsequencing using the thymic lymphoma samples from the ΔNp63Δ/Δ;p53-/-,
ΔNp73Δ/Δ;p53-/- and ΔNfl/fl;p53-/- 48 hours after adenovirus infection. We observed
that ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- lymphoma samples clustered together
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Figure 14: Loss of ΔNp63 and ΔNp73 reveal a novel metabolic gene signature.
Ingenuity Pathway Analysis (IPA) of RNA-sequencing from thymic lymphomas 48
hours after infection with adenoviruses (a).

Red oval indicates significantly

upregulated metabolic genes. Q-RT-PCR for IAPP (b), GLS2 (c) and TIGAR (d) in
thymic lymphomas or MEFs of the indicated genotypes using a non-targeting shRNA
(shNT) or shRNAs for TAp63 (shTAp63) or TAp73 (shTAp73) (e-f), n=4, p<0.005.
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and separately from the ΔNfl/fl;p53-/- thymic lymphoma samples (Appendix 1).
Ingenuity pathway analysis (IPA) (Figure 14a) revealed a novel metabolic gene
signature between the ΔNfl/fl;p53-/- versus ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/thymic lymphoma samples. To further determine the TAp63 and TAp73 targets,
genes that have a 2-fold mRNA expression in both the ΔNp63Δ/Δ;p53-/- and
ΔNp73Δ/Δ;p53-/- thymic lymphomas compared to the ΔNfl/fl;p53-/- tumors were
analyzed. Further, genes that shared a p53-consensus binding site were shortlisted.
qRT-PCR was performed to determine the fold-change expression levels of these
genes in the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- tumors samples. Based on the
relative fold-change expression, three genes were shortlisted, two of which namely,
GLS2 (Figure 14c) and TIGAR (Figure 14d), which were previously characterized
p53-regulated metabolic targets and another novel less characterized gene called
IAPP(85). GLS2 and TIGAR play critical roles in mitochondrial respiration(82) and
glycolysis(123). Islet amyloid polypeptide (IAPP) is a 37 amino acid polypeptide that
encodes for amylin(84). IAPP had a >2-fold expression in both ΔNp63Δ/Δ;p53-/- and
ΔNp73Δ/Δ;p53-/- samples (Figure 14b). Further, upon downregulating TAp63 and
TAp73 in the double mutant MEFs, expression levels of IAPP and GLS2 were
significantly downregulated (Figure 14e & f). This suggests that IAPP could be
activated by TA isoforms of p63 and p73. Since IAPP was expressed at higher
levels in the double mutant thymic lymphomas I suspect that IAPP could be
functionally implicated in the tumor regression associated with loss of ΔN isoforms of
p63 and p73 in p53-deficient cancers.
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Table 2: Table showing TAp63 and TAp73 consensus binding sites on the
IAPP promoter
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Figure 15: IAPP functions as a downstream target of TAp63 and TAp73.
Q-RT-PCR of Chromatin Immunoprecipitation using MEFs (a & b) and thymocytes
(c & d) of the indicated genotypes, n=3, p<0.005. Dual luciferase reporter assay for
pGL3-IAPP (e & f) and a mutant version of the IAPP reporter gene (pGL3-IAPP
MUT) (g & h). Genotypes of MEFs and vectors used are shown. V represents
pcDNA3 vector. Western blot analysis of the indicated MEFs expressing IAPP or
siRNAs for a non targeting sequence (siNT) or IAPP (siIAPP) (l & m). Statistical
significance indicated by black asterisks.
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4.2.2. IAPP functions as a downstream target of TAp63 and TAp73
IAPP expression was significantly upregulated in the ΔNp63Δ/Δ;p53-/- and
ΔNp73Δ/Δ;p53-/- thymic lymphoma tissues compared to the ΔNfl/fl;p53-/- tumors.
Since, ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- tumors have increased expression of
TAp63 and TAp73, I hypothesized that TAp63 and TAp73 could transcriptionally
activate IAPP. To test whether this was the case, chromatin immunoprecipitation
assay was performed (ChIP) on the promoter and intron 2 site of the IAPP gene
using MEFs (Figure 15a & b) and thymocytes (Figure 15 c & d) (Table 2). I observed
that binding of TAp63 and TAp73 onto the IAPP sites were observed in the ΔNp63-/;p53-/- and ΔNp73-/-;p53-/- MEFs. Similarly, increased binding of TAp63 and TAp73
on the promoter of IAPP was observed upon deleting ΔNp63/ ΔNp73 in the p53deficient thymocytes. This data suggests that TAp63 and TAp73 bind to the
promoter region of IAPP and could transcriptionally activate IAPP.
To test whether TAp63 and TAp73 transcriptionally activate IAPP, luciferase
reporter assay was performed using p63-/-;p53-/- and p73-/-;p53-/- double mutant
MEFs. Upon, transfecting the MEFs with indicated plasmids, I observed that TAp63
and TAp73 to be a strong inducer of IAPP expression (Figure 15 e & f). However,
when the TAp63/TAp73 consensus-binding site on the IAPP promoter region was
mutated (Figure 15 g-h), no luciferase activity was observed. This suggests that
TAp63 and TAp73 transcriptionally activate IAPP.
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Figure 16: IAPP functions as a regulator of glycolysis in mouse embryonic
fibroblasts. Western blot analysis for IAPP in the indicated MEFs and treatment
conditions, (n=3) (a& b). Seahorse glyocolysis stress assay using the indicated
MEFs(c) (n=3).
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4.2.3. IAPP functions as a critical regulator of glycolysis in mouse embryonic
fibroblasts
Majority of the genes in the RNA-sequencing analysis have an enriched
metabolic gene signature. Particularly, TIGAR and GLS2 function as regulators of
glycolysis(123) and mitochondrial respiration(82). Similarly, IAPP has been
previously characterized to play roles in glucose metabolism, apoptosis and
autophagy(83). IAPP has been demonstrated to reduce glucose uptake and inhibit
glycolysis(84, 124). IAPP inhibits glycolysis by reducing hexokinase activity indirectly
by increasing glucose-6-phosphate levels. Hence to test the potential role of IAPP in
glycolysis, I performed a glycolysis stress assay using MEFs of the indicated
genotypes. The ΔNp63-/-;p53-/- and ΔNp73-/-;p53-/- MEFs have increased
expression of IAPP (Figure 16 a & b) and have reduced glycolytic capacity similar to
the wild-type MEFs in comparison to the p53-/- MEFs (Figure 16c). Upon,
expressing IAPP in the p53-/- MEFs resulted in a shift in the glycolytic capacity
closer to the wild-type MEFs (Figure 16c). This suggests that IAPP functions to
reduce glycolysis in these p53-deficient cells. To test whether IAPP functions a
critical regulator of glycolysis, the IAPP expression was down regulated in the
ΔNp63-/-;p53-/- and ΔNp73-/-;p53-/- MEFs (Figure 16 a & b). I observed a significant
increase in the glycolytic capacity much closer to p53-/- MEFs (Figure 16c). This
highlights the role of IAPP as a critical regulator of glycolysis.
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Figure 17: IAPP functions as a tumor suppressor in vivo. Western blot analysis
showing IAPP expression in the indicated thymic lymphomas, n=5 mice (a). Thymic
lymphomas were infected with Adenovirus (Ad)-mCherry (b & i), Adenovirus (Ad)IAPP-mCherry (+IAPP)(c & j), Ad-shIAPP-mCherry (d, e, k & l), or treated with
pramlintide intratumoural (I.T.) (f & m) or intraveneous (I.V.) (g & n), or 2-DG (h &
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o).

Yellow dashed lines indicate tumour. Volume of tumour shown. UN-D =

undetectable. Quantification of the indicated thymic lymphomas (p-v). n=7 mice per
group. Significance indicated by the asterisks, p<0.005. Kaplan Meier survival
indicating thymic lymphoma free survival (w). n=8 mice per group, p<0.005
Quantification of in vivo pyruvate to lactate conversion using dynamic magnetic
resonance spectroscopy as a measurement of glycolysis, n=3 mice, p<0.005 (x)
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4.2.4. IAPP functions as a tumor suppressor in vivo
IAPP has been demonstrated to inhibit glycolysis by blocking hexokinase
activity(84). Also, I have observed that expressing IAPP in p53-deficient MEFs
reduces glycolytic capacity in these cells highlighting the role of IAPP as a regulator
of glycolysis. Since, cancer cells and tumors support the notion of Warburg’s
hypothesis with increased glycolytic rates(75, 76), I wanted to test whether IAPP can
inhibit glycolysis in the p53-deficient tumors in vivo. Hence, IAPP was expressed in
the p53-deficient thymic lymphomas (Figure 17a). Interestingly, upon expressing
IAPP, the p53-deficient thymic lymphomas had a massive tumor regression and
increased survival compared to the p53-deficient thymic lymphomas that do not
express IAPP (Figure 17 b-c, i-j, p-q & w). To test whether IAPP could function as
tumor suppressor by itself, IAPP expression was down regulated in the
ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- thymic lymphomas in which IAPP expression
is high (Figure 17a). Upon down regulating IAPP expression in these thymic
lymphomas, the tumors continued to progress similar to the p53-deficient thymic
lymphomas (Figure 17 d-e, k-l, r-s & w). Importantly, IAPP expressing p53-deficient
mice had increased survival compared to the p53-deficient or ΔNp63/p53 and
ΔNp73/p53 double deficient mice in which IAPP was down regulated. This suggests
that IAPP functions as bonafide tumor suppressor in p53-deficient cancers.
To further determine whether IAPP mediates the tumor regression in the p53deficient thymic lymphomas by glycolytic inhibition. We performed an in vivo
dynamic magnetic hyper-sense resonance spectroscopy to measure the total
amount of pyruvate getting converted into lactate, which serves as a proxy for
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Figure 18: IAPP expression induces ROS accumulation and apoptosis in the
p53-deficient thymic lymphomas. Immunohistochemistry for reactive oxygen
species (ROS) or cleaved caspase 3 (a). Positive nuclei are brown.
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glycolysis(110) within the tumor (Figure 17x). We observed that in the ΔNp63/p53
and ΔNp73/p53 double deficient tumors and p53-deficient tumors expressing IAPP,
lactate levels were significantly down regulated indicative of reduced glycolysis
compared to the p53-deficient tumors. Conversely, when IAPP was down regulated
in the ΔNp63/p53 and ΔNp73/p53 double deficient tumors lactate levels were
significantly higher and similar to the p53-deficient tumors suggesting increased
glycolytic activity (Figure 17x). This suggests that IAPP functions a critical regulator
of glycolysis in vivo. Importantly, IAPP mediated metabolic inhibition results in tumor
regression in p53-deficient mice.
4.2.5. IAPP mediates tumor regression in p53-deficient mice through induction
of ROS and cell death in vivo
IAPP functions as a bonafide tumor suppressor in p53-deficient mice by
glycolytic inhibition. I wanted to delineate the mechanism by which glycolytic
inhibition in the tumors results in tumor regression. Previous studies have reported
that tumor cells are particularly sensitive to metabolic stress(125). Metabolic stress
encountered by the tumor cells correlate with intracellular reactive oxygen species
(ROS) levels(125). In general, ROS levels are maintained at low levels and promote
tumor cell proliferation. However, under increased metabolic stress in the tumor
cells, ROS levels tremendously increase resulting in cell death or cellular
senescence(125). Recently, p53 has been demonstrated to induce metabolic stress
inhibiting glycolytic pathway resulting in ROS mediated cellular senescence(126).
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Figure 19: ΔNp63/ΔNp73 ablation induces apoptosis and cell-cycle arrest in
p53-deficient human cancer cells. Representative western blot analysis (a), n=4.
Immunofluorescence (IF) for apoptosis and EdU incorporation (b). Quantification of
apoptosis (c) and proliferation (d), n=20 fields of 3 biological replicates, p<0.005.
Q-RT-PCR for the target genes indicated on the x-axis in the indicated H1299 cells
expressing the indicated siRNAs (e), n=4. Asterisks indicate statistical significance
(p<0.005) relative to siNT.
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Interestingly, IAPP functions to inhibit glucose uptake and block glycolysis. This
results in increased nutrient related stress for the tumor cells probably leading to
intracellular accumulation of ROS and apoptosis (Figure 18a). Indeed, in the
ΔNp63/p53 and ΔNp73/p53 double deficient tumors and p53-deficient tumors
expressing IAPP, had increased accumulation of ROS that correlated with increased
apoptosis compared to the p53-deficient tumors. On the contrary, ΔNp63/p53 and
ΔNp73/p53 double deficient tumors in which IAPP was down regulated had no
accumulation of ROS or cell death (Figure 18a). This suggests that IAPP mediates
tumor regression in p53-deficient mice through the induction of ROS and cell death.
4.2.6. TAp63 and TAp73 compensate for p53-loss by metabolic reprogramming
in p53-deficient human cancer cells
By targeting the oncogenic isoforms of p63 and p73, I have demonstrated a
novel approach to treat p53-deficient tumors in mice. The tumor regression observed
in the p53-deficient thymic lymphomas is through the activation of tumor suppressive
isoforms, TAp63 and TAp73. Interestingly, TAp63 and TAp73 transactivate IAPP, a
metabolic regulator that functions to mediate tumor regression in p53-deficient mice.
However, ~50% of the human cancers exhibit either deletions or mutations in the
p53 gene. Since, therapeutic approaches to treat p53-altered human cancers are
ineffective, I wanted to test whether tumor regression mediated by loss of ΔNp63
and ΔNp73 could be extended to p53-deficient cancers. To test this hypothesis, I
extended my analysis to a panel of p53-deficient and mutant cancers. p53-deficient
human lung adenocarcinoma cells were co-transfected with siRNA’s targeting either
ΔNp63 or ΔNp73 in combination with siRNA’s for TAp63 and TAp73. I observed that
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Figure 20: IAPP mediated glycolytic inhibition results in ROS-induced cell
death in p53-deficient cancer cells. Western blot analysis of H1299 cells treated
with the indicated siRNAs (a). Extracellular acidification rate as a measure of
glycolysis (b), n=3, p<0.005. Legend in c is color-coded and corresponds to panels
b, d-g.

Immunofluorescence (IF) (d) and quantification (e) for ROS (red) or

apoptosis (green or green/red) (f & g)
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upon down-regulation of ΔNp63 or ΔNp73, TAp63 and TAp73 upregulation
correlated with the increase in IAPP expression in these p53-deficient human cancer
cells (Figure 19a). The increase in expression of TA isoforms of p63 and p73 also
resulted in the upregulation of apoptosis and cell-cycle arrest targets which in-turn
results in the induction of apoptosis and cell cycle arrest (Figure 19b-e).
4.2.7. IAPP directs p53-deficient human cancer cells to a ROS-induced cell
death through metabolic reprogramming
IAPP expression was upregulated in p53-deficient human cancer cells after
down-regulation of ΔNp63 and ΔNp73 (Figure 20a). This suggests that IAPP could
have functional implications in targeting p53-deficient cancer cells to undergo
apoptosis. Hence, to test whether IAPP functions as a metabolic regulator in p53deficient human cancer cells. p53-deficient lung adenocarcinoma cells were
transfected with siRNA’s for ΔNp63, ΔNp73 individually or in combination with
siRNA’s for IAPP. Also, IAPP was expressed directly in the p53-deficient cancer
cells as well. I observed that after down regulation of ΔNp63/ΔNp73 or expressing
IAPP there was significant reduction in the glucose uptake and glycolytic capacity in
the p53-deficient human cancer cells compared to the non-targeting treated cells.
(Figure 20b). Conversely, upon down regulating ΔNp63/ΔNp73 in combination with
IAPP the glycolytic capacity was very similar to the p53-deficient human cancer cells
treated with non-targeting siRNA’s (Figure 20b). This suggests that IAPP functions
as a critical regulator of glycolysis in p53-deficient human cancer cells.

	
  

89	
  

Figure 21: IAPP suppresses glycolysis by inhibiting hexokinase. Western blot
analysis of H1299 cells expressing the indicated siRNAs and expression of HKII (a).
Bar graph indicating glucose dependent proton secretion as a measure of glucose
uptake (b) and intracellular levels of glucose-6-phosphate in H1299 cells with the
indicated siRNAs and treatments (c).	
  	
   Color coded legend for panels b & c (d).
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To test whether IAPP mediated glycolytic inhibition resulted in ROS accumulation
and cell death, the p53-deficient human cancer cells were treated with the different
indicated siRNA’s. Upon knockdown of ΔNp63/ΔNp73 or expression of IAPP, a
significant accumulation of intra-cellular ROS (Figure 20d & e) that correlated with
the cellular apoptosis (Figure 20f & g) was observed. This effect was completely
rescued upon treating the cells with siRNA’s for ΔNp63/IAPP and ΔNp73/IAPP or by
using an anti-oxidant like N-acetyl cysteine (NAC), functions as a scavenger
reducing cellular ROS. This suggests that targeting ΔNp63/ΔNp73 or expressing
IAPP can be used as a viable option to treat p53-deficient cancers.
4.2.8. IAPP functions as a metabolic regulator by inhibiting hexokinase
IAPP functions as a bonafide tumor suppressor in p53-deficient human
cancer cells. However, the mechanism by which IAPP exhibits its tumor suppressive
functions remains unclear. Previous biochemical analysis has revealed that at
physiological levels, IAPP functions to inhibit glucose uptake and also increase
glucose-6-phosphate (G-6-P) levels(84). Subsequent increase in G-6-P levels
results in a feedback inhibition of hexokinase, the rate-limiting enzyme in the
glycolytic pathway. Hence to test whether IAPP mechanistically functions in the
similar manner in p53-deficient human cancer cells, I measured glucose uptake and
gluose-6-phosphate accumulation in the p53-deficient cancer cells. I observed that
upon down regulating ΔNp63/ΔNp73 or expressing IAPP there was a significant
reduction in the glucose uptake (Figure 21b) and accumulation of the glucose-6phosphate levels (Figure 21c) in the p53-deficient cancer cells. However, this effect
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Figure 22: Systemic delivery of pramlintide mediates tumor regression in p53deficient mice. Cartoon indicating schedule of MRI imaging and injection (Inj.) of
pramlintide in mice with p53 deficient thymic lymphomas (a). MRI imaging at 10, 11,
12 and 13 weeks after treatment with placebo (b-e) or pramlintide (g-n).
Quantification of tumour volumes in placebo (n=3) (f) and pramlintide treated mice
(n=7) (o), p<0.005. Statistical significance indicated by black asterisk.
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Figure 23: 2-deoxy-D-glucose functions as potent glycolytic inhibitor.
Immunofluorescence analysis for ROS (red) or apoptosis (green or green/red) in
H1299 cells expressing the indicated siRNAs and treated with 2DG and/or NAC (a).
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was rescued after treating the cells with siRNA’s for either ΔNp63/IAPP or
ΔNp73/IAPP.
Additionally, to further validate whether IAPP suppresses glycolysis through
inhibition of hexokinase, Hexokinase II (HKII) was expressed after knockdown of
either ΔNp63 or ΔNp73 in the p53-deficient human cancer cells (Figure 21a). A
significant increase in the glucose uptake (Figure 20b & 21b) and the glycolytic
capacity (Figure 20b) and reduction in the G-6-P levels (Figure 21c) in the p53deficient cancer cells similar to the cells treated with NT siRNA’s was observed. This
further correlated with very less or no intra-cellular ROS accumulation (Figure 20d &
e) and no induction of apoptosis (Figure 20f & g). This suggests that IAPP functions
to suppress glycolysis by inhibiting hexokinase activity in the p53-deficient cancer
cells.
4.2.9. Pramlintide, a synthetic analog of IAPP: as a glycolytic inhibitor to treat
p53-deficient cancer cells
IAPP encodes for amylin, a 37-amino acid peptide secreted from the beta
cells in the pancreas. I have demonstrated that IAPP functions as a bonafide tumor
suppressor in a p53-deficient model of thymic lymphoma and also in p53-deficient
cancer cells. IAPP exhibits its tumor suppression through metabolic reprogramming
and inhibiting glycolysis. Interestingly, a synthetic analog of amylin called
pramlintide(89) is used in the treatment of diabetes type I and II. Hence, I was
interested to test whether pramlintide could be used as an anti-cancer drug to treat
p53-deficient tumors and human cancer cells.
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Hence, to test the use of pramlintide as an anti-cancer drug, p53-deficient
mice that had a significant thymic lymphoma at 10 weeks were administered a single
dose of pramlintide intratumorally. By 13 weeks, I observed that the pramlintide
treated mice had a significant reduction in the tumor volume compared to the p53deficient mice treated with placebo (Figure f-g, m-n, t-u). This tumor regression
correlated with the reduction in the lactate production as measured by the in vivo
conversion of C13-pyruvate to lactate suggesting that pramlintide also functions to
inhibit glycolysis (Figure 17x). Additionally, pramlintide treatment resulted in the
accumulation of intracellular ROS and induction of apoptosis in the p53-defcient
tumors highlighting the mechanism of tumor regression (Figure 18a). To test
whether pramlintide functions similar to other known glycolytic inhibitors, I treated
the p53-deficient mice with 2-deoxy D-glucose (2-DG), a known glycolytic inhibitor
(Figure 17h, o & v). I observed similar phenotype of reduction in the lactate
production, accumulation of ROS and apoptosis in the p53-deficient tumors upon
treating the mice with 2-DG suggesting that pramlintide functions as a glycolytic
inhibitor mediating tumor regression. Finally, to test whether systemic in vivo delivery
of pramlintide mediates tumor regression in the p53-deficient mice, a bi-weekly dose
of pramlintide was administered for a period of 3 weeks intravenously to the p53deficient mice with significant thymic lymphoma (Figure 22a). I observed that,
systemic in vivo delivery of pramlintide resulted in rapid tumor regression in the p53deficient mice compared to the placebo treated mice (Figure b-n). This highlights the
use of pramlintide as an anti-cancer drug to treat p53-deficient tumors.
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To further test the effect of pramlintide in treating p53-deficient human cancer
cells, human lung cancer cells were treated with pramlintide. Upon administration of
pramlintide, I observed a significant reduction in the glucose uptake and glycolytic
capacity (Figure 20b & 21b)) and an increase in the G-6-P levels (Figure 21c) of the
p53-deficient human cancer cells. This further correlated with the accumulation of
intracellular ROS and cell death in the p53-deficient cancer cells, which was further
rescued upon treatment with the N-acetyl cysteine (Figure 20c-f). This suggests that
pramlintide, a synthetic analog of amylin, functions to suppress glycolysis by
inhibiting hexokinase II (HKII). Importantly, I have also demonstrated the use of a
diabetic drug as a potential anti-cancer drug to treat p53-deficient cancers.
Discussion:
Deletion of ΔNp63/ΔNp73 in the p53-deficient mouse tumors, mediates tumor
regression in a TAp63 and TAp73 dependent manner. Interestingly, TA isoforms of
p63 and p73, which function as transcriptional regulators mediate tumor suppression
through activating multiple pathways like apoptosis and cell-cycle arrest. In the p53deficient thymic lymphomas, I observe that TAp63 and TAp73 induce metabolic
reprogramming by recruiting a metabolic regulator IAPP, upon deleting ΔNp63 and
ΔNp73. IAPP, which encodes for amylin is a 37-amino acid peptide that functions to
maintain glucose homeostasis(84). In the p53-deficient tumors and p53-deficient
cancer cells, IAPP functions as tumor suppressor inhibiting glucose uptake and
suppressing glycolysis. IAPP, mediates its tumor suppressive function by inhibiting
hexokinase (HKII) rate-limiting enzyme in the glycolysis pathway. IAPP mediated
glycolytic inhibition results in the accumulation of intracellular ROS resulting in
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apoptosis in the cancer cells. Additionally, pramlintide, a synthetic analog of IAPP,
used in the treatment of diabetes(89), mediates tumor regression and tumor cell
death in p53-altered cancers. Pramlintide mediates tumor cell death in p53-altered
cancers by glycolytic inhibition resulting in ROS accumulation and apoptosis whose
functions are very similar to known glycolytic inhibitor, 2-DG (Figure 23). However,
unlike 2-DG which is highly toxic, pramlintide is less toxic and is also commercially
available. Thus, this chapter highlights the identification of a novel metabolic
regulator, IAPP and potential use of pramlintide to treat p53-deficient cancers
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Chapter 5: IAPP functions through the Calcitonin and RAMP3 receptors to
suppress tumorigenesis
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Chapter 5: IAPP functions through the calcitonin and RAMP3 receptors to
suppress tumorigenesis
Contents of this chapter is based on Venkatanarayan, A., Raulji, P., Norton, W.,
Chakravarti, D., Coarfa, C., Su, Xiaohua., Sandur, S.K., Ramirez, M.S., Lee,
Jaehyuk., Kingsley, C.V., Sananikone, E.F., Rajapakshe, K., Naff, K., ParkerThornburg, J., Bankson, J.A., Tsai, K.Y., Gunaratne, P.H. and Flores, E.R. IAPP
driven metabolic reprogramming induces regression of p53-deficient tumors in vivo.
Nature. 2015; 517(7536),626-630. doi:10.1038/nature13910.

Copyright permission not required since Nature journal policy states “Author retains
the copyright to the published materials”
5.1. Introduction and Rationale
IAPP that encodes amylin functions as a secreted protein mediating glucose
clearance at physiological conditions(84). IAPP functions as a tumor suppressor
inhibiting glycolysis in p53-deficient cancers. Since, IAPP is a secreted protein it is
still unclear the mode of action of IAPP to execute its tumor suppressive functions.
Previous studies have demonstrated that IAPP requires and binds to the calcitonin
and RAMP family of receptors(127). Since, IAPP could execute its functions both
intrinsically and extrinsically, it is important to understand and determine the role of
the receptors in IAPP-mediated tumor suppression in p53-deficient cancers.
Additionally, the activity of the receptors could serve as a biomarker in identifying a
subgroup of patients responding to pramlintide-based therapies.
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5.2. Results
5.2.1. Calcitonin and RAMP3 receptors are required for secreted IAPP function
in p53-deficient cancer cells
Since, IAPP is a secreted protein and has been previously demonstrated to
show sensitivity to the Calcitonin and RAMP3 receptors(127), I wanted to determine
whether IAPP requires the activity of the receptors to execute its tumor suppressive
functions. To test whether this is the case, media enriched for IAPP was
concentrated after treating the p53-deficient cancer cells with siRNA’s for ΔNp63
(siΔNp63M) and ΔNp73 (siΔNp73M). This concentrated media (siΔNp63M or
siΔNp73M) was added to the p53-deficient cancer cells in which expression of the
Calcitonin and RAMP3 receptors were downregulated after siRNA treatment or to
the cells treated with NT siRNA (Figure 24a-c). I observed a significant reduction in
glycolysis (Figure 24d) and increase in intra-cellular ROS (Figure 24f) and cell death
(Figure 24g) upon addition of IAPP (siΔNp63M/ siΔNp73M) enriched media to the
p53-deficient cancer cells treated with NT siRNA’s. However, this effect was not
observed in the p53-deficient cancer cells in which calcitonin receptor and RAMP3
receptor was downregulated (Figure 24 d,f-g). This suggests that IAPP requires the
activity of the calcitonin and RAMP3 receptors to execute its tumor suppressive
functions.
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Figure 24: IAPP functions through the activity of the calcitonin and RAMP3
receptors. Cartoon depicting treatment of cells expressing the indicated siRNAs and
treated with media from the cells secreting IAPP on the left (a). Western blot
analysis of H1299 cells expressing the indicated siRNAs (b) or concentrated media
derived from H1299 cells expressing siNT, si∆Np63, or si∆Np73 (c). Extracellular
acidification rate (ECAR) in H1299 cells (d). Extracellular acidification rate (ECAR)
using H1299 cells expressing the indicated siRNAs and treated with the indicated
media containing secreted IAPP and treated with the indicated Amylin Inhibitor (A.I.)
(e)Immunofluorescence (IF) for ROS (f) and apoptosis (g)

	
  

101	
  

Figure 25: Calcitonin and RAMP3 receptor are required for IAPP/Pramlintide
function in vivo. MRI and quantification of thymic lymphomas treated with placebo
(a, d, & g), pramlintide (b, e, & h), or pramlintide plus calcitonin inhibitor (CalR I) (c,
f, & i), n=5 mice
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To test whether glycolytic inhibition in the p53-deficient cancer cells is
mediated through the IAPP enriched in the media, the NT siRNA treated cancer cells
were further treated with amylin inhibitor (A.I.). The amylin inhibitor functions as an
agonist and prevents secreted IAPP binding to the receptors. Upon addition of
media enriched with IAPP (siΔNp63M or siΔNp73M) to p53-deficient cells treated with
A.I. I did not observe any differences in the glycolytic capacity (Figure 24e) or
accumulation of ROS (Figure 24f) and apoptosis (Figure 24g). This suggests that
secreted IAPP is required to induce glycolytic inhibition, ROS accumulation and
apoptosis p53-deficient cancer cells. Further, to test whether, cell death observed in
the p53-deficient cancer cells upon IAPP induction is through the intrinsic cell death
pathway, siNT treated p53-deficient cells were treated with caspase inhibitor. The
treatment with caspase inhibitor completely rescued the effect of IAPP on induction
of cell death (Figure 24g). This suggests that IAPP activates cell death machinery to
mediate its tumor suppressive function in the p53-deficient human cancer cells.
5.2.2. Pramlintide therapy requires the activity of the calcitonin and RAMP3
receptors
IAPP requires the activity of the calcitonin and RAMP3 receptors to perform
its tumor suppressive function in the p53-deficient human cancer cells. To further
determine the importance of the receptors in vivo, p53-deficient mice with thymic
lymphoma at 10 weeks of age were treated with pramlintide by itself or in
combination with calcitonin receptor inhibitor (Figure 25). The calcitonin receptor
inhibitor prevents binding of IAPP/pramlintide to the calcitonin receptor. Upon
pramlintide
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tumors

regressed

as

previously

demonstrated (Figure 25 b, e & h). However, upon inhibition of the calcitonin
receptor, pramlintide treatment was ineffective and the tumors progressed to grow
similar to the placebo treated p53-deficient mice (Figure 25 c,f & i). This suggests
that calcitonin and RAMP3 receptors are required the tumor suppressive function
exhibited by IAPP/Pramlintide in treating p53-deficient cancers.
Discussion
IAPP is cosecreted along with insulin from the beta cells of the pancreas.
Although, IAPP was previously demonstrated to utilize the calcitonin and RAMPfamily of receptors, the mode of action of IAPP was still unclear. I have
demonstrated that IAPP/pramlintide mediates its tumor suppressive function through
the calcitonin and RAMP3 receptors. Abolishing the activity of either calcitonin or the
RAMP3 receptor renders IAPP/pramlintide function ineffective. This highlights an
important association of IAPP function with its receptors. Since, pramlintide could be
used as a potential drug to treat p53-deficient cancers, determining the status of the
receptors will enable selecting patient cohorts responding to the pramlintide
treatment and also ensure improved drug efficacy.
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Chapter 6: Therapeutic approaches to treat p53-mutated human cancers
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Chapter 6: Therapeutic approaches to treat p53-mutated human cancers
6.1. Introduction and Rationale:
TP53 functions as well-documented tumor suppressor. However, most human
cancers, harbor p53-mutations altering its function(118). Majority of the human
cancers carry a common set of mutations commonly referred to as “Hot Spot”
mutations. Mutations in the p53-gene have gain of function activities and in many
cases promote tumor progression. The oncogenic properties of mutant p53 are
carried out by competitive binding to other tumor suppressors or by activating
oncogenes. Current therapeutic strategies are aimed towards downregulating the
activity of mutant p53 in human cancers and reactivating wild-type p53(128).
However, this therapeutic strategy has been challenging due to the multiple
interactions of p53 with other pathways. Hence, this necessitates the need to identify
other novel mechanisms to treat mutant p53 tumors. In this chapter, I aim to
delineate the interaction between mutant p53 and the p53-family members p63 and
p73. Additionally, use of pramlintide to therapeutically treat p53-mutated cancers will
be tested.
6.2. Results
6.2.1. Interaction between mutant p53 and p53-family members, p63 and p73
Previously, I have demonstrated that targeting the oncogenic ΔN isoforms of
p63 and p73, results in tumor regression in p53-deficient cancers. This tumor
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Figure 26: Deletion of ΔNp63/ΔNp73 in combination with genotoxic stress
induces apoptosis and cell-cycle arrest in p53-mutant human breast cancer
cells. Representative western blots with the indicated genotypes (a & b) (n=3).
Immunofluorescence (IF) and quantifications for apoptosis (c & e) and proliferation
(d & f) for the indicated siRNA’s with or without doxorubicin treatment. (n=3) Q-RT
PCR analysis for the apoptosis and cell-cycle arrest targets for the indicated siRNA’s
with of without doxorubicin treatment (n=3, p<0.0005). Asterisks represent
significance.
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Figure 27: Deletion of ΔNp63/ΔNp73 in combination with genotoxic stress
induces apoptosis and cell-cycle arrest in p53-mutant human colorectal
cancer cells. Representative western blots with the indicated genotypes (a & b)
(n=3). Immunofluorescence (IF) and quantifications for apoptosis (c & e) and
proliferation (d & f) for the indicated siRNA’s with or without doxorubicin treatment.
(n=3) Q-RT PCR analysis for the apoptosis and cell-cycle arrest targets for the
indicated siRNA’s with of without doxorubicin treatment (n=3, p<0.0005). Asterisks
represent significance.
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regression is mediated through the activation of tumor suppressive isoforms of p63
and p73, namely TAp63 and TAp73. Hence, to determine whether targeting ΔNp63
and ΔNp73 could mediate tumor regression in mutant p53 human cancer cells,
ΔNp63 and ΔNp73 was downregulated to two mutant human cancer cells namely,
MDA MD468 breast adenocarcinoma cells (Figure 26) and SW 480 colorectal
adenocarcinoma (Figure 27) that harbor p53 mutations. Upon silencing ΔNp63 and
ΔNp73 in the mutant p53 human cancer cells, I observed a significant increase in
the expression of TAp63 and TAp73 (Figure 26a & 27a), validating our previous
finding that loss of ΔN isoforms of p63 and p73 restores the expression of TAp63
and TAp73 in human cancer cells. To further test whether increased expression of
TAp63 and TAp73 correlates with the cell death and cell cycle arrest, qRT-PCR for
apoptosis and cell cycle targets and an apoptosis assay and EdU incorporation
assay was performed in the mutant p53-cancer cells after downregulating either
ΔNp63/ΔNp73. Interestingly, no increase in expression levels of the targets (figure
26e & 27e), cell death (Figure 26c,g & 27c,g) or decrease in cell cycle arrest (Figure
26d,h & 27d,h) was observed in the ΔNp63/ΔNp73 downregulated p53-mutant
cancer cells compared to the cells treated with the NT siRNA’s. This suggests that
although loss of ΔN isoforms of p63 and p73, restores the expression of TAp63 and
TAp73 in mutant human cancer cells, the TA isoforms of p63 and p73 could not
execute its tumor suppressive function in the mutant p53-cancer cells. One of the
reasons for TAp63 and TAp73 to not execute its tumor suppressive function in
mutant p53-human cancer cells could be due the gain-of function effect of mutant

	
  

109	
  

Figure 28: Deletion of ΔNp63/ΔNp73 in combination with mutant p53 induces
apoptosis and cell cycle arrest in p53-deficient human breast cancer cells.
Representative western blot analysis with the indicated siRNA’s (a) (n=3).
Immunofluorescence (IF) and quantification for apoptosis (b & c) and for cell-cycle
arrest (b & d) for the indicated siRNA treatment conditions.
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Figure 29: Deletion of ΔNp63/ΔNp73 in combination with mutant p53 induces
apoptosis and cell cycle arrest in p53-deficient human colorectal cancer cells.
Representative western blot analysis with the indicated siRNA’s (a) (n=3).
Immunofluorescence (IF) and quantification for apoptosis (b & c) and for cell-cycle
arrest (b & d) for the indicated siRNA treatment conditions.
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p53 which could form tetramers with TA isoforms of p63 and p73, preventing its
transcriptional function(129).
6.2.2. Targeting the ΔN isoforms of p63 and p73 combined with genotoxic
stress induces cell death and cell-cycle arrest in mutant p53 human cancer
cells
Gain of function effects of mutant-p53 prevents TAp63 and TAp73 from
executing their tumor suppressive function after ablation of ΔNp63 or ΔNp73 in the
p53- mutant human cancer cells. However, a significant increase in the expression
TAp63 and TAp73 after ablation of ΔNp63/ΔNp73 in the mutant p53-cancer cells
was observed. Since, TAp63 and TAp73 also respond to genotoxic stress, I wanted
to determine whether loss of ΔN isoforms of p63 and p73 in combination with
genotoxic stress would mediate cell death or cell-cycle arrest in the mutant p53
cancer cells. Interestingly, loss of ΔNp63/ΔNp73 in combination with genotoxic
stress resulted in a significant increase in the expression of TAp63/TAp73 (Figure
26b & 27b), which further correlated with the increase in expression of apoptosis and
cell cycle targets (Figure 26f & 27f), induction of cell death (Figure 26 c,g & 27 c,g)
and cell cycle arrest (Figure 26d,h & 27d,h) in the mutant p53-human cancer cells.
This suggests that significantly increasing the expression of TAp63 and TAp73 in the
mutant p53 cancer cells could function to overcome the gain-of function effect of
mutant p53 resulting in cancer cell death and cell-cycle arrest.
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6.2.3. Mutant p53 inhibits TAp63 and TAp73 mediated tumor suppression in
human cancer cells
Targeting ΔNp63 and ΔNp73 in mutant p53 human cancer cells restores
expression of TAp63 and TAp73. However, due to the gain of function effects of
mutant p53, TAp63 and TAp73 tumor suppressive function is inhibited. Hence, to
test whether this is the case, siRNA’s targeting p53 was used by itself or in
combination with siRNA’s for ΔNp63 and ΔNp73 in the mutant p53 human cancer
cells (Figure 28a & 29a). An increase in apoptosis (Figure 28b-c & 29b-c) and
decrease in proliferation (Figure 28b,d & 29b,d) in the mutant p53 human cancer
cells was observed upon downregulating both ΔNp63/p53 and ΔNp73/p53 in
comparison to downregulating only p53. Induction of apoptosis and cell cycle arrest
correlated with the increased expression of TAp63 and TAp73 in the p53-mutant
human cancer cells. This suggests that mutant p53 inhibits TAp63 and TAp73 from
mediating its tumor suppressive functions. Hence, targeting ΔN isoforms of p63 and
p73 in combination with mutant p53, serves as novel approach to treat these cancer
types.
6.2.4. Pramlintide based therapy to treat p53-mutant cancers
Previously, I have demonstrated that Pramlintide, synthetic analog of
amylin/IAPP mediates cancer cell death in p53-deficient cancer cells. Pramlintide
mediates its tumor suppressive function by suppressing glycolysis through the
inhibition of hexokinase activity. Importantly, the function of Pramlintide is mediated
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Figure 30: Pramlintide treatment suppresses glycolysis and results in ROSinduced apoptosis in p53-mutant human cancer cells. Extracellular acidification
rate (ECAR) as a measure of glycolysis in SW480 (a), MDA- MB-468 (b), SRB12 (c)
and COLO16 (d) human cancer cell lines after treatment with placebo, pramlintide,
or pramlintide and a calcitonin receptor inhibitor (CalR I.), n=3, p< 0.005. Glucose,
oligomycin, and 2-Deoxy-D-Glucose (2-DG) were supplied to the media at the
indicated time points shown on the x-axis. Immunofluorescence for ROS (red) (h)
and apoptosis (green) (i) on the indicated cells, n=3.
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downstream of the transcriptional activity of p53 and its family members. This
highlights a novel approach to treat p53-mutated cancers as the pramlintide
mediates its function independently of p53-status. Hence, to test whether pramlintide
could be used to treat p53-mutant cancers, a panel of mutant p53 human cancer cell
lines that include, SW480 (colorectal adenocarcinoma) (Figure 30a), MDA- MB-468
(breast adenocarcinoma) (Figure 30b), COLO16 and SRB12 (squamous cell
carcinoma) (Figure 30c&d) were selected. Upon treating the mutant p53 human
cancer cells with pramlintide, significant reduction in the glycolytic capacity that
correlated with an increase in intracellular ROS (Figure 30e) and cell death (Figure
30f) compared to the cell lines treated with the placebo was observed. To test
whether apoptosis observed in the mutant p53 cancer cells is due effect of
pramlintide, the cancer cells were treated with pramlintide by itself or in combination
with calcitonin receptor inhibitor. The p53-mutant human cancer cells treated with
calcitonin receptor inhibitor did not respond to pramlintide treatment suggesting that
pramlintide mediated inhibition of glycolysis mediates tumor cell death in the p53mutant human cancer cells. Importantly, the use of Pramlintide serves as a novel
approach to treat hard to treat p53-mutant human cancer cells.
6.2.5. Pramlintide based therapy to treat squamous cell cancers (SCC)
Squamous cell cancers (SCC) are a type of skin cancer. SCC is caused
primarily due to the multiplication of the epithelial cells of the skin, head and neck,
linings of the digestive tract, lungs and genitals(106, 130). One of the factors that
promote SCC formation is the exposure to UV skin light over an extended period of

	
  

115	
  

Table 3: Table representing a panel of patient derived human squamous cell
carcinomas cells with alterations in p53.
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Table 4: Table representing a classification of human SCC cells based on the
basal glycolytic profile
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Figure 31: Pramlintide treatment suppresses glycolysis in human SCC cells.
Extracellular acidification rate as a measure of glycolysis in a panel of human SCC
cells SRB1 (a), SRB12 (b), COLO16 (c), RDE B2 (d), RDE B3 (e), RDE B4 (f), SCC
T1 (g), SCC T2 (h), SCC T3 (i), SCC T8 (j) and SCC 1C1 (k) subjected to indicated
doses of pramlintide treatment.
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Figure 32: Pramlintide treatment induces apoptosis in human SCC cells.
Quantification of apoptosis (Annexin V and PI) in a panel of human SCC cells SRB1
(a), SRB12 (b), COLO16 (c), RDE B2 (d), RDE B3 (e), RDE B4 (f), SCC T1 (g),
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SCC T2 (h), SCC T3 (i), SCC T8 (j) and SCC 1C1 (k) subjected to indicated doses
of pramlintide treatment.
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time promotes loss of elasticity and pigmentation of the cells. Approximately,
700,000 cases of SCC have been diagnosed every year(130). There are multiple
gene alterations that drive tumor formation and one of the alterations occur in the
TP53 gene due to point mutations and truncating mutations(113, 114). Currently,
therapeutic approaches to treat SCC are limited. Since, pramlintide treatment has
shown tremendous potential in treating p53-mutant human cancer cells, I was
interested in determining the therapeutic efficacy of treating SCC human cancer
cells with pramlintide. Hence a panel SCC human cancer cells with mutations in p53
gene were selected (Table 3). Since, pramlintide functions by inhibiting glycolysis,
the basal glycolytic capacity of these SCC panel of cells was determined to classify
the cells based on their glycolytic profile (Table 4). The SCC human cancer cells
were classified into three types, highly glycolytic, medium glycolytic and less
glycolytic based on their glycolytic prolife (Table 4). I suspect that SCC cells with
higher glycolytic rate would respond with better efficacy to pramlintide treatment.
6.2.6. Pramlintide treatment inhibits glycolysis and induces cell death in the
human SCC cells
To test whether pramlintide mediates glycolytic inhibition in the human SCC
cells, the glycolytic capacity of the cells was measured with increasing
concentrations of pramlintide. I observed differences in the response to pramlintide
depending on the basal glycolytic profile of the SCC cells (Figure 31). However, in
most of the SCC cells, I observed an increased suppression of glycolysis at a higher
concentration of pramlintide. Additionally, the glycolytic inhibition correlated with a
increase in cell death in the SCC cells as measured by the Annexin V and propidium
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iodide staining (Figure 32). This highlights the importance to using pramlintide-based
therapy to treat human SCC cancers. Currently, I am testing the use of pramlintide in
the patient derived models (PDX) using the human SCC cells. Also, I am interested
in determining whether pramlintide affects mitochondrial respiration in the SCC cells.
Discussion
Approximately, 50% of human cancer harbor mutations in the p53 gene(122).
Mutant p53 functions as a proto-oncogene promoting tumorigenesis. Further,
because of its gain of functions effects, targeting mutant p53 in human cancers has
been challenging. In this chapter, I have demonstrated that mutant p53 inhibits
TAp63/TAp73 mediated tumor suppression in p53-mutated human cancers.
Targeting the oncogenic isoforms of p63 and p73 in combination with genotoxic
stress could result in significant accumulation of TAp63 and TAp73, thereby
overcoming mutant p53 effect. However, administration of genotoxic stress results in
non-specific activation multiple other pathways.
As a novel approach to treat p53-mutant cancers, I have proposed the use of
pramlintide, a synthetic analog of IAPP. Pramlintide functions by inhibiting glycolysis
and functions independently of the status of the p53-family members. Preliminary
data from my thesis has shown great promise in mediating tumor cell death in a
panel of mutant p53 human cancer cells. Currently, I have expanded my analysis to
human squamous cell cancers and their treatment with pramlintide. Initial in vitro
results have demonstrated that pramlintide functions effectively in highly glycolytic
tumor cells by blocking glycolysis and inducing apoptosis.
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Chapter 7: Therapeutically targeting the oncogenic isoforms of p63 and p73 to
treat p53-deficient human cancers
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Chapter 7: Therapeutically targeting the oncogenic isoforms of p63 and p73 to
treat p53-deficient human cancers
7.1. Introduction and Rationale
ΔNp63 and ΔNp73 have been demonstrated to function as oncogenes in p53deficient human cancers. Importantly, ablation of these oncogenic isoforms of p63
and p73 has identified a new therapeutic approach to treat p53-deficient cancers.
Previously, I have demonstrated that ablation of ΔNp63 and ΔNp73 mediates tumor
regression through the activation of TAp63 and TAp73, the tumor suppressive
isoforms of p63 and p73. Hence, by therapeutically targeting ΔNp63/ΔNp73 in p53defcient cancers will activate the tumor suppressive properties of TAp63 and TAp73.
Additionally, we have also performed a miRNA-sequencing on the p53-deficient
thymic lymphoma tissues in which either ΔNp63/ΔNp73 was ablated.
To therapeutically target ΔN isoforms of p63 and p73 in p53-deficient
cancers, in vivo, I have adopted a DOPC liposomal nanoparticle(131, 132) delivery
approach of utilizing siRNA’s targeting ΔNp63. These liposomal coated nanoparticle
siRNA’s could be delivered to the site of the tumor and are not phaogcytosed. This
enables us to develop a novel approach to treat p53-deficient tumors by targeting
the oncogenic isoforms of p63 and p73.
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7.2. Results
7.2.1. Liposomal siRNA delivery of ΔNp63 mediates tumor regression in p53deficient mice
Ablation of ΔNp63 mediates tumor regression through the activation of
TAp63. To therapeutically target ΔNp63 in p53-deficient tumors, I performed a
liposomal delivery of siRNA targeting ΔNp63 into the p53-deficient thymic lymphoma
at 10 weeks. Administration of liposomal coated siRNA’s was specifically localized
only to the region of the thymic lymphoma as visualized by the IVIS lumina imaging
(Figure 33a-i). ΔNp63 expression was downregulated 48 hours after administration
of the DOPC liposomal siRNA in the p53-deficient thymic lymphoma. This correlated
with the increase in the expression of TAp63 and also downregulation of DGCR8,
another downstream target of ΔNp63 (Figure 33j). Additionally, the downregulation
of ΔNp63 expression in the p53-deficeint thymic lymphoma tissues correlated with
the increase in apoptosis and cell-cycle arrest 48 hours after treatment with siRNA’s.
(Figure 33k) This suggests that therapeutically targeting ΔNp63 in p53-defcient
tumors in vivo, induces cell death and cell cycle arrest.
Since, targeting ΔNp63 in p53-deficient cancers in vivo was therapeutically
feasible, I wanted to test whether siRNA mediated knockdown of ΔNp63 would
mediate tumor regression in p53-deficient mice. To determine the stability of the
siRNA’s in vivo, a single does of siΔNp63 was administered into the p53-deficient
thymic lymphoma. The thymic lymphomas tissues treated with siΔNp63 were
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Figure 33: Liposomal siΔNp63 administration in p53-deficient thymic
lymphomas induces apoptosis and cell cycle arrest. IVIS Lumina imaging of
p53-deficient thymic lymphomas administered with DOPC liposomal nanoparticle
coated siRNA’s. Presence of the red color marks the region of the siRNA
administration which is localized to the thymic lymphoma (a-i). Representative
western blot analysis of p53-deficient thymic lymphoma tissues 48 hours after
treatment with indicated siRNA’s (j) (n=3). Immunohistochemistry (IHC) panel of for
apoptosis and proliferation in p53-deficient thymic lymphoma tissues 48 hours after
treatment with indicated siRNA’s. Brown nuclei labels the positive cells.
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Figure 34: Therapeutically targeting ΔNp63 by liposomal siRNA’s in p53deficient thymic lymphomas mediates tumor regression. Representative
western blot analysis of p53-deficient thymic lymphomas treated with indicated
siRNA’s (a). Magnetic resonance imaging (MRI) of p53-deficient thymic lymphoma
treated with siNT (b-f) or siΔNp63 (g-k). Tumor volumes (mm3) included in each
panel. Yellow dashed line marks region of the tumor. UN-D refers to undetectable.
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Tumor volume measurements for siNT treated (l) and siΔNp63 treated (j). Kaplan
Meier (KM) plots indicating thymic lymphoma free survival, n=3 mice per group,
p<0.0005.
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collected 1 week after dose administration to determine the expression of ΔNp63.
Interestingly, even 1 week after administering siΔNp63 into the p53-deficient thymic
lymphoma, a significant downregulation of ΔNp63 expression and upregulation of
TAp63 expression was observed (Figure 34a). Based on this analysis, a single dose
of siΔNp63 was administered into the p53-deficeint thymic lymphoma at 10 weeks of
age for period of 3 weeks. A significant reduction the tumor volume (Figure 34b-k)
and increase in the life-span (Figure 34k) as observed in the p53-deficient mice
upon treatment with siΔNp63 compared to the mice treated with non-targeting (NT)
siRNA’s. This highlights an important therapeutic approach to treat p53-deficient
tumors.
Discussion
Current therapeutic approaches to treat p53-deficient human cancers are
aimed towards reactivating wild-type p53 by inhibiting MDM2, negative regulator of
p53(128). Although this approach is currently entering clinical trials some challenges
remain in reactivating wild-type p53 across multiple cancers. However, by utilizing
the function of p53-family members, I have demonstrated a novel approach to treat
p53-deficient cancers in vivo. ΔNp63 and ΔNp73 are expressed in all epithelial
cancers and not mutated making them unique targets for therapeutic intervention. I
have demonstrated that by therapeutically targeting ΔNp63 using liposomal-coated
siRNA’s in p53-deficient model of thymic lymphoma results in tumor regression and
increased survival. Currently, I am expanding my analysis to target ΔNp73 and other
downstream targets of ΔNp63/ΔNp73 that might promote tumor formation.
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Chapter 8. Investigating the roles of p63 and p73 regulated lncRNAs in the
context of genotoxic stress and in p53-deficient cancers
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Chapter 8. Investigating the roles of p63 and p73 regulated lncRNAs in the
context of p53-deficient cancers
8.1. Introduction and Rationale
Long non-coding RNAs (lncRNAs) are similar to mRNAs but do not code for
protein(95, 97). RNA molecules that are generally >200nt in length and those that do
not code for protein are classified as lncRNAs. In general, lncRNAs are not
evolutionary conserved, but have been implicated in disease and development.
Particularly, lncRNAs are involved in multiple diseases from neurodegeneration to
cancer. In cancer, lncRNAs could function as oncogenes or tumor suppressors
depending on the cancer type and tissue context. Particularly, lncRNAs could
mediate its function by either regulating the activity of certain mRNA genes which
could be tumor suppressors or oncogenes. p53 functions to regulate the expression
of

multiple

downstream

targets

and

prevent

tumor

suppression(100-102).

Interestingly, p53 could also regulate lncRNA function as in the case of linc-p21,
PANDA or H19. Alternatively, expression of p53 could be regulated by lncRNAs as
well as in the case of MALAT1, MEG3(99). The functions of these lncRNAs are
executed by recruiting other cofactors to mediate tumor suppression or suppressing
the effect of a mRNA like a tumor suppressor and acting as “sponge” through
competitive endogenous mRNA (ceRNA). Since, lncRNA can also function as a
predictor of disease status in human cancers, I was interested in determining the
regulation of these lncRNA by the p53-family members, p63 and p73. Understanding
the lncRNAs regulated by p63 and p73 would enable us to predict disease outcome
and also unravel new pathways of regulation in p53-altered cancers.
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To determine regulation of lncRNAs by p63 and p73, we performed RNAsequencing using two different cellular systems in a p53-deficient condition. In the
first analysis, since p63 and p73 respond to DNA damage, I was interested in
identifying lncRNA that could respond to genotoxic stress. In the second approach,
to identify lncRNA that could play critical roles in the progression of p53-deficient
lymphomas,

analysis

was

performed

using

the

ΔNp63Δ/Δ;p53-/-

and

ΔNp73Δ/Δ;p53-/- thymic lymphoma samples. By identifying and characterizing the
function of these lncRNAs by the p53-family members, p63 and p73, I aim to
delineate novel regulatory pathways that might help design better therapies to treat
p53-altered cancers.

8.2. Results
8.2.1. p63 and p73 regulated lncRNAs that are responsive to genotoxic stress
p63 and p73 function as transcription factors and similar to p53 and respond
to genotoxic stress and protect the genome by recruiting DNA repair genes. Unlike
p53, which is often mutated in human cancers, p63 and p73 are less frequently
mutated making them unique targets, which could possibly perform DNA repair even
under diseased states. To determine the non-coding regulatory network of p63 and
p73 upon genotoxic stress, mouse embryonic fibroblasts (MEFs) of the indicated
genotypes were treated with or without doxorubicin to induce DNA damage. RNAsequencing was performed using the MEFs treated with or without DOX. A total of
2094 lncRNAs were mapped using the mouse mm9 database. Since, I was
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Figure 35: Pie chart representing the differentially expressed lncRNAs either
dependent or independent of genotoxic stress. lncRNAs that are DOX
dependent (n=7) and lncRNAs that are DOX independent (n=19). Red represents
upregulated and green represents downregulated lncRNAS
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Table 5: List of differentially expressed lncRNAs that are either dependent or
independent of genotoxic stress
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interested in identifying lncRNA that are regulated by p63 and p73, we overlapped
the RNA-sequencing data with a ChIP-sequencing to mark all the lncRNAs that
encode a p53-consensus binding site. Since, p53, p63 and p73 share a consensus
binding site on the target genes, categorizing the lncRNAs based on the consensus
increases stringency and provides more confidence.
By bioinformatic analysis, p63 and p73 lncRNAs were classified under two
groups, lncRNAs that are doxorubicin dependent and lncRNAs that are doxorubicin
independent. Upon, doxorubicin treatment a total of n=7 lncRNA were differentially
expressed in which n=5 had a p53-consensus binding site. Interestingly, I observed
n=4 lncRNAs to be downregulated and n=2 were upregulated. Similarly, upon
analyzing the lncRNAs that are doxorubicin independent a total of n=19 were
identified of which n=7 had a p53-consensus binding site. I observed, n=7 to be
downregulated and n=2 to be upregulated. Currently, I am planning to perform
further stringency analysis based on the expression pattern and develop assays to
test and characterize the function of these novel lncRNAs.

8.2.2. Identification of differentially expressed lncRNAs upon ablation of
ΔNp63 and ΔNp73 in p53-deficient mouse tumors
ΔNp63 and ΔNp73 deletion in p53-deficient cancers results in tumor
regression in vivo. I have identified a novel metabolic reprogramming mechanism
through the recruitment of IAPP, which mediates this tumor regression. However,
IAPP is activated by the tumor suppressor isoforms, TAp63 and TAp73, highlighting
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Figure 36: Differentially expressed lncRNAs upon ablation of ΔNp63 and
ΔNp73 in p53-deficient thymic lymphomas. Piechart representing number of
differentially expressed lncRNAs (a). Pie chart representing lncRNA up and
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downregulated in the thymic lymphoma samples (b). Graph representing the FKPM
fold change values for the selected lncRNAs in the thymic lymphoma samples (c).
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Table 6. List of differentially expressed lncRNA with ensemble ID and
chromosomal location
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the global role played by these genes in tumor suppression. Additionally, loss of ΔN
isoforms of p63 and p73 could have restored the tumor suppressive role of noncoding genes or suppressed the activity of certain oncogenes. Hence, to further
expand our understanding on the p53-deficient tumor regression phenotype and
identify biomarkers for disease prediction we utilized the RNA-sequencing data
obtained by comparing the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- versus the
ΔNfl/fl;p53-/- tumors (Appendix 1).
Using bioinformatic analysis, a total of n=32 lncRNAs were identified to be
differentially expressed between the ΔNp63Δ/Δ;p53-/-, ΔNp73Δ/Δ;p53-/- and
ΔNfl/fl;p53-/- thymic lymphoma samples. Since, loss of both ΔNp63 and ΔNp73
accelerates tumor regression in p53-deficient tumors, I focused on the n=8 lncRNAs
that are differentially expressed. Of the n=8 lncRNAs, one lincRNA was
downregulated and the remaining lncRNAs were all upregulated. Currently, I am
performing experiments to determine a phenotypic characterization of these
lncRNAs.
Discussion
lncRNAs do not code for proteins, however, are implicated in diseases like
cancer. Multiple lncRNAs are significantly expressed in cancer potentiating their
roles as oncogenes. However, some lncRNAs that are regulated by tumor
suppressors like p53 function to prevent cell proliferation and induce cell death. The
gene regulation of lncRNAs is complex and sufficient in vivo models have not been
developed. In an attempt to understand the regulation of p53-family members, p63
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and p73, we mined the database for lncRNA using two distinct approaches. In the
first approach, I aim to identify lncRNA that respond to genotoxic stress which may
help in recruiting DNA repair genes and also induce cell-cycle arrest in a diseased
state. In the second approach, I aim to identify lncRNAs that may play critical roles in
p53-deficient tumor regression upon loss of ΔNp63 and ΔNp73.
Since, lncRNAs do not code for proteins, determining the function of the
lncRNAs is challenging. Normally, from the bioinformatic analysis of the RNAsequencing data, a cluster of differentially expressed lncRNAs is obtained. To
specifically determine the function of a select few lncRNA, I plan to apply the Guilt by
association method (GBA) in which the function of the lncRNA is predicted
depending upon the function and the direction of the mRNA genes. This assessment
will help design assays depending on the predicted function to characterize the
function of lncRNA. Additionally, a few criteria’s like determining the chromatin
marks for activation or repression or the common consensus binding motifs on the
lncRNA promoter will provide leads on determining the function of these lncRNA.
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Chapter 9: Discussion, Conclusions and Future Directions
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9. Discussion
9.1. p53 mediated tumor suppression in human cancers
TP53 gene’s tumor suppressive properties are well documented in multiple
cancer types. At physiological conditions, p53 expression is under tight regulation.
Upon genotoxic stress, p53 expression levels increase to perform its cellular
functions, thereby protecting the genome(133). p53 executes its cellular functions
through the recruitment of multiple downstream targets which induce apoptosis or
cell-cycle arrest(133). p53 expression is regulated by its own target, MDM2, an E3
ubiquitin ligase that functions as an negative regulator of p53. When p53 is
expressed at higher levels, MDM2 inhibits p53 transcriptional activity through its
negative feedback mechanism(134). In normal cells, p53 functions to maintain
cellular homeostasis. p53 functions to protect the genome from cellular insults and
DNA damage. Upon, DNA damage or any form of stress, p53 levels are
tremendously increase and direct the damaged cells to undergo cell death or cell
cycle arrest. The downstream function if p53 is performed by the recruitment of
known p53-targets like PUMA, Noxa or BAX for induction of apoptosis(2, 13)and
p21, p16 and PML for the induction of cell cycle arrest or cellular senescence(17,
135). More recently, the roles of p53 in multiple cellular pathways like
metabolism(79), pluripotency(136), aging(137) etc. are being delineated and this
represents the identification unique and novel targets regulated by p53. These
functions of the TP53, highlight the importance of this gene in maintaining cellular
homeostasis and tumor suppression.

	
  

142	
  

Unfortunately, in a majority of human cancers TP53 function is altered. TP53
gene undergoes a mutation or deletion in most human cancers(118). This results in
either gain of function or loss of function of p53. p53 loss corresponds to no activity
of the p53 gene resulting in tumor progression upon cellular insults, as p53 is not
functional and cannot execute its function of protecting the genome. However,
approximately, 50% of human cancers harbor mutations in the p53 gene that are
commonly referred to as “Hot Spot” mutations, which commonly occur in the DNA
binding domain of p53 gene. As a result of these mutations, p53 exhibits gain of
function properties promoting tumor growth(8, 23, 138). Mutant p53, because of the
mutations in the DNA binding domain cannot be regulated by its negative regulator
MDM2, as a result is constantly active. Further, mutant p53 promotes tumor growth
by forming heterodimers with known tumor suppressors and preventing their function
or by activating oncogenes(26).
In the context of cancer, the status of p53 is critical because one mechanism
by which chemotherapy functions is to induce DNA damage which illicits a p53
response which targets the cells to die. Since, p53 expression is altered in most
cancers, this raises a concern in therapeutically treating p53-altered human cancers.
Hence, the current therapeutic strategy to treat p53-altered cancers has been to
reactivate wild-type p53 in p53-deficient human cancers, as this approach has
shown promise in p53-deficient mouse models(32). In the case of p53-mutated
human cancers, the aim has to been downregulate the expression of mutant p53
through the activation of E3 ubiquitin ligases or other small molecule inhibitors(139).
All these approaches have shown great promise but have been a challenge to
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therapeutically execute them. This raises an unmet need to develop and identify
alternate approaches to treat p53-deficient human cancers.
p53 family members: p63 and p73
In a need to develop alternate approaches to treat p53-deficient human
cancers, we have focused on understanding the role of the p53-family members,
p63 and p73 in tumorigenesis. p63 and p73 are structurally similar to p53(45).
However, unlike p53, both p63 and p73 are less frequently mutated making them
unique targets for therapeutic intervention. p63 and p73 were initially identified as
developmental regulators and their roles in tumorigenesis were controversial. This is
because studies based on in vivo mouse models targeting p63 and p73, had a broad
tumor spectrum highlighting the indispensable roles of these genes in tumor
suppression(46) while some human cancers, expressed higher levels of p63 and
p73, suggesting that they could be oncogenic in nature(49, 60, 140). These
differences are primarily due to the multiple splice isoforms of p63 and p73. The
splice variants of p63 and p73, are broadly classified into N-terminal isoforms and Cterminal isoforms. The major N-terminal isoforms are classified as ones which have
an acidic transactivation domain (TA) isoforms or the ones without a transactivation
domain (ΔN) isoforms(45). The ΔN isoforms of p63 and p73, function as dominant
negatively against p53, TAp63 and TAp73. Previous studies have demonstrated that
the TA isoforms function as bonafide tumor suppressors(65, 120) while the role of
the ΔNp63 and ΔNp73 in tumorigenesis is still unclear. Hence, in this thesis I aimed
to determine the role of the ΔNp63 and ΔNp73 in tumorigenesis.
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ΔNp63 and ΔNp73 conditional knockout mice
To determine the roles of the ΔNp63 and ΔNp73in tumorigenesis, we
generated ΔNp63 and ΔNp73 conditional knockout mice were generated. These
mice were crossed to a Zp3-CRE mouse to generate a ΔNp63+/- and ΔNp73-/mice. In order to determine the role of the ΔN isoforms of p63 and p73, in the
context of p53-deficiency and also to accelerate tumorigenesis, I generated a cohort
of ΔNp63+/-;p53-/- and ΔNp73-/-;p53-/- mice, henceforth referred to as double
mutant mice.
ΔNp63/p53 and ΔNp73/p53 double deficient mice had reduced thymic
lymphomagenesis
ΔNp63/p53 and ΔNp73/p53 double mutant mice had a significant reduction in
the thymic lymphoma incidence and increased survival compared to the p53deficient mice, which develop thymic lymphoma at a 90% incidence rate. This
suggests that loss of ΔNp63/ΔNp73 in the p53-deficient thymic lymphomas reduces
tumor incidence. Upon analysis on the thymic lymphoma tissues of the double
mutant mice, I observed a significant increase in the expression in the TAp63 and
TAp73, the tumor suppressive isoforms of p63 and p73. This correlated with the
induction of apoptosis targets and increase in cell death and also, induction of cellcycle targets and increase in cell-cycle arrest in the double mutant thymic
lymphomas. This suggests that loss of ΔN isoforms of p63 and p73, results in the
upregulation of tumor suppressive TAp63 and TAp73 isoforms mediating cell death
and apoptosis. Since, TAp63 and TAp73 respond to genotoxic stress, 4 week old
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double mutant mice were subjected to gamma radiation. I observed a significant
increase in the expression of the TA isoforms of p63 and p73 that correlated with the
induction of apoptosis and cell cycle targets. This further resulted in the induction of
apoptosis and reduction in proliferation in the double mutant thymus tissues. This
suggests that loss of ΔNp63/ΔNp73 in the p53-deficient thymic lymphomas restores
the tumor suppressive functions of TAp63 and TAp73 thereby suppressing
lymphomagenesis.
Acute deletion of ΔNp63/ΔNp73 in p53-deficient mice reveals a novel
metabolic gene signature that suppresses lymphomagenesis
Total loss of ΔNp63/ΔNp73 in the p53-deficient mice suppresses thymic
lymphomagenesis. To test whether this is the case and also determine the molecular
determinants that mediate this tumor suppression, ΔNp63 and ΔNp73 were acutely
deleted from the p53-deficient thymic lymphoma. The ΔNp63/p53 and ΔNp73/p53
deficient tumors had a significant reduction in the tumor volume and increased
survival. This correlated with the increased expression of TAp63 and TAp73 and
also induction of cell death and cellular senescence through the activation of targets.
I reported that ΔN isoforms of p63 and p73, bind to the promoters of TAp63 and
TAp73 preventing its transcriptional function. Further, TAp63 and TAp73 are
required for the activation of the apoptosis and cell-cycle targets to mediate tumor
regression in the p53-deficient mice.
Since, apoptosis or cellular senescence are downstream functions, I was
interested in determining the global role of TAp63 and TAp73 in suppressing
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tumorigenesis. RNA-Sequencing analysis of ΔNp63/p53 and ΔNp73/p53 tumors
revealed that novel gene signature enriched with metabolic genes compared to the
p53-deficient tumors. Ingenuity pathway analysis revealed a cluster of gene involved
in glycolysis pathway, which includes known metabolic regulators like TIGAR(123)
and GLS2(82) and novel target called IAPP. IAPP expression was significantly
upregulated in the ΔNp63/p53 and ΔNp73/p53 deficient tumors suggesting that both
TAp63 and TAp73 could activate IAPP. Indeed, I reported that TAp63 and TAp73
bind and transcriptionally activate IAPP, which functions as its downstream target
(Figure 35). Although, TIGAR and GLS2 were differentially regulated, I found that
GLS2 was expressed at higher levels in the ΔNp63/p53 tumors suggesting that
GLS2 could function as a TAp63 target. Similarly, TIGAR was significantly
expressed at higher levels in the ΔNp73/p53 tumors suggesting that TAp73 could
regulate TIGAR. For the purpose of this study, I focused on the combined tumor
suppressive roles of TAp63 and TAp73. However, exploring the individual tumor
suppressive functions of TAp63 and TAp73 could provide more mechanistic
evidence of the interplay among the family in tumorigenesis.
IAPP functions as bonafide tumor suppressor in p53-deficient tumors
IAPP encodes amylin, a 37 amino acid peptide secreted from the beta cells in
the pancreas(83). IAPP has been demonstrated to play functional roles in glucose
metabolism and apoptosis(84, 124). Interestingly, I reported that IAPP functions as a
critical metabolic regulator in p53-deficient mouse embryonic fibroblasts (MEFs)
upon ΔNp63/ΔNp73 loss or expressing IAPP. Since, IAPP is expressed at higher
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Figure 37: TAp63 and TAp73 compensate for p53-loss by IAPP driven
metabolic reprogramming. Model depicting loss of ΔNp63 & ΔNp73 in p53deficient cancers results in the upregulation of TAp63 and TAp73. TAp63 and TAp73
recruit IAPP to mediate tumor regression in p53-deficient tumors
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levels in the ΔNp63/p53 and ΔNp73/p53 double deficient tumors, I suspect the role
of IAPP in suppressing thymic lymphomagenesis. However, the role of IAPP in
tumor suppression is relatively less characterized. To determine the role of IAPP in
tumorigenesis, IAPP was expressed in vivo in the p53-deficient thymic lymphomas.
This resulted in significant tumor regression and increase in life span. Conversely,
when IAPP was downregulated in the ΔNp63/p53 and ΔNp73/p53- deficient thymic
the tumors continued to grow very similar to p53-deficient mice. This correlated with
the decreased lactate production and also increased accumulation of intracellular
ROS and cell death. These findings confirm that IAPP functions as a bonafide tumor
suppressor in p53-deficient thymic lymphomas.
Ablation

of

ΔNp63

and

ΔNp73

induces

IAPP

mediated

metabolic

reprogramming in p53-deficient human cancer cells
Loss of ΔNp63/ΔNp73 in a p53-deficient mouse model of thymic lymphoma
induces IAPP mediated metabolic reprogramming that results in suppression of
thymic lymphomagenesis. To extend my analysis, to human cancers, ΔNp63/ΔNp73
was knocked down or IAPP was expressed in p53-deficient human cancer cells. I
observed a significant reduction in the glycolytic capacity that correlated with the
accumulation of ROS and cell death upon ΔNp63/ΔNp73 deletion or IAPP
expression. Previous studies have reported that IAPP at physiological levels,
functions to inhibit the glycolysis pathway by indirectly inhibiting hexokinase through
increasing the levels of glucose-6-phosphate. I observed a similar accumulation of
glucose-6-phosphate upon ablation of ΔNp63/ΔNp73 or expression of IAPP in the
p53-defiicent cells. Indeed, expression of hexokinase II in these p53-deficient cells,
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completely restored glycolysis and reduced ROS levels and rescued cell death in the
p53-deficient cells. This suggests that IAPP mediates its tumor suppressive function
by inhibiting hexokinase the rate-limiting enzyme in the glycolysis pathway (Figure
36).
IAPP requires the activity of the Calcitonin and RAMP3 receptors to perform
its tumor suppressive functions
IAPP is a secreted protein from the pancreas. Previous studies have reported
that IAPP functions through the activity of the calcitonin and RAMP family of
receptors(127) to perform its physiological functions. Since, IAPP functions as a
metabolic regulator mediating tumor suppression in p53-deficient mouse tumors and
p53-deficient human cancer cells, I wanted to determine whether IAPP requires the
activity of the receptors. Interestingly, I demonstrated that IAPP, requires the activity
of both the calcitonin and RAMP3 receptors to perform glycolytic inhibition, induction
of ROS and cell death in the p53-deficient human cancer cells and also p53-deficient
mouse tumors (Figure 36). Importantly, loss of function of any one of the receptor
activity renders IAPP function ineffective. To test whether the expression of IAPP
and its receptors correlate with patient survival, we performed a TCGA analysis of
patient survival data. In a select group of patients harboring p53-mutations, we
observed increased survival when IAPP, RAMP3 and calcitonin receptors are
expressed at higher levels (Figure 37). This analysis proved true across a panel of
human breast (Figure 37a), colorectal (Figure 37b) and lung squamous (Figure 37c)
cell cancers. This data provides important information about selecting a patient
group who might serve as better responders for pramlintide, synthetic analog of
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Figure 38: IAPP mediated mechanism of glycolytic inhibition in p53-altered
cancers. IAPP functions through the calcitonin and RAMP3 receptors to inhibit
glycolysis by suppressing hexokinase activity. IAPP mediated glycolytic inhibition
results in ROS accumulation and apoptosis.
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IAPP, for treatment. Importantly, the patient populations, could be classified based
on the receptor status which could serve as a biomarker. I would suspect that
patients with less alterations in the calcitonin and RAMP3 receptor status would
respond better to pramlintide based therapies.
Pramlintide based therapy to treat p53-altered cancers
IAPP functions as a bonafide tumor suppressor in p53-deficient cancers. This
raises the possibility of using pramlintide as a therapeutic approach to treat p53altered cancers. Pramlintide is a synthetic analog of IAPP, used in the treatment of
Type 1 and Type 2 diabetes. Majority of the human cancers are hard to treat due to
alterations in TP53, which makes them less responsive to chemotherapy. In such
cases, pramlintide based approach may provide an alternative since IAPP functions
by inhibiting glycolysis and does not depend on any alterations or mutations in the
genes. Indeed, p53-deficient mice treated with pramlintide intratumorally and
systemically had a significant thymic lymphoma regression compared to the placebo
treated mice. Further pramlintide treatment in the p53-deficient human cancer cells,
resulted in inhibition of glycolysis that correlated with increases in ROS and cell
death. This suggests that pramlintide functions similar to IAPP in p53-defcient
human cancer cells. Since, pramlintide also functions by inhibition of glycolysis and
metabolic reprogramming, I suspect that pramlintide could be used to treat p53mutant cancer, which are generally hard to target. Indeed, a panel of mutant p53human cancer cells harboring different p53-hotspot mutations where subjected to
pramlintide therapy and I observed an inhibition of glycolysis and significant
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Figure 39: Kaplan Meier Survival plots for expression of IAPP-CALCR-RAMP3
in p53-mutated human cancer patients.
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accumulation of ROS and cell death. Interestingly, pramlintide mediated tumor
suppression was ineffective when the activity of the receptors was blocked.
Currently, I am expanding the possibility of using pramlintide-based therapy to treat
squamous cell cancers as a single agent.
Thus far it has become evident that pramlintide treatment mediates tumor
suppression in p53-altered human and mouse tumors by inhibiting glycolysis. Since,
pramlintide is already used as a diabetic drug, pramlintide use is associated with
reduced cellular toxicity. Hence, I was interested in determining whether long term
and early dosing of pramlintide could be used to prevent tumor formation. To test
whether this is case, a cohort of p53-deficient mice was administered with increasing
doses of pramlintide (30µg/kg, 45µg/kg and 60µg/kg body weight) at 4 weeks of age.
The mice were administered a biweekly dose of pramlintide for a period of 6 weeks
by intravenous (IV) delivery method and tumor progression were monitored by MR
imaging. Additionally, blood glucose levels and body weight of the mice were
measured every week to monitor the health of the mice upon pramlintide treatment.
Interestingly, after 6 weeks of pramlintide treatment, I observed the thymic
lymphoma in the p53-deficient mice were smaller in comparison to the placebo
treated mice (Appendix 3). Interestingly, some of these treated mice had an
extended survival compared to the placebo treated mice. From this initial pilot study,
we were able to demonstrate that pramlintide could be used to p53-deficient mice
and prevent tumor formation. Our current work is to understand how pramlintide
prevents thymic lymphoma progression in these p53-deficient mice and expand our
analysis to a larger cohort.
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Therapeutically targeting ΔNp63 and ΔNp73 in human cancers
ΔNp63 and ΔNp73 function as oncogenes in p53-deficient cancers.
Importantly, I have demonstrated that targeting the ΔN isoforms of p63 and p73
restores the tumor suppressive function of TAp63 and TAp73. Importantly, TAp63
and TAp73 compensate for p53 loss by activating downstream apoptosis and cellcycle targets thereby suppressing tumorigenesis. Additionally, targeting ΔNp63 and
ΔNp73 also suppresses the expression of oncomiRs that promote tumor formation.
Hence, this raises a novel therapeutic opportunity to target ΔNp63 and ΔNp73 to
treat p53-deficient cancers. One approach that I have adopted is to deliver small
interfering RNAs (siRNA’s) through DOPC liposomal nanoparticle based approach.
In this case, siRNA’s targeting ΔN isoforms of p63 and p73, will be coated with
neutral liposomal particles and can be delivered to the site of the tumor either
intratumorally or systemically. Upon, delivering siRNA’s targeting ΔNp63, I observed
a significant reduction in tumor volume of the p53-deficient mice that correlated with
the increase in cell death and cell-cycle arrest. This approach of delivering siRNA’s
targeting ΔNp63 and ΔNp73 can be applied to multiple cancer types and presents a
unique opportunity to therapeutically treat p53-deficient cancers.

9.2. Conclusions
TP53 is a highly mutated tumor suppressor gene rendering cancer therapies
ineffective. Reactivation of the p53-pathway has been challenging to execute in
human cancers. By utilizing the functions of the p53-family members, p63 and p73, I
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have identified a novel approach to treat p53-altered cancers. p63 and p73, although
structurally similar to p53, exhibit different functions depending on there splice
variants. I have demonstrated that the shorter ΔN isoforms of p63 and p73 function
in a dominant negative manner against p53, TAp63 and TAp73. Infact, the ΔN
isoforms of p63 and p73, function as repressors of transcriptional function of TAp63
and TAp73, preventing their tumor suppressive properties. Therefore, I have
demonstrated that ablation of ΔN isoforms of p63 and p73 mediates tumor
regression in p53-deficient mice through activation of tumor suppressive isoforms
namely, TAp63 and TAp73. Importantly, TAp63 and TAp73 compensate for p53-loss
by recruiting IAPP, which induces metabolic reprogramming induced regression of
p53-deficient tumors. Additionally, TAp63 and TAp73 can also activate downstream
apoptosis and cell-cycle targets mediating tumor suppression.
IAPP, 37-amino acid peptide secreted from the beta cells of pancreas
functions as a critical regulator of glucose metabolism. IAPP inhibits glucose uptake
and glycolysis by inhibiting hexokinase, the rate-limiting enzyme in the glycolytic
pathway. This IAPP mediated glycolytic inhibition results in accumulation of
intracellular ROS and cell death resulting in p53-deficient tumor suppression.
Interestingly, Pramlintide a synthetic analog of IAPP, is used in the treatment of
Type I and II diabetes also functions to inhibit glycolysis and result in ROS induced
cell death in the p53-deficient cancer cells. This raises the possibility of utilizing
Pramlintide based therapy to treat p53-deficient cancers. Upon administering
pramlintide,

p53-deficient

mice

showed

significant

reduction

in

thymic

lymphomagenesis. Importantly, I have also identified that IAPP/Pramlintide mediates
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its tumor suppressive function through the activity of the calcitonin and RAMP3
receptors which could be used as biomarkers to classify patients for pramlintide
based therapy.
Further, to expand my understanding of treating p53-mutant cancers, I have
demonstrated that mutant p53 binds and inhibits TAp63/TAp73 mediated tumor
suppression upon ablating ΔNp63/ΔNp73 in p53-mutant human cancer cells. Hence,
two approaches to treat p53-mutant cancers, is to overcome the effect of mutant
p53, by ablating the oncogenic isoforms of p63 and p73 and treating the cells with
DNA damaging agent like doxorubicin. This results in increased accumulation of
TAp63 and TAp73, which could possibly overcome mutant p53 effect. Second
approach is to target the downstream glycolysis pathway using pramlintide based
therapies. Treatment of mutant p53 human cancer cells with pramlintide has resulted
in inhibition of glycolysis and ROS-induced cell death through the activity of the
calcitonin and RAMP3 receptors. Since cancer cells are in general highly glycolytic
supporting Warburg’s hypothesis, pramlintide based therapy would work as novel
approach to treat these cancer types. Further, the only other available glycolytic
inhibitor is 2-deoxy glucose (2-DG), which has potent effect in inhibiting glycolysis,
however, 2-DG is highly toxic and cannot be used for therapeutic intervention. On
the contrary, Pramlintide functions similar to 2-DG and is less toxic and is already
used in the treatment of diabetes. Thus the use of pramlintide highlights a novel
approach to treat p53-mutant cancers.
Finally, since I have demonstrated that ΔNp63 and ΔNp73 function as
oncogenes in p53-deficient cancers, targeting these oncogenic isoforms has raised
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a novel therapeutic opportunity to treat p53-deficient cancers. To therapeutically
target ΔNp63/ΔNp73 in p53-deficient cancers, I delivered liposomal nanoparticle
coated siRNA’s targeting ΔNp63 in vivo in to a p53-deficient thymic lymphoma. This
resulted in a significant reduction in the thymic lymphomagenesis highlighting the
therapeutic applications of targeting the oncogenic isoforms of p63 and p73 to treat
p53-deficient cancers.
Thus far, my work has presented a novel and unique approach to treat p53deficient and mutant cancers. Importantly, understanding the interplay among the
p53-family members has enabled us to delineate the intricate and individual
functions of each of the isoforms in tumorigenesis. Further, by characterizing the
tumor suppressive role of IAPP, I have proposed the possibility of repurposing an
existing diabetic drug with less toxicity towards cancer treatment.
9.3. Future Directions
My thesis thus far has identified the intricate regulations among the p53family members, p63 and p73 and their role in tumor suppression. Importantly, I
have identified novel therapeutic approaches to treat p53-deficient cancers by
multiple approaches, one of which is through metabolic reprogramming induced by
IAPP which mediates tumor regression and second approach by using DOPClabeled siRNA’s to target the oncogenic isoforms of p63 and p73.
Hence, from this study it is evident that both ΔNp63 and ΔNp73 function as
oncogenes in a p53-deficient model of thymic lymphoma. Indeed this has been the
trend in human cancers, were expression of ΔNp63 and ΔNp73 is significantly
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upregulated. However, in some instances, ΔN isoforms could also function as tumor
suppressors (unpublished data). Nevertheless, it is important to further understand
and elucidate the larger roles played by ΔNp63 and ΔNp73 in tumorigenesis. ΔNp63
and ΔNp73 function as repressors of gene function. As a result, it is important to test
whether ΔNp63 and ΔNp73 could repress other transcription factors or even
miRNAs which could function as tumor suppressors. ΔNp63 and ΔNp73 may
perform these functions individually or by recruiting other co-repressors. Hence, by
performing a ChIP-sequencing analysis we can determine the binding partners of
ΔNp63 and ΔNp73.
Additionally, since ΔNp63 and ΔNp73 function as transcription factors, it is
possible that these isoforms could transactivate certain oncogenes by activating
oncogenic pathways to promote tumor formation. Hence, it is important to identify
the transcription related functions of ΔNp63 and ΔNp73 as well. Further to suppress
tumorigenesis, we could direct miRNAs that could function as “sponges” to control
and limit the function of ΔNp63 and ΔNp73 in tumor formation.
Further, previous work and current work as again attested that TAp63 and
TAp73 function as potent tumor suppressors. I have demonstrated that TAp63 and
TAp73 jointly induce metabolic reprogramming by activating IAPP, a metabolic
regulator. However, it is possible that TAp63 and TAp73 do have their individual
targets to mediate tumor suppression. Given the possible role of the TA isoforms in
regulating lncRNAs, TAp63 and TAp73 could play critical roles in activating lncRNAs
to mediate tumor suppression. Also, TAp63 and TAp73 could have distinct tumor
suppressive functions depending upon the tissue context. For example, p53
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restoration in the thymic lymphomas induces apoptosis, while in the osteosarcomas,
induces cellular senescence. Hence, similar to p53, TAp63 and TAp73 could have
diverse functions depending on the tissue context and origin. Hence, it would be
interesting to clearly delineate the diverse cellular process regulated by TA isoforms
of p63 and p73 in tumor suppression.
Finally, metabolic reprogramming is becoming a well-debated topic and even
emerged as one of the hallmarks of cancer. This is due to the fact that cancer cells
are metabolically active promoting tumor cell proliferation and require large influx of
energy to continue this process. Hence, therapeutically inhibiting this pathway
seems more feasible and does not depend on the functional status of different
genes. However, the metabolic circuitry is far more complex and constantly evolving.
I have identified the role of a metabolic regulator called IAPP which functions to
mediate tumor suppression by inhibiting glycolysis. Importantly, synthetic analog of
IAPP called Pramlintide, a diabetic drug has shown tremendous potential towards
the treatment of p53-deficient cancers. Currently, I have tested the use of
pramlintide in multiple cancer types and I aim to test the efficacy of the drug using
preclinical patient derived xenografts models. Results from this study will enable us
to use the drug as a single agent or as a combinatorial drug with other standard of
care therapy drugs.
Previously, as per Warburg’s hypothesis, mitochondrial oxidation does not
contribute to tumor cell proliferation. However, recent evidence has demonstrated
the mutations in the mitochondrial oxidation pathway have lead to tumor cell
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proliferation. Hence as a therapeutic strategy, we could utilize both pramlintide and a
mitochondrial inhibitor to suppress tumor cell proliferation.
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Appendix 1: Mouse thymic lymphoma mRNA heat map.
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Appendix 2: List of genes differentially expressed in ΔNfl/f;p53-/- vs ΔNp63Δ
/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- thymic lymphoma samples
Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Lce6a

0.50623477

0.8510781

3.2239006

0.014574393

Upp1

0.7964159

0.6226899

3.1032262

0.026755208

Ssr4

0.58017164

0.30428436

5.612081

0.004953332

Dph5

0.8363405

0.6458249

2.8655672

0.035176527

Kcnj10

0.6928598

0.8021817

2.8215833

0.025714781

Rplp1

0.89320916

0.40704307

3.2561753

0.047268085

Chst15

0.34172666

0.39977396

7.654346

1.21E-04

AI118078

0.70577794

0.823888

2.684871

0.0313175

1700029J07Rik

0.80049235

0.41755116

3.6963458

0.020902188

NR_033629

0.7805456

0.61027247

3.2125351

0.02366173

Gpr55

0.8152403

0.50371623

3.3865895

0.027616808

Apobec2

0.39166403

0.55679625

5.6879067

7.45E-04

Tnpo2

0.46795464

0.5575977

5.1519804

0.001321112

C1qtnf1

0.31462026

0.490858

6.9381404

2.24E-04

Sncb

0.68061334

0.62077165

3.6268063

0.011007131

Hemk1

0.7203515

0.7550949

2.9178421

0.026706224

Rps2

0.7302686

0.7622172

2.852749

0.029076638

Mapre2

0.8589156

0.5447324

3.0736532

0.037160475

Fbxw2

0.7842838

0.76749945

2.6384406

0.038620915

Clptm1

0.6981217

0.48885804

4.043158

0.015563355

Cdkn2b

0.759716

0.8135128

2.5456023

0.04374917

0.27684957

0.5970781

6.0870256

4.97E-04

0.7297057

0.64692396

3.3024392

0.021417892

Tcstv3
Lrp4
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Snph

0.5002801

0.97959596

2.5421705

0.038541656

Atat1

0.53324264

0.97110534

2.5028503

0.040821623

Ankrd60

0.2085665

0.828321

4.2540317

0.008060685

Fzd3

0.7992467

0.53205603

3.378766

0.027817171

Slc39a10

0.7468975

0.6011655

3.3935597

0.019386165

Pogk

0.79479855

0.80082333

2.4766378

0.04802364

Ssr4

0.67074746

0.58611465

3.8162637

0.012420383

Arf1

0.60844433

0.71573335

3.5322573

0.009568775

Rpl10

0.47247326

0.7212307

4.092963

0.004613714

Glod4

0.58177453

0.9311328

2.5762439

0.036672536

0.7877702

0.7324492

2.755291

0.033059366

Pcdh12

0.71684206

0.77184725

2.8627381

0.028698595

Cpt1a

0.50031483

0.98236585

2.5269172

0.039410077

Jub

0.8114347

0.75536054

2.5871568

0.04136963

Marveld3

0.6655221

0.9202029

2.384675

0.048547305

0.09720916

0.6674868

6.0559745

0.001770923

Smoc2

0.6986251

0.6333105

3.4929614

0.012936638

Usp46

0.7022045

0.66434157

3.3539565

0.015343993

Atp5g1

0.741628

0.8482092

2.4646173

0.04317217

Trpc6

0.52749956

0.8119151

3.3625886

0.012041636

NR_040684

0.14194141

0.77539027

4.846768

0.004687081

Acpp

0.6721452

0.8147476

2.839229

0.02507229

Fut4

0.75040406

0.7059895

2.9948723

0.024167644

Abcc1

0.7909167

0.738919

2.7202146

0.034632906

Rragc

0.79355305

0.8044168

2.467177

0.048643574

Tmem229b

Mael
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Rab25

0.60436094

0.87930626

2.7644632

0.027915865

Ror1

0.39281154

1.0071157

2.6372552

0.038682207

Calu

0.61523455

0.9443378

2.4152248

0.046416476

Marveld1

0.47468898

0.7533694

3.8917649

0.00596181

Slc25a21

0.8176421

0.7046145

2.7429042

0.040651474

Fam46c

0.54810005

0.5812634

4.5079803

0.004069225

Gal3st4

0.6925565

0.81971294

2.7475557

0.02860464

Rpl10a

0.69966877

0.8878008

2.4280963

0.045547623

Gm5077

0.79221207

0.74436057

2.6956744

0.035781357

Tpbg

0.8670789

0.57156676

2.9640145

0.041389212

Smarca2

0.5522846

0.91535926

2.7418885

0.028839475

Lrrc56

0.51858276

0.49713963

5.170814

0.002072778

Mrgpra1

0.03466722

0.717363

5.57638

0.002555353

Fam20b

0.59198934

0.89849436

2.7087545

0.030253453

Rtn4

0.585884

0.93577594

2.541162

0.03859846

Pth2r

0.06894411

0.7952146

4.771537

0.005007988

Foxe1

0.06402541

0.7921452

4.804346

0.004864986

Stt3a

0.68839693

0.6226994

3.5824049

0.011609451

Gdpd4

0.05965448

0.775595

4.963919

0.004233855

Prom2

0.29395136

1.0304649

2.683304

0.036375646

0.3702356

0.7321335

4.4629426

0.002925672

Asb13

0.51346165

0.8901825

2.9896507

0.02023635

NR_038165

0.06112718

0.7859784

4.864335

0.004615638

0.04384523

0.78105056

4.9238796

0.004382753

0.586931

0.8700178

2.8650258

0.024163263

Rffl

10-Mar
Akr1cl
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Rpn2

0.8236423

0.74626064

2.5763524

0.041974813

Iscu

0.3857484

0.7311601

4.404584

0.003139355

Tacr3

0.40059546

0.88987154

3.322399

0.012723062

Large

0.42922392

0.9303198

3.0033495

0.019847875

Pak6

0.58600616

0.6490751

3.9564848

0.005486284

Tuba4a

0.6070302

0.8479222

2.9073396

0.022746634

Krtcap2

0.54625815

0.8307415

3.1979437

0.015108911

NR_045888

0.03359216

0.76225203

5.1121187

0.003731821

Bmp6

0.52605855

0.8455745

3.1881936

0.015315074

Slc36a3

0.72738564

0.880149

2.3753183

0.04921976

0.4426753

0.7864958

3.817456

0.006563929

0.49544

0.8362016

3.3415244

0.012393758

Treml4

0.64355266

0.9215

2.4434934

0.04453018

Spic

0.48758885

0.97271717

2.6121955

0.034802

Galnt9

0.47929856

0.8997125

3.0390067

0.018873326

1810046K07Rik

0.4811074

0.8500687

3.3114579

0.01291566

Zkscan3

0.5762213

0.76946473

3.4009442

0.011427785

Sbf2

0.5884245

0.8156363

3.1275332

0.01666711

Ufsp2

0.3882136

0.93116844

3.1038597

0.017228816

Tex2

0.6097382

0.6423541

3.872926

0.008237901

0.046098124

0.7693352

5.0349994

0.003983822

Bcap31

0.74081314

0.71593606

2.9943774

0.024183095

Sync

0.41539133

0.7837205

3.9364207

0.00562912

1520402A15Rik

0.4395788

0.66299117

4.6181703

0.00243139

Fastkd2

0.6023917

0.85377264

2.8944259

0.023169441

Apoc4
Rhox4b

NR_015497
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Muc15

0.48963168

1.0017498

2.4464188

0.044339523

Tanc1

0.3942968

0.69174206

4.6445045

0.002357065

Efhb

0.64946467

0.826088

2.8665035

0.024112253

Nqo2

0.70100087

0.70463

3.1969662

0.018671393

Ptgs2

0.6398621

0.92783684

2.4242017

0.04580874

0.47836643

0.8383031

3.3869758

0.01164735

1.09E-05

0.78030497

4.9450326

0.007788752

Mrpl32

0.7962867

0.80487895

2.4562397

0.04937077

Klrc2

0.6295951

0.68254524

3.5947902

0.01143785

Nfyc

0.42785197

0.8803824

3.3011353

0.013100242

Ocln

0.53484064

0.67174685

4.088315

0.004640799

Sec61g

0.5311733

0.91416025

2.8096251

0.026160005

Manba

0.47241944

0.90458584

3.031675

0.019069478

Pik3c2g

0.5235649

0.77561355

3.572338

0.00906853

Tgfbr2

0.6057456

0.9590669

2.3689172

0.049685277

Med11

0.5247877

0.68585765

4.058766

0.004817104

Mrps6

0.5970628

0.87763494

2.795532

0.026695142

NR_030738

0.5055372

1.0090405

2.3675964

0.049781892

Abcb1b

0.5881341

0.9499241

2.463673

0.04323195

Pla2g4c

0.6487061

0.7689414

3.1268964

0.016681964

0.37614614

0.7640406

4.2150292

0.003960948

0.7017584

0.88372415

2.4395854

0.044786185

0.516418

0.7758566

3.5985727

0.00875646

0.5621396

0.7359082

3.6270857

0.00843042

0.66979957

0.90549463

2.4397695

0.044774093

Egfr
NR_015516

Iapp
Zmpste24
Praf2
Traf3ip2
Naip7
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Adamts14

0.64072967

0.8861263

2.6184433

0.034487177

Clta

0.27749223

0.64808947

5.579663

8.34E-04

Gnas

0.86566114

0.6538075

2.7268248

0.041436642

1300017J02Rik

0.40781325

0.95330995

2.9224846

0.022261126

Ly9

0.60790765

0.957329

2.371578

0.04949123

0.6981446

0.8721835

2.5015848

0.040897276

Galnt6

0.558411

0.7451528

3.5949407

0.008798962

Cab39l

0.67603004

0.76048815

3.0611315

0.018294284

6330409D20Rik

0.2894976

0.87401193

3.7218037

0.009831389

Dhx29

0.6045901

0.9455439

2.43939

0.044799034

Cd151

0.4969481

0.91345584

2.9121544

0.022591082

Pgam2

0.43017796

0.9631706

2.8098369

0.026152052

Rpl38

0.55708057

0.8995604

2.8088906

0.026187617

Cd82

0.5228897

0.7125258

3.919965

0.005749298

0.48725036

0.85251766

3.277781

0.013528376

0.671924

0.8576328

2.6498168

0.032950453

0.5289441

0.841474

3.2003438

0.015058617

NR_033495

0.45328638

0.8283428

3.5287938

0.009613382

C2cd2

0.60580796

0.82422304

3.0252416

0.019243384

0610010O12Rik

0.5705635

0.9569846

2.4763649

0.042435452

Slc25a12

0.7201853

0.86228335

2.4744027

0.042557597

Ap4m1

0.5918478

0.8213844

3.0874119

0.017630924

Gstp1

0.4371063

0.95067763

2.8648202

0.024170365

Mrpl47

0.5924998

0.95079786

2.447101

0.044295173

Rps24

0.5697426

0.9511336

2.5086052

0.04047941

NR_033567

Tspan32
Extl2
Psma5
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Gene Name

Ncald

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.5127015

0.94034237

2.7223492

0.02966473

Cacna1f

0.47335693

1.0060757

2.4611814

0.043390118

BC048546

0.33758682

0.7778202

4.260159

0.003745855

Fbxo10

0.49252775

0.9984751

2.4575386

0.04362243

0.5712679

0.94908345

2.5148673

0.0401104

0.49137715

0.86753416

3.181155

0.015465769

0.6111891

0.9431995

2.4322996

0.045267522

Ugt1a1

0.44555384

0.9623292

2.7765749

0.027433163

1810006K21Rik

0.21862034

1.0390533

2.7403898

0.04077316

Eps8l1

0.43315858

1.0194954

2.4765108

0.042426385

Arhgef17

0.61637163

0.84924567

2.8701138

0.023988103

Med22

0.36853078

0.9276793

3.1742754

0.019214507

NR_029468

0.35080907

0.9451299

3.107887

0.020905085

0.2620157

0.8053907

4.2967877

0.005110728

Scml4

0.65128565

0.9152222

2.4501765

0.04409585

Asah2

0.46289924

0.8275435

3.5008683

0.009981358

Fam98a

0.62171805

0.9417445

2.4094806

0.04680969

Taz

0.13061292

0.9723755

3.2965355

0.021557627

Fau

0.48894367

0.9964673

2.4774058

0.0423708

0.6946559

0.8758147

2.4966183

0.041195575

Syvn1

0.47107065

0.77000326

3.8079958

0.006645221

Pdlim1

0.6388014

0.91971564

2.4659784

0.04308614

NR_003965

0.6674969

0.89619136

2.4893866

0.041633945

Mup8

0.28921473

1.0305451

2.6907148

0.036018368

Afg3l2

0.47320518

0.9837088

2.587048

0.03609968

Cryaa
Clnk
Fam19a1

Scgb3a2

NR_045290

	
  

169	
  

Gene Name

4931408A02Rik

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.5731959

0.94342273

2.5383627

0.038756575

Ssu72

0.20708062

1.0556824

2.6451163

0.045694012

Pigu

0.47711998

0.94269335

2.805804

0.026303977

0.7243802

0.88134074

2.3795633

0.0489135

2.46E-05

0.87987256

4.069787

0.00963597

Gm3258

0.33341172

1.0345705

2.588222

0.041310463

Tspan8

0.77924377

0.7922718

2.562129

0.04278586

Nmur2

0.32798997

0.99668837

2.8342068

0.029792687

Lman1

0.26106992

0.92545706

3.4305842

0.013961174

NR_033474

0.34091642

0.8583539

3.6919248

0.010185443

B230217C12Rik

0.41473922

0.88270944

3.325502

0.012669002

Sv2b

0.51376563

0.9290682

2.7799869

0.027298767

Ptp4a2

0.27657467

0.9073741

3.5217657

0.012491772

Ankrd6

0.46388268

0.80018413

3.6573663

0.008098511

Fau

0.46296304

1.0127833

2.4475908

0.04426337

Folh1

0.5174267

0.9502935

2.656049

0.03265377

Arid5a

0.51709694

0.9645196

2.5805302

0.03644415

Mup2

0.47848442

0.9453433

2.7874343

0.027007809

Klra4

0.37658283

0.9900398

2.7747087

0.03222138

Slc40a1

0.1771824

1.0311472

2.8428626

0.036124878

Glrx3

0.5580255

0.8876175

2.8671272

0.024090758

Tbc1d5

0.4829335

0.90015644

3.0259233

0.019224878

4.46E-06

0.9485071

3.5368476

0.0166182

0.010931266

0.9003462

3.9053736

0.011347706

9930012K11Rik
Clrn1

NR_045514
2310008H09Rik
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Gene Name

Tnfrsf19

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.1674707

0.93556035

3.5172882

0.016968133

Cfhr2

0.23195125

1.0613495

2.5768409

0.0496218

Llgl1

0.0021698

0.892555

3.9677355

0.010660225

0.37240082

0.8146346

3.8862486

0.006004374

Rpl19

0.079263635

0.9787726

3.2910182

0.021689147

Nsun4

0.4416605

0.91613525

3.0523489

0.018521847

Cnih4

0.39498183

0.95586914

2.938306

0.021765612

Nadk

0.42643613

1.03985

2.372246

0.04944263

Ankrd34a

0.19225873

0.7893165

4.612589

0.00577403

Dhrs1

0.39609712

0.9833172

2.7718215

0.027621552

Hopx

0.5611796

0.9375947

2.601936

0.035325464

Ltb4r2

0.32045794

1.0218899

2.6908607

0.03601137

0.5017128

0.8816087

3.0717993

0.018021865

Ermap

0.100690484

1.0353256

2.881328

0.034534495

Ubac2

0.4101417

0.93958837

2.9980452

0.01999735

Pcdhgb1

0.28273576

0.98378414

3.0019758

0.023947064

Rgs22

0.44141433

1.0208169

2.4505277

0.04407315

Paqr7

0.6668556

0.76181465

3.089987

0.017567312

Klrb1a

0.22580683

1.0472682

2.6770046

0.04397767

Tmsb10

0.17267758

1.0051781

3.023695

0.029292101

Sdr9c7

0.1983991

1.0443401

2.7305067

0.041255385

Dnm2

0.29322225

0.99542636

2.9078968

0.02705447

Cops7a

0.40569085

0.9745358

2.8019078

0.026451634

Ccl19

0.22727525

0.9722433

3.1730046

0.02473142

Ttll11

0.21911533

0.9631975

3.247384

0.02276186

D630023F18Rik

G630090E17Rik
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Pold4

0.2391084

0.92063814

3.506603

0.01716284

Gm1987

0.2326995

1.0171548

2.865371

0.035184603

Syn1

0.010146572

0.9074213

3.8498783

0.012002615

Atrnl1

0.42843425

1.0190974

2.4892452

0.04164256

Klk1b8

0.39827925

0.9093671

3.2101076

0.014855861

Tmem87a

0.52063036

0.97502416

2.5148137

0.04011355

0.5213376

0.865152

3.0992453

0.01734063

Eif4a2

0.09404888

1.0454574

2.8158395

0.037290826

Lpcat1

0.16151527

1.0282186

2.8792467

0.03461853

Sec24c

0.34898728

0.91431296

3.3065064

0.016275393

Prl2c5

0.16585448

0.88248074

3.9134727

0.011255602

NR_045551

0.27606234

0.8820939

3.6977692

0.010115091

Slc25a13

0.3427428

0.97040373

2.968056

0.025020428

Spryd4

0.4059689

1.0225371

2.517598

0.045434296

Col6a4

0.42790028

0.99260974

2.6444578

0.033207808

Mrps10

0.19412164

1.0520066

2.6845717

0.043580882

Wwtr1

0.5607859

0.9568985

2.503545

0.040780153

Eml1

0.31955248

1.0166045

2.7256072

0.034385867

Kank3

0.33374676

0.98271513

2.910037

0.026979113

4930579G22Rik

0.24159038

1.0129989

2.8796208

0.03460341

Ptpn3

0.18376632

1.009624

2.9804668

0.030783365

BC068157

0.44300586

1.0300736

2.3934824

0.047922913

Kcnj16

0.1452977

0.9886137

3.1676726

0.02487983

Cubn

0.4371116

0.9212942

3.0348473

0.018984344

C030006K11Rik

0.3596322

1.0092193

2.69375

0.035873126

5830411N06Rik
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Wscd1

0.3796186

1.0385841

2.475681

0.048085954

Filip1

0.3174312

1.0554887

2.4859033

0.04742458

0.27832347

1.0483567

2.5945826

0.040959068

2.04E-04

1.0830048

2.5851943

0.049121927

Hn1l

0.33259466

1.0364295

2.5781753

0.04187205

Naaa

0.3033944

1.0623595

2.4658666

0.048730098

Lrp11

0.4181843

1.0247229

2.4786282

0.04229501

Zp3

0.33273584

1.0134135

2.7208018

0.034605913

BC020535

0.13597594

1.0502218

2.75375

0.040131155

NR_003559

0.31307563

1.0081371

2.7907507

0.031546272

Ap4s1

0.47268093

0.97784877

2.621144

0.034352

Spink8

0.17779204

1.0021979

3.038038

0.02881531

Grhl2

0.33539027

0.9735747

2.9638171

0.025158186

Trim65

0.29378456

1.0665808

2.4543815

0.04949545

1110067D22Rik

0.33296582

1.027188

2.6348464

0.038807075

Kap

0.18033898

0.9351312

3.5023742

0.0172406

0.1973908

1.0033227

3.006044

0.029891029

Higd1b

0.30218932

1.0357987

2.6355996

0.038767986

Lce1a2

0.12076877

0.96750176

3.3405473

0.020540189

Lyplal1

0.30945802

1.0592098

2.4758434

0.04807537

Tmprss2

0.25288934

1.0497423

2.6236742

0.046889488

Hbb-bh1

0.096041106

0.94791174

3.5035288

0.017219327

0.15691313

0.9495058

3.4307046

0.018621366

0.2076112

1.048915

2.689168

0.043341804

1.30E-04

1.0293053

2.9558487

0.031670462

Epb4.1l5
Pou2f1

Bnip1

Gsc
Scube1
AW551984
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Gene Name

Dab1

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.0501478

0.9338845

3.635904

0.014967592

Kcnk16

0.106278725

0.9433708

3.5284772

0.016766937

Pou5f1

0.21591836

1.0218856

2.857435

0.035512984

NR_040725

0.050579414

1.0547882

2.771202

0.039309315

Serpine3

0.071880594

1.0747625

2.6265485

0.046727255

Triobp

0.001302765

0.95452374

3.4921272

0.01743069

Cpb2

0.17187624

1.0402282

2.7875478

0.03855644

Wdsub1

3.49E-04

1.0074637

3.1093168

0.026571333

Pla2g10

0.08787624

0.9853477

3.238725

0.022981795

Sall3

0.16996822

1.001712

3.0504706

0.028409056

Prss3

0.16676864

1.0712739

2.5847702

0.049147174

B020004J07Rik

0.050596338

0.9881912

3.2372963

0.02301831

Prkg1

0.016211495

1.0360569

2.9079576

0.033479154

NR_045499

0.121789984

0.9866879

3.2035015

0.023901505

Dcst1

0.023635086

0.9728535

3.355415

0.02020886

Hist1h1t

0.12700328

1.0330417

2.8779435

0.034671262

Nr2e3

0.06102681

0.9930714

3.1982481

0.024042198

Ppp1r42

0.10658224

1.0088007

3.0608091

0.028076116

1.44E-05

1.0836018

2.5811038

0.049366016

0.064044625

0.9909495

3.211993

0.023676045

0.07664614

1.0190103

3.0081723

0.029818088

0.009730205

0.98342794

3.2806072

0.021939807

0.07147401

1.0313613

2.9248602

0.03282796

0.066882834

1.0650269

2.6951408

0.043033276

6.77E-06

1.0829573

2.5855205

0.049102522

Serpina1a
Nog
NR_045471
Gpr123
NR_045403
Dync1i2
Fam178b
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Gene Name

NR_045139

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.06735169

1.008584

3.085693

0.027292563

0.053612288

1.0680281

2.6793606

0.043853704

Prkag3

0.06384879

1.0049062

3.1131773

0.026455523

Slc22a20

0.03645663

0.9997913

3.159037

0.025122324

Kcnq2

0.036764227

1.0096254

3.089353

0.027179392

Caps2

0.015649516

0.9968863

3.1835794

0.024440022

Gm5415

0.034550942

1.0045222

3.125965

0.026075933

0.03275477

1.0138159

3.06079

0.028076725

Plec

0.045199126

1.0173177

3.0328953

0.028985256

Gpr45

0.012568595

0.99713814

3.182096

0.024480665

Gpr151

0.034017283

1.0244093

2.9862201

0.030580075

Mas1

0.021702003

1.0055172

3.1214514

0.026209213

Ugt2b35

0.015060733

0.9937249

3.2062118

0.02382928

Opn4

0.025556093

1.0219386

3.00519

0.029920353

NR_045633

0.019177223

1.0061882

3.1170616

0.026339568

Sez6l2

0.010578183

1.0408726

2.8749948

0.034790907

Gm15085

0.014337389

1.0038928

3.133896

0.02584359

Nkain2

0.012200879

1.0196103

3.0232098

0.029308382

Dlg5

0.005792228

1.0646698

2.7109206

0.042229768

Fkbp10

0.002660292

1.042329

2.8652275

0.03519051

Kcnq2

0.001736278

1.0002984

3.1601448

0.02509107

Sgce

6.18E-06

1.0689567

2.6815572

0.043738477

Mum1l1

1.76E-06

1.0081193

3.1046782

0.026711244

NR_040301

0.008865041

0

436.87704

5.24E-06

NR_040302

0.06453177

0

59.975018

1.02E-05

Naaladl1

Hsd17b13
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Gene Name

Defb19

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.71080106

0

4.9688

0.015658686

Myt1

0

0.001229972

3856.5217

0

Myt1

0

0.012753357

371.91794

2.67E-12

Myt1

0

0.06677306

70.94985

1.05E-08

Ccdc34

0.7565142

0.7743096

2.7106729

0.035074696

NR_038063

0.9059068

0.108112104

3.610451

0.03649204

Hsd3b1

0.9762237

0.1183075

3.242564

0.047757953

0.71784025

0.876197

2.4221497

0.04594694

0.7443213

0.27466303

4.3815093

0.022009687

0

0.17948449

26.190445

1.52E-06

Dnm2

0.7816765

0.7036265

2.8824856

0.027966736

Ccdc73

0.7500891

0.80644923

2.606324

0.04031871

0.899202

0.49879313

3.0194435

0.039184667

0.6512607

0.85505253

2.728589

0.029398533

Ssb

0.89562666

0.46026605

3.1269035

0.035290547

Ppfia1

0.17896304

0.4426226

9.011467

4.23E-05

NR_015569

0.8817025

0.6314438

2.7326956

0.04114804

Cspp1

0.9237553

0.30175745

3.3034446

0.04561552

Nr1h2

0.80819005

0.7916678

2.465703

0.048740912

Ccar1

0.7473373

0.33813232

4.2108502

0.024464315

Cd97

0.7391347

0.7507099

2.8657172

0.028586878

0.56713337

0.34691033

5.5523005

0.005149068

Larp7

0.7287209

0.7800584

2.7866962

0.031715456

NR_040337

0.9435602

0.2577174

3.270256

0.046767995

Brd3

0.9159391

0.5309495

2.8696134

0.045486327

NR_045294
Rsrc2
Bcl2l10

Gast
Cnnm3

Rbm25
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Tob2

0.8125718

0.69766694

2.785804

0.03863599

NR_027656

0.4660744

0.40277642

6.213478

0.00157788

0.68383205

0.74108434

3.1140285

0.02074208

Fam100b

0.8499497

0.54074174

3.1237369

0.035398606

Celf2

0.8482771

0.6944917

2.662934

0.04472609

Ap1m1

0.8313259

0.30461124

3.7822196

0.03239436

Bod1l

0.8083337

0.27769783

3.9667544

0.028626364

Cdk5r1

0.8614844

0.46018153

3.283664

0.030395865

0.88041836

0.30041733

3.5238216

0.038810708

0.9409301

0.5197001

2.7949195

0.04906509

Rnf6

0.44702148

0.908454

3.0818298

0.017769653

Srek1

0.81591403

0.58965653

3.126639

0.026056103

4930578N16Rik

0.59512186

0.44799608

4.8665276

0.004606811

Itgb5

0.73957336

0.3174806

4.313101

0.022953564

Crebzf

0.6561649

0.8002372

2.9595892

0.021117367

Abcc5

0.51673055

0.36533624

5.938121

0.004032765

Btbd6

0.7685415

0.50855094

3.6003833

0.022750376

NR_045578

0.9126684

0.48834902

2.9865665

0.040475197

Arpp21

0.8975752

0.33963913

3.3679037

0.043478187

Asb13

0.51212585

0.8886454

3.0019608

0.019886896

0.7172673

0.7719071

2.860952

0.028765805

Mmadhc

0.75836766

0.47774488

3.7490823

0.01996297

Rps11

0.35408777

0.9651544

2.9759834

0.024764983

Dcaf17

0.5781421

0.69776237

3.7513547

0.007155442

Rtf1

0.5206674

0.43033463

5.5381308

0.002633922

Calm2

Brd9
Zfp161

NR_037588
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Zrsr1

0.56968236

0.9738193

2.3920841

0.04802149

Mfsd2b

0.93503726

0.53652716

2.7782524

0.049907636

Ube2d2

0.8636002

0.6110902

2.8639185

0.03524445

Ttbk1

0.8831647

0.62915653

2.7337832

0.041094817

Zfp574

0.55221087

0.5197923

4.810299

0.002969328

Dhx30

0.7612478

0.6757851

3.0636566

0.027985187

Ahdc1

0.7171415

0.684632

3.2106376

0.01835228

0.56960326

0.4479001

5.0545273

0.003918179

Mgat1

0.7375186

0.8573658

2.4397557

0.044775

Wscd2

0.8613684

0.5395813

3.0772598

0.037030213

0.83794755

0.6719081

2.7754176

0.039113607

0.6503541

0.9072962

2.4900734

0.0415921

Rock1

0.71568114

0.7212333

3.0715823

0.021897644

Kin

0.89099675

0.48331088

3.092922

0.036470704

Hmg20b

0.66140604

0.52969086

4.095439

0.009396655

0.8640084

0.40957704

3.3909113

0.04274617

Cklf

0.7687318

0.72835547

2.8410273

0.029527117

Zc3h14

0.7551423

0.62978643

3.255054

0.022569034

0.38079923

0.9247394

3.1617765

0.0158889

Arhgef10l

0.6336453

0.5946082

3.9706135

0.007361795

N6amt1

0.7559443

0.85042006

2.4093246

0.04682041

Rbm17

0.85908145

0.6336144

2.8141544

0.037364904

NR_028577

0.6761663

0.7327598

3.1792881

0.019093057

Fndc1

0.8455971

0.46573249

3.3447828

0.02870774

Syk

0.5447683

0.9641938

2.5088084

0.040467385

Pura

Csnk1g2
Ssb

2-Mar

Taf3

	
  

178	
  

Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Hnrnpm

0.800717

0.46694723

3.561675

0.023550654

NR_030673

0.835641

0.5774963

3.0792713

0.03695779

Uimc1

0.7633097

0.48195842

3.7100184

0.020653702

Shc1

0.44396058

0.68393433

4.4583945

0.002941736

Ing3

0.7795554

0.72993296

2.7948492

0.031376243

Phf14

0.82985073

0.5457115

3.198287

0.03295459

Mex3b

0.6063178

0.43012962

4.864984

0.004613023

Anxa2

0.8367505

0.67850846

2.7584453

0.039908197

Reck

0.6805226

0.69872534

3.3054204

0.016297424

Bptf

0.76309305

0.8378896

2.4369915

0.044956952

Rnf39

0.40021583

1.0008725

2.6583276

0.032546

Raf1

0.8120058

0.4597659

3.5246024

0.024348741

Lrrcc1

0.7895861

0.44642094

3.6763673

0.021271734

Thoc2

0.2576664

0.5756566

6.437475

3.54E-04

0.70253646

0.8906831

2.406515

0.047014035

0.794924

0.45385212

3.6278434

0.022202266

0.90529424

0.57521474

2.7983265

0.048894897

0.6243755

0.5619415

4.165929

0.005905252

0.84929556

0.524234

3.1724238

0.033779275

Mier2

0.8059555

0.78203076

2.5090163

0.04596432

Cir1

0.7852969

0.5092136

3.5151021

0.024558416

Bcl11b

0.6159637

0.46623135

4.6406145

0.005629563

Cetn4

0.6991679

0.73771614

3.0688279

0.021975018

Cyth2

0.75424033

0.7992667

2.6206896

0.039549675

0.822884

0.7263186

2.6487508

0.04549472

4933430H15Rik
Pigv
NR_030779
E030030I06Rik
Snap23

Palm
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Vps4a

0.7282406

0.5738591

3.5787551

0.015895769

Kif5a

0.62185764

0.48612505

4.515499

0.00630892

0.6356815

0.78147686

3.118717

0.01687398

Tulp2

0.54497343

0.7128762

3.8204868

0.006538115

Lmo4

0.66365415

0.8370295

2.7692146

0.027725447

0.6500399

0.9239539

2.4127975

0.046582222

Elavl4

0.15755658

0.63556826

6.255576

0.001530557

Fbxl14

0.6255018

0.6577499

3.7264848

0.009777168

Akap5

0.75391114

0.69257015

3.0312917

0.023059575

Igfbp6

0.7547445

0.652518

3.1749818

0.024676641

Csnk1g3

0.6171592

0.5976586

4.04312

0.006778718

Klk5

0.6948286

0.6554953

3.4215493

0.014116849

0.83182234

0.5254681

3.2476401

0.031445812

Csnk1e

0.7655034

0.600903

3.3106167

0.021226026

Ube2n

0.6042501

0.6818456

3.7117028

0.007537909

Ddhd1

0.5254294

0.62025064

4.422035

0.003073707

Ints3

0.68637633

0.56756693

3.810743

0.012490577

Dcaf8

0.6433541

0.9240245

2.4321096

0.045280144

Syf2

0.75671476

0.73409146

2.8644576

0.028634055

Rai1

0.7688361

0.58904004

3.336076

0.020641034

Mlf2

0.55079055

0.5159931

4.8399463

0.002880945

0.8180218

0.7322675

2.6456184

0.038251977

Brd4

0.78793657

0.523612

3.4582684

0.02585857

Axin1

0.6970009

0.743669

3.0525334

0.022438858

Zfp295

0.8054627

0.76213

2.5836973

0.041562386

Wrnip1

Ppp1r10

4930452B06Rik

NR_015349
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Top1

0.6067318

0.6072432

4.0532465

0.006701471

Arid4b

0.5123038

0.77038735

3.644609

0.008236586

Rfesd

0.45654958

0.84788245

3.4036427

0.011385886

BC005561

0.5326797

0.6388459

4.2796435

0.003656983

NR_033442

0.6421799

0.7713979

3.1403644

0.01637085

Dbndd1

0.8621894

0.64172083

2.7772841

0.039027292

Adamtsl5

0.79542696

0.5411376

3.368849

0.028073633

Wdr33

0.69219875

0.80477273

2.8128295

0.026039911

Ndufs1

0.7671161

0.7572592

2.7382882

0.033812333

Dact1

0.5049645

0.5545078

4.9262686

0.001701469

Sorbs1

0.72754884

0.62102324

3.4090002

0.019064002

Wdr53

0.56409645

0.978322

2.3835714

0.04862613

Ubl7

0.421326

0.61160135

5.075129

0.001438832

Alx3

0.5302911

0.9404301

2.6734247

0.031841222

Aagab

0.6572083

0.63159823

3.6926894

0.010176208

Zfp672

0.13123523

0.7517969

5.088889

0.003805714

Tbxa2r

0.7575673

0.60550946

3.3301222

0.020776184

Mknk2

0.44224867

1.0299667

2.3957646

0.047762465

Fam177a

0.5899091

0.68773896

3.7481132

0.007185903

NR_027957

0.5725367

0.61177254

4.212026

0.005610548

Tcp11

0.79367644

0.70578396

2.8290186

0.036717057

Gpc3

0.6709766

0.7733604

3.0243428

0.019267814

Rad52

0.5025112

0.9872908

2.494428

0.041327845

NR_027859

0.7378596

0.68268377

3.1330378

0.020246252

0.51094145

0.9664823

2.5860868

0.036150273

Hectd2
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

NR_027008

0.6537888

0.63087565

3.712074

0.009945159

Dact3

0.6942757

0.8681166

2.5316873

0.03913635

Mtap4

0.657026

0.7007251

3.3952367

0.014581224

0.68146247

0.7189174

3.2168279

0.018209754

0.8634628

0.6797194

2.6541584

0.045199968

Dcaf4

0.45337337

0.56417084

5.2055607

0.001245379

Upf3b

0.48036706

0.60581875

4.763459

0.002051215

Fbxo46

0.40984645

0.89562535

3.2615662

0.013834438

0.87334

0.63144875

2.7650402

0.03959734

Srek1ip1

0.8395489

0.6457891

2.8530421

0.03569622

Zkscan3

0.45221916

0.74121994

4.0579915

0.004821822

Etl4

0.17413361

0.6203647

6.3700395

7.03E-04

Dguok

0.7053372

0.89199996

2.392085

0.048021425

Atxn2l

0.4271552

0.76592535

4.0048165

0.0051582

Adarb2

0

0.7746691

4.9992986

0.004107182

Phf21a

0.70575136

0.82782346

2.6682532

0.032080833

1300018I17Rik

0.5401398

0.7832738

3.4681034

0.010432599

Arnt

0.6687846

0.7261573

3.2368786

0.017756354

Angptl1

0.8247388

0.6986858

2.7365696

0.040958814

Cox7a2l

0.23154019

0.6239354

6.0568757

9.18E-04

Cep97

0.5411474

0.93019515

2.696865

0.030778343

NR_045268

0.5481574

0.74986714

3.6121795

0.008599197

Rnase10

0

0.7747412

4.998601

0.004109637

Myt1

0

0.7747441

4.998573

0.004109736

0.21065246

0.7395884

4.998531

0.002455932

Prss53
2310035K24Rik

Rexo1

Usp16
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Anapc11

0.62159806

0.75412816

3.298472

0.013148325

D330028D13Rik

0.81690884

0.6869514

2.8058786

0.03773109

0.6036144

0.8308061

3.0011466

0.01990981

0.61332154

0.87530315

2.7555535

0.028276635

0

0.7751593

4.9945555

0.004123905

Bcl2l1

0.83993524

0.65894616

2.8096044

0.03756574

NR_045836

0.78177375

0.5636572

3.3609936

0.02008611

Ubxn6

0.49219784

0.72642493

3.976024

0.005350981

Npepps

0.6244869

0.7334903

3.382713

0.011715255

Trp53i13

0.7999554

0.78777355

2.5082364

0.046012808

Rhoa

0.6461705

0.76251376

3.1653295

0.015810406

0.89041245

0.5714423

2.8684409

0.045540113

0.7922065

0.65131646

3.024311

0.02927144

0

0.7783602

4.9636917

0.004234684

Map2k7

0.6341646

0.90655434

2.5423002

0.03853436

Cep164

0.87164605

0.66907

2.6570299

0.045044303

Ythdc1

0.76479363

0.67449814

3.0539968

0.028295005

Pi4kb

0.10819078

0.77908874

4.872118

0.004584393

0

0.77953666

4.952396

0.004276094

Pptc7

0.7900982

0.79142

2.528216

0.04478743

Phf14

0.44339877

0.8663194

3.3374078

0.012463856

Mta3

0.6046586

0.73495823

3.4565203

0.010597348

4930404N11Rik

0.6045984

0.922098

2.5550313

0.03782484

Celf1

0.510967

0.90942675

2.893551

0.023198381

Wnt11

0.8077902

0.6352808

3.0144293

0.029604806

NR_037865
Klc3
CK137956

Shank2
Zfp14
NR_037994

Dnajc5b
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Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

Pik3ca

0.43003753

0.79575723

3.806954

0.006654241

Dalrd3

0.4499849

0.63253427

4.7649264

0.002047728

Abca6

0.78884876

0.78179115

2.568847

0.042400736

Med10

0.68042433

0.9132144

2.3725033

0.04942393

0

0.7790405

4.9571567

0.004258584

0.49998307

0.7044652

4.068538

0.004757999

Os9

0.6712847

0.916248

2.3858652

0.048462443

Armcx2

0.5472892

0.9352324

2.65326

0.032786198

AI597468

0.15942389

0.98546755

3.1743722

0.024693517

Nprl2

0.44184563

0.80489534

3.708528

0.007569478

NR_037957

0.64764315

0.8573473

2.729844

0.029345294

Prkg1

0.5095542

0.7167073

3.955685

0.005491902

Dync1i2

0.2762159

0.85682684

3.8763223

0.008205559

Safb2

0.7134781

0.8293146

2.63606

0.033615317

Ppil2

0.07427365

0.9993173

3.1475754

0.0254483

Foxp4

0.71792686

0.7712024

2.861434

0.028747648

Senp8

0.6936455

0.75356686

3.0240614

0.02327509

Galnt1

0.72600716

0.87310547

2.4097717

0.04678968

Bcl7b

0.5419179

0.668453

4.0718465

0.00473817

Cdkn1b

0.6115648

0.86368525

2.8168738

0.025889166

Phf17

0.52273506

0.97663397

2.5007133

0.040949456

Htatsf1

0.7188913

0.66379094

3.2844977

0.016728327

0

0.7861389

4.88947

0.004515614

Zranb2

0.6593553

0.8404091

2.7683823

0.027758704

Wipf2

0.6554555

0.8603764

2.6906781

0.031055236

Rnase10
Lrrc55

Nms

	
  

184	
  

Gene Name

NR_045199

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.7937492

0.7310667

2.738319

0.033810955

Dgcr6

0.59782135

0.74148375

3.4529839

0.010648205

Snx15

0.55247813

0.9107759

2.764956

0.027896052

Rps9

0.5673595

0.9254546

2.6464233

0.033113178

Zfp865

0.6092422

0.681453

3.690992

0.007746457

Ubap2l

0.49465027

0.90207225

2.98109

0.020483203

Prpf38b

0.14805315

0.8123992

4.508817

0.006347803

Sema3c

0.6181054

0.9336318

2.4593935

0.04350398

Egfl8

0.5520453

0.9853867

2.3781722

0.049013652

0.771046

0.70845985

2.9057271

0.02713109

Fam76b

0.6104966

0.9041898

2.6249244

0.034163717

Tfap2b

0.6116507

0.7360093

3.4230442

0.011089454

0.542541

0.8724677

2.9934573

0.0201276

0.3917597

0.67028075

4.811871

0.001939541

0.59446603

0.79876924

3.188295

0.015312916

Map3k1

0.5970785

0.9522292

2.4271564

0.0456105

NR_028296

0.6637605

0.87100047

2.6157708

0.034621477

Abtb1

0.50172323

0.87733525

3.0950723

0.017442416

Abcf3

0.5553815

0.8647535

2.9924054

0.02015759

Sdccag8

0.5323854

0.81639963

3.3214037

0.012740452

Hoxa7

0.5585729

0.8714137

2.9481747

0.021462454

Apcdd1

0.5051843

0.7833241

3.6003404

0.008735855

Zfp653

0.49923918

0.8417716

3.2979968

0.013156923

Stau1

0.4474471

0.94864327

2.8500662

0.0246861

Mylpf

0.50479585

0.81522506

3.425224

0.011056672

Mex3d

2010109K11Rik
Hmg20b
Cnot3
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Gene Name

Fsd1

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0

0.7863221

4.887735

0.004522437

Il11ra2

0.61620104

0.76958287

3.2469985

0.014115741

Safb

0.37423646

0.7603252

4.2480645

0.003802212

Ppm1h

0.6729283

0.8142038

2.8389108

0.025083728

Lrrc58

0.5103216

0.8714947

3.1000147

0.017321933

Jkamp

0.41460916

0.75396657

4.1315413

0.004395489

Psmd8

0.5353771

0.89093375

2.919222

0.02236478

Sirt2

0.14304742

0.78501093

4.7576427

0.005070019

Zxdb

0.47418293

1.0151492

2.4081335

0.046902396

Hnrnpd

0.5728875

0.81935

3.1637008

0.015846336

Ankrd11

0.43313587

0.8988593

3.1767614

0.015560637

Zfand2b

0.39990926

0.94115597

3.0143824

0.019540753

Otud1

0.56800467

0.8183331

3.1859396

0.015363161

Sema4d

0.5153147

0.85833365

3.1551049

0.016037423

Ubqln2

0.4239337

0.83499956

3.586618

0.0088972

Casp7

0.50147617

0.8450988

3.2722661

0.013631649

0.6683331

0.90442926

2.449092

0.04416604

Zfp575

0.53988343

0.9070609

2.821359

0.02572306

Fnbp1

0.68849593

0.8814452

2.4909873

0.0415365

Polr3gl

0.4477471

0.90510195

3.099109

0.017343946

0.42112926

0.9808967

2.7284148

0.029405933

Pias1

0.4457344

0.8892454

3.1966069

0.015137001

Fbxw2

0.15463954

0.81758016

4.4528923

0.006684369

Kif5b

0.43570784

1.0276177

2.4237242

0.045840863

Tnrc6c

0.66337115

0.87159204

2.6143215

0.034694538

Pfn1

Gm1965
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Gene Name

Gltp

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.38288268

0.82021946

3.8148606

0.006586124

Zcchc9

0.5295479

0.8421459

3.1947608

0.015175884

Zfp746

0.55000275

0.986537

2.3774047

0.049068995

Luc7l2

0.4103945

0.7733772

4.0217533

0.005048355

Mbd6

0.6565342

0.8940796

2.5326927

0.039078906

Vps52

0.7230967

0.74511886

2.9476469

0.025691297

Madd

0.19218214

0.8782817

3.9008439

0.011399596

Tmem87a

0.22999342

0.8496132

4.040552

0.006798464

Zfx

0.41627964

0.8609656

3.4525816

0.010654006

Brpf3

0.29247937

0.9484173

3.213643

0.01828293

0.5435012

0.9413882

2.6317518

0.033826392

Rbm39

0.48131838

0.9155187

2.9452748

0.02155107

Golga4

0.30404538

1.030618

2.6651375

0.037267577

Tfap2a

0.60686105

0.881113

2.7478771

0.028591381

Ccnd3

0.56583333

0.838158

3.0933197

0.017485354

Spata2

0.6961633

0.8437004

2.6320195

0.033813234

0.68034136

0.9147077

2.3659296

0.04990409

0.4199101

0.8802602

3.3251781

0.012674631

Fam160a2

0.44770044

0.80820495

3.667785

0.00798761

Lemd3

0.28939173

0.92756474

3.3578362

0.015270467

Traf2

0.58860505

0.88668454

2.7774503

0.027398612

0.511472

0.9447334

2.7020664

0.030547556

0.65506744

0.9291513

2.373567

0.04934667

Dlg4

0.5196946

0.8870266

2.9876306

0.020294316

Gmfg

0.42317215

0.7901299

3.867104

0.006154682

Jrkl

4931406P16Rik
Slc9a3r1

Tnrc6a
NR_029456
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Gene Name

Upf3a

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.6123128

0.8699901

2.7842424

0.02713211

0.41805092

0.96476513

2.8300912

0.025402868

Smarca4

0.6719411

0.90782696

2.4226136

0.045915656

Awat2

0.5209645

0.9677513

2.5530062

0.03793679

Rnf40

0.3068969

1.0508443

2.5327797

0.044512395

Rbbp6

0.5850337

0.80909884

3.1716893

0.015670931

Brf1

0.4712073

1.0162349

2.4089258

0.046847846

Rltpr

0.34825724

1.0382304

2.5381734

0.044189647

Zfp944

0.6489769

0.89386845

2.5568717

0.037723396

Acbd3

0.40046698

1.0362217

2.447836

0.04993729

Ppt2

0.37942636

0.96377856

2.9272077

0.026382707

Otud5

0.49579063

1.0041763

2.4180584

0.046223752

Klraq1

0.533447

0.82808465

3.255893

0.013943267

Kctd18

0.5246526

0.93503547

2.7176883

0.02986521

Nosip

0.5893446

0.9329006

2.5456784

0.038344756

Zbtb6

0.47570738

1.0147368

2.4068995

0.04698749

Son

0.47068703

0.9096398

3.0082474

0.019710906

NR_033144

0.33773857

0.901285

3.4182365

0.014174408

NR_033533

0

0.8434303

4.37366

0.007197289

0.47495085

0.93557715

2.851272

0.024643514

Arfgap1

0.4605324

0.958281

2.7617369

0.028025743

Morf4l1

0.16247232

1.0578351

2.678828

0.043881696

NR_040364

0.33407247

1.0161631

2.7011828

0.03552007

Ctxn1

0.4020231

0.97524655

2.806226

0.026288034

Rpl7

0.1919353

1.0504241

2.6975646

0.04290877

Pnn

Rara
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Gene Name

Hnrnpm

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

0.2584016

0.882235

3.7372499

0.009653731

Ip6k2

0.29890493

0.9385806

3.2647974

0.017145496

Csrnp2

0.38077858

1.01384

2.6223764

0.039460406

Taok2

0.1777848

1.0426848

2.7648022

0.039608512

Gm15308

0.4768259

0.99174565

2.5332248

0.039048538

Padi4

0.36532962

0.90153503

3.3457909

0.012321553

Mad2l1bp

0.12638676

1.020686

2.9631574

0.031404153

Tnip1

0.22696185

1.059517

2.59527

0.048526328

Fbxw5

0.15047543

1.0633327

2.65292

0.04526728

Hnrnpa2b1

0.17599827

0.96665406

3.2853882

0.021824293

Dnajc5b

0

1.0000035

3.1622527

0.02503172

Htr1a

0

1.0000107

3.1622012

0.025033167

Trpc5

0

1.0000254

3.1620963

0.025036117

NR_046179

0

1.0000457

3.161953

0.025040148

NR_040623

0

1.0000765

3.1617327

0.025046345

Hs3st2

0

1.0001408

3.1612759

0.025059203

Abcc6

0

1.0001798

3.160998

0.025067024

Hoxc13

0

1.0001892

3.1609318

0.025068892

4921517D21Rik

0

1.0001997

3.1608567

0.025071006

NR_045048

0

1.0002116

3.1607728

0.025073372

Serpinb9f

0

1.0002161

3.1607397

0.025074305

6030405A18Rik

0

1.0003294

3.1599348

0.025096994

Sstr5

0

1.0003574

3.1597345

0.025102643

NR_003959

0

1.0012333

3.1535068

0.025279019

Dnajc5b

0

1.0015857

3.1510015

0.025350364

	
  

189	
  

Gene Name

ΔNfl/fl;

ΔNp63Δ/Δ;p53-/-

p53-/-

ΔNp73Δ/Δ;p53-/-

t-value

p-value

NR_033632

0

1.0018922

3.1488233

0.02541258

Tas2r129

0

1.0064082

3.1167903

0.02634765

NR_024257

0

1.0238483

2.9939997

0.03030757

Tecrl

0

1.0314263

2.941053

0.03221734

NR_024326

0

1.0000061

3.1622343

0.03411084

NR_045451

0

1.0006084

3.157949

0.03425143
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Appendix 3: Pramlintide treatment as a preventive approach to suppress
thymic lymphomagenesis in p53-deficient mice
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